1550 genotypes with 2187 annotations displayed
of selected term and subterms
|
Searched Term: increased malignant tumor incidence
|
A4gnttm1Jnaka/A4gnttm1Jnaka
(B6.129S6-A4gnttm1Jnaka)
|
increased gastric adenocarcinoma incidence
|
J:184485
|
Abcb4tm1Bor/Abcb4tm1Bor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N))
|
increased hepatocellular carcinoma incidence
|
J:21232
|
Abcb4tm1Bor/Abcb4tm1Bor
(FVB.129P2-Abcb4tm1Bor/J)
|
increased hepatocellular carcinoma incidence
|
J:217802
|
Abcb4tm1Bor/Abcb4tm1Bor
(CAnNCrl.12P2(FVB)-Abcb4tm1Bor)
|
increased hepatocellular carcinoma incidence
|
J:217802
|
Abraxas1tm1.1Bwng/Abraxas1+
(involves: 129S6/SvEvTac * C57BL/6NCrl * FVB/N)
|
increased histiocytic sarcoma incidence
|
J:269823
|
increased lung adenocarcinoma incidence
|
J:269823
|
Acot12em1Holi/Acot12em1Holi
(involves: C57BL/6J * C57BL/6N)
|
increased hepatocellular carcinoma incidence
|
J:335836
|
Acox1lampe1/Acox1lampe1
(involves: C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:174942
|
Acox1tm1Jkr/Acox1tm1Jkr
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:35794
|
Acp3tm1Pivi/Acp3tm1Pivi
(B6.Cg-Acp3tm1Pivi)
|
increased prostate gland adenocarcinoma incidence
|
J:207558
|
Actbtm1(PyVT)Arge/Actb+
(involves: 129S1/Sv)
|
increased mammary adenocarcinoma incidence
|
J:87544
|
Actbtm1(PyVT)Arge/Actb+ Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary adenocarcinoma incidence
|
J:87544
|
Actbtm2(Tag)Arge/Actb+
(involves: 129S1/Sv)
|
increased sarcoma incidence
|
J:87544
|
Actbtm2(Tag)Arge/Actb+ Tg(Hsp70-1-cre)1Arge/0
(involves: 129S1/Sv * C57BL/6J * CBA)
|
increased leiomyosarcoma incidence
|
J:87544
|
Ahrtm1Yfk/Ahrtm1Yfk
(involves: 129S/SvEv * C57BL/6J)
|
increased urinary bladder carcinoma incidence
|
J:179919
|
Aicdatm1(cre)Mnz/Aicda+ Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6070Njen/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased medulloblastoma incidence
|
J:153656
|
increased skin squamous cell carcinoma incidence
|
J:153656
|
Akt1Gt1Pnt/Akt1Gt1Pnt Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt1Gt1Pnt/Akt1Gt1Pnt Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt2tm1.1Mbb/Akt2tm1.1Mbb Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt2tm1.1Mbb/Akt2tm1.1Mbb Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt3tm1Mbb/Akt3tm1Mbb Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt3tm1Mbb/Akt3tm1Mbb Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Albtm1(cre/ERT2)Mtz/Alb+ Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
(involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6)
|
increased cholangiocarcinoma incidence
|
J:192740
|
Albtm1(cre/ERT2)Mtz/Alb+ Krastm4Tyj/Kras+ Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae)
|
increased cholangiocarcinoma incidence
|
J:254370
|
increased hepatocellular carcinoma incidence
|
J:254370
|
Alktm1.1(ALK*F1174L)Heno/Alk+ Tg(Mpz-cre)94Imeg/0 Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * SJL)
|
increased neuroblastoma incidence
|
J:294092
|
Alktm1.1(ALK*F1174L)Heno/Alktm1.1(ALK*F1174L)Heno Tg(Mpz-cre)94Imeg/0 Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * SJL)
|
increased neuroblastoma incidence
|
J:294092
|
Alktm1.1Ics/? Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J)
|
increased neuroblastoma incidence
|
J:261033,
J:228124
|
Alktm2.1Ics/? Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J)
|
increased neuroblastoma incidence
|
J:261033,
J:228124
|
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S/SvEv * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2.1Rob Smad5tm1Huy/Smad5tm1Huy
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2Rob Smad5tm1Huy/Smad5tm1Zuk
(involves: 129P2/OlaHsd * 129S/SvEv * 129S7/SvEvBrd * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2Rob Smad5tm1Huy/Smad5tm1Zuk Smad9tm1Jfm/Smad9tm1Jfm
(involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
Anxa7tm1Pll/Anxa7+
(B6.Cg-Anxa7tm1Pll)
|
increased hepatocellular carcinoma incidence
|
J:93685
|
ApcM1Tno/Apc+
(either: B6JJcl.B6(D2JJcl)-ApcM1Tno or (involves: C57BL/6 * C57BL/6JJcl * DBA/2JJcl))
|
increased mammary adenocarcinoma incidence
|
J:218227
|
increased osteosarcoma incidence
|
J:218227
|
ApcMin/Apc+
(involves: AKR/J * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:10209
|
ApcMin/Apc+
(involves: C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:94108
|
ApcMin/Apc+
(B6(AKR)-ApcMin)
|
increased intestinal adenocarcinoma incidence
|
J:10209
|
ApcMin/Apc+
((AKR/J x C57BL/6J-ApcMin)F1)
|
increased intestinal adenocarcinoma incidence
|
J:21369
|
ApcMin/Apc+ Ccdc80tm1.1Ftk/Ccdc80tm1.1Ftk
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * C57BL/6J * C57BL/6N)
|
increased colon adenocarcinoma incidence
|
J:216704
|
ApcMin/Apc+ Esr1tm1.1Mma/Esr1+
(involves: 129S2/SvPas * C57BL/6J)
|
increased carcinoma incidence
|
J:118600
|
ApcMin/Apc+ Hdac2Gt(W035F03)Joe/Hdac2Gt(W035F03)Joe
(involves: 129S2/SvPas * C57BL/6J)
|
increased small intestine adenocarcinoma incidence
|
J:152134
|
ApcMin/Apc+ Ppardtm1Jps/Ppardtm1Jps
(involves: 129/Sv * AKR/J * C57BL/6 * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:90337
|
ApcMin/Apc+ Spata18tm1.2Hifa/Spata18+
(involves: C57BL/6J)
|
increased colon adenocarcinoma incidence
|
J:254117
|
increased intestinal adenocarcinoma incidence
|
J:254117
|
increased small intestine adenocarcinoma incidence
|
J:254117
|
ApcMin/Apc+ Spata18tm1.2Hifa/Spata18tm1.2Hifa
(involves: C57BL/6J)
|
increased colon adenocarcinoma incidence
|
J:254117
|
increased intestinal adenocarcinoma incidence
|
J:254117
|
increased small intestine adenocarcinoma incidence
|
J:254117
|
ApcMin/Apc+ Tcf7tm1Cle/Tcf7tm1Cle
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased mammary adenoacanthoma incidence
|
J:57721
|
ApcMin/Apc+ Tgfbr1tm1Bopa/Tgfbr1+
(involves: 129S1/SvImJ * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:143706
|
ApcMin/Apc+ Tgfbr1tm1Bopa/Tgfbr1+
(B6.Cg-Tgfbr1tm1Bopa ApcMin)
|
increased intestinal adenocarcinoma incidence
|
J:143706
|
ApcMin/Apc+ Thbs1tm1Hyn/Thbs1tm1Hyn
(involves: C57BL/6J)
|
increased carcinoma incidence
|
J:79641
|
ApcMin/Apc+ Trp53tm1Mlh/Trp53tm1Mlh
(involves: 129P2/OlaHsd * C57BL/6 * SWR)
|
increased pancreatic acinar cell carcinoma incidence
|
J:29664
|
ApcMin/Apctm1Tno Ctnnb1tm4.1Wbm/Ctnnb1+
(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:156864
|
Apctm1.1Rsmi/Apc+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased large intestine adenocarcinoma incidence
|
J:159883
|
increased small intestine adenocarcinoma incidence
|
J:159883
|
Apctm1Cip/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:94108
|
increased mammary adenocarcinoma incidence
|
J:94108
|
Apctm1Cip/Apc+ H19tm1Lda/H19+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)
|
increased intestinal adenocarcinoma incidence
|
J:138826
|
Apctm1Hsa/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:61978
|
Apctm1Mmt/Apc+ Smad4tm1Mmt/Smad4+
(involves: 129S2/SvPas * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:46242
|
increased pancreatic ductal adenocarcinoma incidence
|
J:46242
|
Apctm1Rak/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:20443
|
increased intestinal adenocarcinoma incidence
|
J:20443
|
Apctm1Rak/Apc+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:65142
|
Apctm1Rak/Apc+ Cdh1tm1Cbm/Cdh1+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:65142
|
Apctm1Rak/Apc+ Dcctm1.1Mehl/Dcctm1.1Mehl
(involves: 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:181517
|
Apctm1Rak/Apc+ Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased adenocarcinoma incidence
|
J:53451
|
increased carcinoma incidence
|
J:53451
|
Apctm1Rak/Apc+ Smad4E6sad/Smad4+
(B6.129P2-Apctm1Rak +/+ Smad4E6sad)
|
increased intestinal adenocarcinoma incidence
|
J:107273
|
Apctm1Rsmi/Apc+ Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased intestinal adenocarcinoma incidence
|
J:159883
|
increased large intestine adenocarcinoma incidence
|
J:159883
|
increased small intestine adenocarcinoma incidence
|
J:159883
|
Apctm1Tno/Apc+
(involves: 129 * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:156864
|
Apctm1Tno/Apc+ Brf1tm1Arte/Brf1tm1Arte Tg(Cyp1a1-cre)1Dwi/0
(involves: C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:285667
|
Apctm1Tno/Apc+ Ptentm2Mak/Ptentm2Mak Tg(Cyp1a1-cre/ERT)1Dwi/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)
|
increased intestinal adenocarcinoma incidence
|
J:143082
|
Apctm1Tno/Apc+ Tg(CDX2-cre)101Erf/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:126018
|
Apctm1Tno/Apc+ Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased small intestine adenocarcinoma incidence
|
J:126018
|
Apctm1Tno/Apctm1Tno
(involves: 129 * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:156864
|
Apctm1Tno/Apctm1Tno Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased ovarian carcinoma incidence
|
J:120955
|
Apctm1Tno/Apctm1Tno Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:120308
|
Apctm2.1Cip/Apc+ Krastm4Tyj/Kras+ Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * 129S4/SvJae * FVB)
|
increased intestinal adenocarcinoma incidence
|
J:132357
|
Apctm2.1Cip/Apc+ Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased intestinal adenocarcinoma incidence
|
J:132357
|
Apctm2.1Cip/Apctm2.1Cip
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased hepatocellular carcinoma incidence
|
J:94721
|
Apctm2Rak/Apctm2Rak
(involves: 129/Sv * C57BL/6J * SJL)
|
increased carcinoma incidence
|
J:156532
|
Apctm2Rak/Apctm2Rak Krastm4Tyj/Kras+
(involves: 129 * 129S4/SvJae * C57BL/6J * SJL)
|
increased adenocarcinoma incidence
|
J:156532
|
increased carcinoma incidence
|
J:156532
|
Apctm2Rfo/Apc+
(B6.129P2-Apctm2Rfo)
|
increased mammary adenocarcinoma incidence
|
J:151494
|
Apctm2Rfo/Apc+
((C57BL/6J x 129P2/OlaHsd)F1)
|
increased mammary adenocarcinoma incidence
|
J:204440,
J:151494
|
Apctm2Rfo/Apc+
(129P2/OlaHsd-Apctm2Rfo)
|
increased mammary adenocarcinoma incidence
|
J:151494
|
Apctm2Rfo/Apc+ Smad4E6sad/Smad4+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:151494
|
Apex1tm1Ecf/Apex1+
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
|
increased carcinoma incidence
|
J:70397
|
increased sarcoma incidence
|
J:70397
|
Artm1Verh/Y Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:172730
|
Arid1atm1.1Mag/Arid1atm1.1Mag Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
(involves: 129S6/SvEvTac * CD-1)
|
increased ovarian carcinoma incidence
|
J:219794
|
Arid4atm1Alb/Arid4atm1Alb
(involves: 129S7/SvEvBrd)
|
increased sarcoma incidence
|
J:141004
|
Arid4atm1Alb/Arid4atm1Alb Arid4btm1Alb/Arid4b+
(involves: 129S7/SvEvBrd)
|
increased sarcoma incidence
|
J:141004
|
Asxl1tm1.1Mjxu/Asxl1+
(involves: 129 * C57BL/6)
|
increased malignant tumor incidence
|
J:208085
|
increased sarcoma incidence
|
J:208085
|
Atad5Gt(RRF055)Byg/Atad5+
(involves: 129P2/OlaHsd)
|
increased hemangiosarcoma incidence
|
J:176672
|
increased liver adenocarcinoma incidence
|
J:176672
|
increased lung adenocarcinoma incidence
|
J:176672
|
increased lung carcinoma incidence
|
J:176672
|
increased sarcoma incidence
|
J:176672
|
increased spindle cell carcinoma incidence
|
J:176672
|
Atmtm1Awb/Atmtm1Awb
(A.129S6-Atmtm1Awb)
|
increased hepatocellular carcinoma incidence
|
J:208539
|
Atmtm1Mfl/Atm+
(involves: 129T2/SvEms * C57BL/6J)
|
increased sarcoma incidence
|
J:78527
|
Atp2a2tm1Ges/Atp2a2+
(involves: 129X1/SvJ * Black Swiss)
|
increased squamous cell carcinoma incidence
|
J:69754
|
Atp2c1tm1Ges/Atp2c1+
(involves: 129X1/SvJ * Black Swiss)
|
increased squamous cell carcinoma incidence
|
J:124662
|
Atp11cambr/Y
(C57BL/6-Atp11cambr)
|
increased hepatocellular carcinoma incidence
|
J:171924
|
Atrxtm1Rjg/Y Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1)
|
increased osteosarcoma incidence
|
J:329449
|
Atrxtm1Rjg/Atrxtm1Rjg Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1)
|
increased osteosarcoma incidence
|
J:329449
|
AurkaGt(XQ0149)Wtsi/Aurka+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lung carcinoma incidence
|
J:143099
|
increased squamous cell carcinoma incidence
|
J:143099
|
Aurkbtm1.2Mama/Aurkb+
(involves: 129/Sv * BALB/cJ * C57BL/6 * CD-1 * SJL)
|
increased adenocarcinoma incidence
|
J:173575
|
increased liver adenocarcinoma incidence
|
J:173575
|
B2mtm1Unc/B2mtm1Unc Il2tm1Hor/Il2tm1Hor
(involves: 129 * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:51450
|
B3gnt6tm1Lx/B3gnt6tm1Lx
(involves: 129S1/Sv * C57BL/6J)
|
increased adenocarcinoma incidence
|
J:123826
|
increased carcinoma incidence
|
J:123826
|
B3gnt6tm1Lx/B3gnt6tm1Lx C1galt1tm1.1Rpmc/C1galt1tm1.1Rpmc Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2)
|
increased duodenum adenocarcinoma incidence
|
J:239765
|
Bak1tm1Thsn/Bak1tm1Thsn Baxtm1Sjk/Baxtm2Sjk Krastm4Tyj/Kras+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased adenocarcinoma incidence
|
J:125101
|
Bap1em1Test/Bap1+
(involves: FVB)
|
increased lung carcinoma incidence
|
J:231692
|
increased mammary adenocarcinoma incidence
|
J:231692
|
increased squamous cell carcinoma incidence
|
J:213725
|
Bap1em2Test/Bap1+
(involves: FVB)
|
increased lung carcinoma incidence
|
J:231692
|
increased mammary adenocarcinoma incidence
|
J:231692
|
increased pancreatic islet cell carcinoma incidence
|
J:231692
|
Bap1em3Test/Bap1+
(involves: FVB)
|
increased lung carcinoma incidence
|
J:231692
|
increased mammary adenocarcinoma incidence
|
J:231692
|
Bard1tm1Thl/Bard1tm2Thl Waptm1(cre)Arge/0
(involves: 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Bard1tm2Thl/Bard1tm2Thl Brca1tm1Thl/Brca1tm1Thl Waptm1(cre)Arge/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Bard1tm2Thl/Bard1tm2Thl Waptm1(cre)Arge/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Becn1tm1Blev/Becn1+
(involves: 129X1/SvJ * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:86953
|
increased histiocytic sarcoma incidence
|
J:86953
|
increased lung adenocarcinoma incidence
|
J:86953
|
increased lung carcinoma incidence
|
J:86953
|
increased malignant tumor incidence
|
J:86953
|
Becn1tm1Htz/Becn1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:86982
|
increased lung adenocarcinoma incidence
|
J:86982
|
Bhlha15tm2(Kras)Skz/Bhlha15+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:105076
|
increased pancreatic acinar cell carcinoma incidence
|
J:105076
|
Bhlha15tm2(Kras)Skz/Bhlha15+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:105076
|
Bhmttm1.2Zei/Bhmttm1.2Zei
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:177569
|
Bin1tm1Gcp/Bin1tm2Gcp Tg(MMTV-Myc)141-3Led/0 Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)
|
increased mammary adenocarcinoma incidence
|
J:117330
|
Bin3tm1Gcp/Bin3tm1Gcp
(involves: 129 * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:133313
|
Blmtm1Ches/Blmtm4Ches Tg(LGB-cre)74Acl/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)
|
increased mammary adenocarcinoma incidence
|
J:112115
|
Bmpr1atm2.1Bhr/Bmpr1atm2.1Bhr Ctnnb1tm1Mmt/Ctnnb1+ Krt14tm1.1(cre)Wbm/Krt14+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * 129X1/SvJ)
|
increased squamous cell carcinoma incidence
|
J:199091
|
Braftm1.1Brd/Braf+ Cdkn2atm1.1Brn/Cdkn2atm1.1Brn Tg(Vil1-cre)997Gum/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased carcinoma incidence
|
J:199307
|
Braftm1.1Brd/Braf+ Tg(Vil1-cre)997Gum/0
(involves: 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased carcinoma incidence
|
J:199307
|
Braftm1Cpri/Braftm1Cpri Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(Tyr-cre/ERT2)1Lru/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL)
|
increased melanoma incidence
|
J:147434
|
Braftm1Cpri/Braftm1Cpri Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * FVB/NCr)
|
increased thyroid carcinoma incidence
|
J:168249
|
Braftm1Cpri/Braftm1Cpri Tg(Tyr-cre/ERT2)1Lru/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased melanoma incidence
|
J:147434
|
Braftm1Mmcm/Braf+
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:121715
|
Braftm1Mmcm/Braf+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+ Ezh2tm1.1Nesh/Ezh2+ Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:239472
|
Braftm1Mmcm/Braf+ Ptentm1Mro/Ptentm1Mro Tg(Tyr-cre/ERT2)1Lru/0
(B6.Cg-Braftm1Mmcm Tg(Tyr-cre/ERT2)1Lru Ptentm1Mro)
|
increased cutaneous melanoma incidence
|
J:188523
|
Braftm1Mmcm/Braf+ Ptentm1Rdp/Ptentm1Rdp Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased cutaneous melanoma incidence
|
J:151023
|
Braftm1Mmcm/Braf+ Ptentm2.1Ppp/Pten+ Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB)
|
increased cutaneous melanoma incidence
|
J:151023
|
Braftm1Mmcm/Braf+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB)
|
increased cutaneous melanoma incidence
|
J:151023
|
Braftm1Mmcm/Braf+ Tg(Tg-cre/ERT2)#Mmcm/0
(involves: 129P2/OlaHsd)
|
increased thyroid carcinoma incidence
|
J:172205
|
Braftm1Mmcm/Braf+ Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+ Tg(TPO-cre/ERT2)1139Tyj/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:121715
|
Braftm1Mmcm/Braf+ Trp53tm1Brn/Trp53tm3.1Tyj Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+ Trp53tm3.1Tyj/Trp53+ Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braftm1Mmcm Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+ Ptentm1Hwu/Pten+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:191327
|
Braftm1Rima/Braf+ Tg(GFP/KRAS2/ALPP)1Brn/0 Tg(Tyr-cre/ERT2)1Lru/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased melanoma incidence
|
J:161180
|
Braftm1Sva/Braftm1Sva Krastm1Bbd/Kras+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Braftm1Tuv/Braftm1Tuv Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+ Tg(Tyr-cre/ERT2)13Bos/0 TgTn(sb-T2/Onc)#Dla/0
(involves: 129S6/SvEvTac * FVB/N)
|
increased melanoma incidence
|
J:177503
|
Brca1tm1Aash/Brca1tm1Aash Tg(LGB-cre)74Acl/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased salivary adenocarcinoma incidence
|
J:119996
|
Brca1tm1Aash/Brca1tm1Aash Trp53tm1Brd/Trp53+ Tg(LGB-cre)74Acl/0
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA)
|
increased mammary gland ductal carcinoma incidence
|
J:119996
|
increased salivary adenocarcinoma incidence
|
J:119996
|
Brca1tm1Arge/Brca1tm1Thl Waptm1(cre)Arge/0
(involves: 129S/SvEv * 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Brca1tm1Bhk/Brca1+ Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(C.129-Cdkn2ctm1Yxi Brca1tm1Bhk)
|
increased mammary adenocarcinoma incidence
|
J:198018
|
Brca1tm1Brn/Brca1tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased carcinoma incidence
|
J:189304
|
increased ovarian carcinoma incidence
|
J:189304
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(KRT5-cre)5132Jlj/0
(involves: 129S6/SvEvTac * C57BL/6)
|
increased squamous cell carcinoma incidence
|
J:85354
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(KRT5-cre)5132Jlj/0 Tg(KRT5-E2F1)2Dgj/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
increased squamous cell carcinoma incidence
|
J:85354
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(KRT5-E2F1)2Dgj/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
increased squamous cell carcinoma incidence
|
J:85354
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * Black Swiss * FVB)
|
increased mammary adenocarcinoma incidence
|
J:54533
|
Brca1tm1Thl/Brca1tm1Thl Waptm1(cre)Arge/0
(involves: 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Trp53tm1Brd/Trp53+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased carcinoma incidence
|
J:122899
|
Brca1tm2Cxd/Brca1+ Tg(KRT5-E2F1)2Dgj/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
increased squamous cell carcinoma incidence
|
J:85354
|
Brca1tm2Mak/Brca1tm2Mak Chek2tm1Mak/Chek2tm1Mak Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased mammary adenocarcinoma incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak Trp53tm1Brd/Trp53+ Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased mammary adenocarcinoma incidence
|
J:90512
|
Brca1tm4Cxd/Brca1tm4Cxd
(involves: 129S6/SvEvTac * NIH Black Swiss)
|
increased mammary gland ductal carcinoma incidence
|
J:112308
|
Brca2tm1Arge/Brca2tm2Arge Waptm1(cre)Arge/Wap+
(involves: 129S/SvEv * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:70564
|
Brca2tm1Brn/Brca2+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:73028
|
Brca2tm1Brn/Brca2tm1Brn Ptch1tm1Mps/Ptch1+ Trp53tm1Tyj/Trp53+ Tg(Nes-cre)1Kln/0
(involves: 129 * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Brca2tm1Brn/Brca2tm1Brn Ptch1tm1Mps/Ptch1+ Trp53tm1Tyj/Trp53tm1Tyj Tg(Nes-cre)1Kln/0
(involves: 129 * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Brn/Trp53+ Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:73028
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:73028
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Tyj/Trp53+ Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Tyj/Trp53tm1Tyj Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Brca2tm1Brn/Brca2tm1Cam Krastm4Tyj/Kras+ Trp53tm3Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic acinar cell carcinoma incidence
|
J:166678
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2+ Krastm4Tyj/Kras+ Trp53tm3Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2tm1Brn Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2tm1Brn Tg(Pdx1-cre)6Tuv/0 Trp53tm3Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased malignant tumor incidence
|
J:166678
|
increased sarcoma incidence
|
J:166678
|
Brca2tm1Hst/Brca2tm1Hst
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased carcinoma incidence
|
J:82434
|
Brca2tm1Kamc/Brca2tm1Kamc Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6)
|
increased osteosarcoma incidence
|
J:109193
|
Brca2tm1Mak/Brca2tm2Mak Trp53tm1Brd/Trp53tm1Brd Tg(Lck-cre)548Jxm/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA)
|
increased malignant tumor incidence
|
J:79697
|
increased osteosarcoma incidence
|
J:79697
|
Brca2tm2Arge/Brca2tm2Arge Waptm1(cre)Arge/Waptm1(cre)Arge
(involves: 129S1/Sv * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:70564
|
Brf1tm1Arte/Brf1tm1Arte Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S7/SvEvBrd * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:285667
|
Brip1Gt(RRI409)Byg/Brip1Gt(RRI409)Byg
(involves: 129P2/OlaHsd)
|
increased adenocarcinoma incidence
|
J:227115
|
Btg3tm1Tya/Btg3tm1Tya
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lung carcinoma incidence
|
J:149382
|
Bub1tm1.1Jvd/Bub1tm2Jvd
(involves: 129/Sv * C57BL/6)
|
increased sarcoma incidence
|
J:135093
|
Bub1tm2Jvd/Bub1tm2Jvd
(involves: 129/Sv * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:135093
|
increased sarcoma incidence
|
J:135093
|
Bub1bGt(neo-btk)1Dai/Bub1b+
(involves: 129S4/SvJae)
|
increased intestinal adenocarcinoma incidence
|
J:88094
|
Bub1btm1.1Hsl/Bub1b+
(involves: 129 * C57BL/6)
|
increased adenocarcinoma incidence
|
J:201641
|
increased fibrosarcoma incidence
|
J:201641
|
increased hemangiosarcoma incidence
|
J:201641
|
increased hepatocellular carcinoma incidence
|
J:201641
|
increased lung adenocarcinoma incidence
|
J:201641
|
increased rectum adenocarcinoma incidence
|
J:201641
|
increased sarcoma incidence
|
J:201641
|
Cables1tm1Lrz/Cables1tm1Lrz
(involves: 129S1/Sv)
|
increased endometrial carcinoma incidence
|
J:87478
|
Calcatm1.1(cre/ERT2)Ptch/Calca+ Trp53tm1Brn/Trp53tm1Brn Rb1tm2Brn/Rb1tm2Brn
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased lung small cell carcinoma incidence
|
J:190366
|
Calcatm1.1(cre/ERT2)Ptch/Calca+ Trp53tm1Brn/Trp53tm1Brn Rb1tm2Brn/Rb1tm2Brn Ptentm1Hwu/Ptentm1Hwu
(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * BALB/c * FVB/N)
|
increased lung small cell carcinoma incidence
|
J:190366
|
Cbx7tm1Afus/Cbx7+
(involves: C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:184383
|
Cbx7tm1Afus/Cbx7tm1Afus
(involves: C57BL/6J)
|
increased carcinoma incidence
|
J:184383
|
increased hepatocellular carcinoma incidence
|
J:184383
|
increased lung carcinoma incidence
|
J:184383
|
Ccdc80tm1.1Ftk/Ccdc80tm1.1Ftk
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6N)
|
increased hepatocellular carcinoma incidence
|
J:216704
|
Ccdc80tm1Ppal/Ccdc80tm1Ppal
(Not Specified)
|
increased ovarian carcinoma incidence
|
J:217742
|
Ccn6tm1.1Cgkl/Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam/0
(FVB/N-Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam)
|
increased mammary adenocarcinoma incidence
|
J:241259
|
Ccn6tm1.1Cgkl/Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam/0 Tg(MMTV-PyVT)634Mul/0
(FVB/N-Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam Tg(MMTV-PyVT)634Mul)
|
increased mammary adenocarcinoma incidence
|
J:241259
|
Ccnd1tm4Pisc/Ccnd1tm4Pisc Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:156591
|
Ccndbp1tm1Riet/Ccndbp1tm1Riet
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:121623
|
Cd19tm1(cre)Cgn/Cd19+ Inpp5dtm1Rav/Inpp5dtm1Rav Ptentm1Hwu/Ptentm1Hwu
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased malignant tumor incidence
|
J:166155
|
Cdh1tm1Jjon/Cdh1+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
increased squamous cell carcinoma incidence
|
J:116152
|
Cdh1tm1Jjon/Cdh1+ Trp53tm1Brn/Trp53tm1Brn Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:171765
|
Cdh1tm1Jjon/Cdh1tm1Jjon Trp53tm1Brn/Trp53+ Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
Cdh1tm1Jjon/Cdh1tm1Jjon Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
Cdh1tm2Kem/Cdh1+ Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)7Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:212549
|
Cdh1tm2Kem/Cdh1+ Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)6Tuv/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased duodenum adenocarcinoma incidence
|
J:212549
|
increased gastric adenocarcinoma incidence
|
J:212549
|
increased squamous cell carcinoma incidence
|
J:212549
|
Cdh1tm2Kem/Cdh1+ Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(Vil1-cre)20Syr/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased intestinal adenocarcinoma incidence
|
J:212549
|
Cdh1tm2Kem/Cdh1tm2Kem Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)6Tuv/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased gastric adenocarcinoma incidence
|
J:212549
|
Cdk4tm1.1Bbd/Cdk4+ Krastm1Bbd/Kras+ Tg(CMV-cre)1Cgn/?
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:86101
|
increased sarcoma incidence
|
J:86101
|
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb/0
(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb)
|
increased cutaneous melanoma incidence
|
J:111992
|
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd Tg(Tyr-NRAS*Q61K)1Bee/0
(FVB.Cg-Cdk4tm1.1Bbd Tg(Tyr-NRAS*Q61K)1Bee)
|
increased cutaneous melanoma incidence
|
J:222847
|
Cdk4tm2.1Bbd/Cdk4tm2.1Bbd Krastm1Bbd/Krastm2Bbd Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
increased adenocarcinoma incidence
|
J:161780
|
Cdk5rap2an/Cdk5rap2an Tyrp1B-lt/Tyrp1B-lt
(WBB6F1)
|
increased histiocytic sarcoma incidence
|
J:102334
|
Cdk6tm1Bbd/Cdk6tm1Bbd Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:161780
|
Cdkn1atm1(HBsAg)Xya/Cdkn1a+
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:88078
|
Cdkn1atm1(HBsAg)Xya/Cdkn1atm1(HBsAg)Xya
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:88078
|
Cdkn1atm1Led/Cdkn1atm1Led Ctnnb1tm1Mmt/Ctnnb1tm1Mmt Tg(Upk2-cre)6Xrw/0
(involves: 129S6/SvEvTac * 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:234236
|
Cdkn1atm1Tyj/Cdkn1a+
(involves: 129S1/SvImJ * 129S2/SvPas * C57BL/6J)
|
increased malignant tumor incidence
|
J:83967
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased carcinoma incidence
|
J:70894
|
increased hemangiosarcoma incidence
|
J:70894
|
increased histiocytic sarcoma incidence
|
J:70894
|
increased lung carcinoma incidence
|
J:70894
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129/Sv * 129S2/SvPas * C57BL/6)
|
increased squamous cell carcinoma incidence
|
J:72780
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S1/SvImJ * 129S2/SvPas * C57BL/6J)
|
increased malignant tumor incidence
|
J:83967
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * 129S2/SvPas * C57BL/6 * C57BL/6J * SJL)
|
increased squamous cell carcinoma incidence
|
J:72780
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129 * C57BL/6 * CD-1 * DBA/2)
|
increased carcinoma incidence
|
J:204886
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj Fahtm1Mgo/Fahtm1Mgo
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:138701
|
increased renal carcinoma incidence
|
J:138701
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj Ptentm1Hwu/Ptentm1Hwu Tg(Fabp1-cre)1Jig/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:106662
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj Tg(MMTV-vHaras)SH1Led/0
(involves: 129S2/SvPas * C57BL/6J * CD-1 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:66183
|
increased salivary adenocarcinoma incidence
|
J:66183
|
Cdkn1atm2(HBx)Xya/Cdkn1a+
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:88078
|
Cdkn1atm2(HBx)Xya/Cdkn1atm2(HBx)Xya
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:88078
|
Cdkn1btm1Ako/Cdkn1b+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0
(129S1.Cg-Cdkn1btm1Ako Tg(TPO-cre)1Shk Ptentm2.1Ppp)
|
increased thyroid carcinoma incidence
|
J:165293
|
Cdkn1btm1Ako/Cdkn1btm1Ako
(involves: 129S1/Sv)
|
increased lung adenocarcinoma incidence
|
J:120835
|
Cdkn1btm1Ako/Cdkn1btm1Ako Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2)
|
increased carcinoma incidence
|
J:50053
|
Cdkn1btm1Jro/Cdkn1btm1Jro Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:318035
|
Cdkn1btm1Mlf/Cdkn1b+ Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:205254
|
increased medulloblastoma incidence
|
J:205254
|
increased rhabdomyosarcoma incidence
|
J:205254
|
Cdkn1btm1Mlf/Cdkn1b+ Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:210015
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:205254
|
increased medulloblastoma incidence
|
J:205254
|
increased rhabdomyosarcoma incidence
|
J:205254
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:210015
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Trp53tm1Brd/Trp53tm1Brd
(involves: C3H * C57BL/6J * NIH)
|
increased sarcoma incidence
|
J:87536
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Trp53tm1Brd/Trp53tm1Brd
(involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J)
|
increased sarcoma incidence
|
J:87536
|
Cdkn2atm1(GFP)Cjs/Cdkn2atm1(GFP)Cjs
(involves: 129S1/Sv * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:87339
|
increased histiocytic sarcoma incidence
|
J:87339
|
increased sarcoma incidence
|
J:87339
|
Cdkn2atm1.1Brn/Cdkn2a+ Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased rhabdomyosarcoma incidence
|
J:132943
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased rhabdomyosarcoma incidence
|
J:132943
|
Cdkn2atm1.1Gsu/Cdkn2atm1.1Gsu Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/N)
|
increased adenocarcinoma incidence
|
J:198619
|
Cdkn2atm1Cjs/Cdkn2a+
(involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd)
|
increased carcinoma incidence
|
J:93298
|
Cdkn2atm1Cjs/Cdkn2a+ Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129X1/SvJ * FVB)
|
increased rhabdomyosarcoma incidence
|
J:237183
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
(involves: 129X1/SvJ * C57BL/6)
|
increased carcinoma incidence
|
J:44427
|
increased fibrosarcoma incidence
|
J:44427
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
(involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd)
|
increased carcinoma incidence
|
J:93298
|
increased squamous cell carcinoma incidence
|
J:93298
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Pax7tm1Pgr/Pax7+ Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129S2/SvPas * 129X1/SvJ * FVB)
|
increased rhabdomyosarcoma incidence
|
J:237183
|
increased sarcoma incidence
|
J:237183
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Pax7tm1Pgr/Pax7tm1Pgr Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129S2/SvPas * 129X1/SvJ * FVB)
|
increased rhabdomyosarcoma incidence
|
J:237183
|
increased sarcoma incidence
|
J:237183
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Sclt1Tg(CAG-sb10)1Dla/0 TgTn(sb-T2/Onc)68Dla/0
(involves: 129X1/SvJ * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:99991
|
increased osteosarcoma incidence
|
J:99991
|
increased sarcoma incidence
|
J:99991
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Sclt1Tg(CAG-sb10)1Dla/0 TgTn(sb-T2/Onc)76Dla/0
(involves: 129X1/SvJ * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:99991
|
increased osteosarcoma incidence
|
J:99991
|
increased sarcoma incidence
|
J:99991
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Tacstd2tm1Lsm/Tacstd2tm1Lsm
(involves: 129X1/SvJ * C57BL/6)
|
increased carcinoma incidence
|
J:182647
|
increased skin squamous cell carcinoma incidence
|
J:182647
|
increased spindle cell carcinoma incidence
|
J:182647
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129X1/SvJ * FVB)
|
increased rhabdomyosarcoma incidence
|
J:237183
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * NIH/OlaHsd)
|
increased carcinoma incidence
|
J:93298
|
Cdkn2atm1Nesh/Cdkn2atm1Nesh
(involves: 129S6/SvEvTac * FVB/N)
|
increased lung carcinoma incidence
|
J:88365
|
increased osteosarcoma incidence
|
J:88365
|
increased sarcoma incidence
|
J:88365
|
Cdkn2atm1Nesh/Cdkn2atm1Nesh X/Tg(Tyr-HRAS)60Lc
(involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB)
|
increased melanoma incidence
|
J:85075
|
Cdkn2atm1Rdp/Cdkn2a+ Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased neurofibrosarcoma incidence
|
J:131914
|
Cdkn2atm1Rdp/Cdkn2a+ Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
increased sarcoma incidence
|
J:120065
|
Cdkn2atm1Rdp/Cdkn2a+ Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0 Tg(Pdx1-cre)6Tuv/0 Tg(tetO-MYC)36Bop/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197052
|
Cdkn2atm1Rdp/Cdkn2a+ X/Tg(Tyr-HRAS)60Lc
(involves: 129/Sv * C57BL/6J * CBA/J * FVB/N * SJL)
|
increased intraocular melanoma incidence
|
J:140820
|
Cdkn2atm1Rdp/Cdkn2a+ Tg(Tyr-NRAS*Q61K)1Bee/?
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
|
increased cutaneous melanoma incidence
|
J:98545
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6 * SJL)
|
increased cutaneous melanoma incidence
|
J:98545
|
increased fibrosarcoma incidence
|
J:53805
|
increased hemangiosarcoma incidence
|
J:53805
|
increased sarcoma incidence
|
J:53805
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
|
increased sarcoma incidence
|
J:88365
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6 * C57BL/6J * SJL)
|
increased squamous cell carcinoma incidence
|
J:72780
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Col1a1tm1(CAG-EGFR)Char/Col1a1tm1(CAG-EGFR)Char Ptentm1Hwu/Ptentm1Hwu
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL)
|
increased glioblastoma incidence
|
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Col1a1tm1(CAG-EGFR)Char/Col1a1tm2(CAG-EGFR*)Char Ptentm1Hwu/Ptentm1Hwu
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL)
|
increased glioblastoma incidence
|
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Col1a1tm2(CAG-EGFR*)Char/Col1a1tm2(CAG-EGFR*)Char Ptentm1Hwu/Ptentm1Hwu
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL)
|
increased glioblastoma incidence
|
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Ctnnb1tm1Mmt/Ctnnb1tm1Mmt Ptentm1Rps/Ptentm1Rps Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129/Sv * C57BL/6J * FVB * SJL)
|
increased melanoma incidence
|
J:155731
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+ Pdgfratm12Sor/Pdgfra+
(involves: 129 * C57BL/6J * SJL)
|
increased fibrosarcoma incidence
|
J:146617
|
increased sarcoma incidence
|
J:146617
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptentm1Rdp/Ptentm1Rdp Tg(tetO-BRAF*V600E)29Lc/0 Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129/Sv * C57BL/6J * FVB * SJL)
|
increased melanoma incidence
|
J:221902
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Krastm4Tyj/Kras+
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * FVB/N * SJL)
|
increased lung adenocarcinoma incidence
|
J:124682
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased neurofibrosarcoma incidence
|
J:131914
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Ptentm1Rps/Ptentm1Rps Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J * FVB/N * SJL)
|
increased melanoma incidence
|
J:155731
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
increased sarcoma incidence
|
J:120065
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(Mt1-Hgf)19Lmb/0
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
|
increased melanoma incidence
|
J:79704
|
increased rhabdomyosarcoma incidence
|
J:79704
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-Kras2)12Hev/0
(involves: 129 * C57BL/6J * FVB/N * SJL)
|
increased lung adenocarcinoma incidence
|
J:166963,
J:73468
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(tetO-BRAF*V600E)29Lc/0 Tg(Tyr-rtTA)37Lc/0
(involves: 129/Sv * C57BL/6J * SJL)
|
increased prostate gland adenocarcinoma incidence
|
J:144358
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(tetO-Nras*Q61K)#Lc/0 Tg(Tyr-rtTA)37Lc/0
(FVB.Cg-Cdkn2atm1Rdp Tg(tetO-Nras*Q61K)#Lc Tg(Tyr-rtTA)37Lc)
|
increased cutaneous melanoma incidence
|
J:238049
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(Tyr-BRAF*V600E)470Fgh/0
(involves: 129/Sv * C57BL/6J * CBA * SJL)
|
increased melanoma incidence
|
J:151455
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(Tyr-BRAF*V600E)476Fgh/0
(involves: 129/Sv * C57BL/6J * CBA * SJL)
|
increased melanoma incidence
|
J:151455
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp X/Tg(Tyr-HRAS)60Lc
(involves: 129/Sv * C57BL/6J * CBA/J * SJL)
|
increased melanoma incidence
|
J:164588
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(Tyr-NRAS*Q61K)1Bee/?
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
|
increased cutaneous melanoma incidence
|
J:98545
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(Tyr-NRAS*Q61K)1Bee/0
(involves: 129/Sv * C57BL/6J * DBA/2 * SJL)
|
increased cutaneous melanoma incidence
|
J:193443
|
Cdkn2atm2.1Brn/Cdkn2atm2.1Brn
(involves: 129P2/OlaHsd * FVB/N)
|
increased carcinoma incidence
|
J:71393
|
increased melanoma incidence
|
J:71393
|
increased sarcoma incidence
|
J:71393
|
Cdkn2atm2.1Nesh/Cdkn2a+ Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:164588
|
increased spindle cell carcinoma incidence
|
J:164588
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Ezh2tm1.1Nesh/Ezh2+ Nrastm1.1Nesh/Nras+ Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129 * 129S4/SvJae * 129P2/OlaHsd * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:239472
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Krastm4Tyj/Kras+ Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129S4/SvJae * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:164588
|
increased spindle cell carcinoma incidence
|
J:164588
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Krastm4Tyj/Kras+ Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Cdkn2atm2.1Nesh Krastm4Tyj)
|
increased cutaneous melanoma incidence
|
J:220627
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:164588
|
increased spindle cell carcinoma incidence
|
J:164588
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Nrastm1.1Nesh/Nras+ Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129 * 129S4/SvJae * 129P2/OlaHsd * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:239472
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Nrastm1.1Nesh/Nrastm1.1Nesh Stk11tm1.1Rdp/Stk11tm1.1Rdp Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1.1Nesh Cdkn2atm2.1Nesh Stk11tm1.1Rdp)
|
increased cutaneous melanoma incidence
|
J:220627
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Nrastm1.1Nesh/Nrastm1.1Nesh Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1.1Nesh Cdkn2atm2.1Nesh)
|
increased cutaneous melanoma incidence
|
J:220627
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Nrastm1Tyj/Nrastm1Tyj Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1Tyj Cdkn2atm2.1Nesh)
|
increased cutaneous melanoma incidence
|
J:220627
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Trp53tm1Brn/Trp53tm1Brn Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
|
increased melanoma incidence
|
J:164588
|
Cdkn2atm2.1Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
|
increased osteosarcoma incidence
|
J:88365
|
increased sarcoma incidence
|
J:88365
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased adenocarcinoma incidence
|
J:198619
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp X/Tg(Tyr-HRAS)60Lc
(involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB)
|
increased melanoma incidence
|
J:85075
|
Cdkn2atm2Brn/Cdkn2atm2Brn Nf2tm2Gth/Nf2tm2Gth
(involves: 129P2/OlaHsd)
|
increased rhabdomyosarcoma incidence
|
J:132943
|
Cdkn2atm2Brn/Cdkn2atm2Brn Tg(Tyr-cre/ERT,-Hras1*,-Trap1a)10BJvde/0
(involves: C57BL/6 * FVB/N)
|
increased cutaneous melanoma incidence
|
J:107175
|
increased neurofibrosarcoma incidence
|
J:107175
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:195492
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased sarcoma incidence
|
J:125101
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased malignant tumor incidence
|
J:87196
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130,
J:108298,
J:87196
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:187012
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Myf6tm1(cre)Mrc/Myf6+ Pax3tm1Mrc/Pax3tm1Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased rhabdomyosarcoma incidence
|
J:93444
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Nf1tm1Par/Nf1tm1Par
(involves: 129S1/Sv * 129X1/SvJ)
|
increased neurofibrosarcoma incidence
|
J:234760
|
increased rhabdomyosarcoma incidence
|
J:234760
|
increased sarcoma incidence
|
J:234760
|
Cdkn2btm1Bbd/Cdkn2btm1Bbd
(involves: 129S1/Sv * C57BL/6)
|
increased adenocarcinoma incidence
|
J:63299
|
increased sarcoma incidence
|
J:63299
|
Cdkn2btm1Bbd/Cdkn2btm1Bbd Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6)
|
increased sarcoma incidence
|
J:63299
|
Cdkn2ctm1Bbd/Cdkn2c+ Trp53tm1Tyj/Trp53+
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2c+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:63299
|
increased renal carcinoma incidence
|
J:63299
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased medulloblastoma incidence
|
J:205254
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd Trp53tm1Brn/Trp53tm1Tyj Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(B6.129-Cdkn2ctm1Yxi)
|
increased lung adenocarcinoma incidence
|
J:120835
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi Men1tm1.1Ctre/Men1+
(involves: 129/Sv * 129S6/SvEvTac * C57BL/6)
|
increased adenocarcinoma incidence
|
J:120835
|
increased lung adenocarcinoma incidence
|
J:120835
|
Cebpatm1Gonz/Cebpatm1Gonz Tg(KRT5-cre)5132Jlj/0
(involves: 129X1/SvJ * C57BL/6 * DBA/2J)
|
increased squamous cell carcinoma incidence
|
J:123139
|
Cers2Gt(S16-4B1)Sor/Cers2Gt(S16-4B1)Sor
(involves: 129S4/SvJaeSor * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:156841
|
Chek1tm1Sje/Chek1+ Tg(Wnt1)1Hev/0
(Not Specified)
|
increased mammary adenocarcinoma incidence
|
J:62919
|
Chek1tm2.1Sje/Chek1+ Trp53tm1Brn/Trp53+ Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
increased mammary adenocarcinoma incidence
|
J:162126
|
Chuktm1Yhu/Chuktm1Yhu Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased carcinoma incidence
|
J:141162
|
Chuktm2Yhu/Chuktm2Yhu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased skin squamous cell carcinoma incidence
|
J:197037
|
Chuktm2Yhu/Chuktm2Yhu Tg(Lor-CHUK)8Yhu/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased lung squamous cell carcinoma incidence
|
J:197037
|
Chuktm2Yhu/Chuktm2Yhu Tg(Lor-CHUK)8Yhu/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased squamous cell carcinoma incidence
|
J:197037
|
Col1a1tm1(CAG-EGFR*T790M*C797S*L858R)Mje/Col1a1+
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:235747
|
Col1a1tm1(tetO-EML4/ALK)Kkw/Col1a1+ Tg(Scgb1a1-rtTA)1Jaw/0
(involves: 129 * C57BL/6)
|
increased lung carcinoma incidence
|
J:166724
|
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6)
|
increased sarcoma incidence
|
J:194505
|
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+ H2az2Tg(Wnt1-cre)11Rth/H2az2+ Tg(CAG-cat,-lacZ)11Miya/0
(involves: 129S4/SvJae * C57BL/6 * CBA/J * DBA/2)
|
increased sarcoma incidence
|
J:194505
|
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(EYFP)Cos Tg(Mpz-cre)94Imeg/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:194505
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1+ Tg(Cebpb-tTA)#Bjd/0
(B6.Cg-Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd)
|
increased hepatocellular carcinoma incidence
|
J:217463
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1+ Tg(Cebpb-tTA)#Bjd/0 Trp53tm1Gev/Trp53+
(B6.Cg-Trp53tm1Gev Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd)
|
increased hepatocellular carcinoma incidence
|
J:217463
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd/0
(B6.Cg-Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd)
|
increased hepatocellular carcinoma incidence
|
J:217463
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+ Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Tg(KRT14-cre)1Amc/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)
|
increased skin squamous cell carcinoma incidence
|
J:171057
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+ Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:222916
|
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:214230
|
Cop1Gt(XR0653)1.1Wtsi/Cop1Gt(XR0653)1.1Wtsi
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased histiocytic sarcoma incidence
|
J:178271
|
Cop1tm2.1Vmd/Cop1+ Tg(Pbsn-cre)4Prb/0
(B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb)
|
increased prostate gland adenocarcinoma incidence
|
J:172653
|
Coro1ctm1c(KOMP)Wtsi/Coro1ctm1c(KOMP)Wtsi Ptentm2Mak/Ptentm2Mak Trp53tm1Brn/Trp53tm1Brn Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0
(involves: 129P2/OlaHsd * C57BL/6N * FVB/NJ)
|
increased glioblastoma incidence
|
J:290447
|
Crebbptm1Dli/Crebbp+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:60630
|
Csf2tm1Dran/Csf2tm1Dran Ifngtm1Ts/Ifngtm1Ts Il3tm1Glli/Il3tm1Glli
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
|
increased carcinoma incidence
|
J:83086
|
increased ovarian carcinoma incidence
|
J:83086
|
Csnk1a1tm1.1Ybn/Csnk1a1+ Tg(Vil1-cre/ERT2)23Syr/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * C57BL/6 * CD-1 * DBA/2)
|
increased carcinoma incidence
|
J:204886
|
Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn Tg(Vil1-cre/ERT2)23Syr/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * C57BL/6 * CD-1 * DBA/2)
|
increased carcinoma incidence
|
J:204886
|
Ctnnb1tm1.2Wvv/Ctnnb1+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:185942
|
Ctnnb1tm1Mmt/Ctnnb1+ Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Prom1tm1(cre/ERT2)Gilb/Prom1+
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
increased intestinal adenocarcinoma incidence
|
J:144215
|
Ctnnb1tm1Mmt/Ctnnb1+ Igs2tm1(CAG-Met)Zsu/Igs2+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:284956
|
Ctnnb1tm1Mmt/Ctnnb1+ Pik3catm1Gilb/Pik3ca+ Trp53tm1Brn/Trp53+ Tg(Fabp7-cre,-lacZ)3Gtm/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
|
increased medulloblastoma incidence
|
J:186709
|
Ctnnb1tm1Mmt/Ctnnb1+ Ptentm1Hwu/Ptentm1Hwu Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:164579
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Msx2-rtTA)885Lma/0 Tg(tetO-cre)1Jaw/0
(involves: 129 * 129X1/SvJ * C57BL/6)
|
increased urinary bladder carcinoma incidence
|
J:202618
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased hepatoblastoma incidence
|
J:112659
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Pbsn-cre)4Prb/0
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:143034,
J:284956
|
Ctnnb1tm1Mmt/Ctnnb1+ Trp53tm1Brn/Trp53+ Tg(Fabp7-cre,-lacZ)3Gtm/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
|
increased medulloblastoma incidence
|
J:186709
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt Krastm4Tyj/Kras+ Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:234236
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt Ptentm1Hwu/Ptentm1Hwu Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:164579
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased hepatoblastoma incidence
|
J:112659
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt Tg(Upk2-cre)6Xrw/0 Tg(Upk2-HRAS*Q61L)5Xrw/0
(involves: 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:234236
|
Cul9tm1.2Yxi/Cul9+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased sarcoma incidence
|
J:170976
|
Cul9tm1.2Yxi/Cul9tm1.2Yxi
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased sarcoma incidence
|
J:170976
|
Cxcr6tm1Lex/Cxcr6+
(involves: 129S/SvEvBrd * C57BL/6J)
|
increased medulloblastoma incidence
|
J:120952
|
Cxcr6tm1Lex/Cxcr6tm1Lex
(involves: 129S/SvEvBrd * C57BL/6J)
|
increased medulloblastoma incidence
|
J:120952
|
Cytiptm1Tes/Cytiptm1Tes
(involves: 129S1/Sv * FVB/N)
|
increased sarcoma incidence
|
J:110320
|
Dcctm1.1Mehl/Dcctm1.1Mehl
(Not Specified)
|
increased intestinal adenocarcinoma incidence
|
J:181517
|
Dcctm1Nki/Dcctm1Nki Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/?
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:181090
|
increased spindle cell carcinoma incidence
|
J:181090
|
Dclre1atm1Rleg/Dclre1a+
(involves: 129S7/SvEvBrd)
|
increased histiocytic sarcoma incidence
|
J:102381
|
Dclre1atm1Rleg/Dclre1a+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd)
|
increased sarcoma incidence
|
J:102381
|
Dclre1atm1Rleg/Dclre1atm1Rleg
(involves: 129S7/SvEvBrd)
|
increased histiocytic sarcoma incidence
|
J:102381
|
increased sarcoma incidence
|
J:102381
|
Dcntm1Ioz/Dcntm1Ioz Trp53tm1Brd/Trp53tm1Brd
(involves: 129/Sv * Black Swiss * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:53511
|
Ddb2tm1Vri/Ddb2+
(involves: 129P2/Ola * SKH1)
|
increased squamous cell carcinoma incidence
|
J:103406
|
Ddb2tm1Vri/Ddb2tm1Vri
(involves: 129P2/Ola * SKH1)
|
increased squamous cell carcinoma incidence
|
J:103406
|
Ddit3tm1.1Irt/Ddit3tm1.1Irt Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ Tg(Mup3-Plau)350-2Eps/?
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:233146
|
Del(4C4-C5)1Lap/Del(4C4-C5)1Lap
(involves: 129S6/SvEvTac)
|
increased hemangiosarcoma incidence
|
J:158126
|
increased osteosarcoma incidence
|
J:158126
|
increased sarcoma incidence
|
J:158126
|
Del(4Cdkn2a-Cdkn2b)1Brn/+
(involves: 129P2/OlaHsd)
|
increased sarcoma incidence
|
J:125189
|
Del(4Cdkn2a-Cdkn2b)2Brn/+
(involves: 129P2/OlaHsd * FVB/N)
|
increased intestinal adenocarcinoma incidence
|
J:125189
|
increased melanoma incidence
|
J:125189
|
increased sarcoma incidence
|
J:125189
|
Del(4D4Mit190-D4Mit51)2Aam/+
(involves: 129S7/SvEvBrd)
|
increased squamous cell carcinoma incidence
|
J:121726
|
Del(15Krt7-Krt18)1Tmm/+ Igs11tm1Tmm/Igs11+ Krt1ctm1Tmm/Krt1c+ Tg(ACTB-KRAS*G12V,-luc)#Lche/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:199528
|
DgkdGt(RRT600)Byg/Dgkd+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased sarcoma incidence
|
J:126380
|
Dicer1tm1Mmk/Dicer1tm1Mmk Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * C57BL/6 * CD-1)
|
increased myeloid sarcoma incidence
|
J:158901
|
Dicer1tm1Snj/Dicer1tm1Snj Trp53tm1Brn/Trp53+ Tg(KRT5-cre/PGR)1Der/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6N * FVB/N * ICR)
|
increased basal cell carcinoma incidence
|
J:216813
|
Dicer1tm1Snj/Dicer1tm1Snj Trp53tm1Brn/Trp53tm1Brn Tg(KRT5-cre/PGR)1Der/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6N * FVB/N * ICR)
|
increased skin squamous cell carcinoma incidence
|
J:216813
|
Dicer1tm1Tara/Dicer1tm1Tara Ptentm1Hwu/Ptentm1Hwu Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
increased carcinoma incidence
|
J:182161
|
increased ovarian carcinoma incidence
|
J:182161
|
Dicer1tm1Tara/Dicer1tm1Tara Ptentm1Hwu/Ptentm1Hwu Trp53tm2Tyj/Trp53+ Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
increased carcinoma incidence
|
J:222579
|
increased ovarian carcinoma incidence
|
J:222579
|
Diras2em1Gpt/Diras2em1Gpt Krastm4Tyj/Kras+ Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae * C57BL/6J * C57BL/6JGpt)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:348744
|
Dkc1tm1Ppp/Y
(involves: 129S1/Sv)
|
increased fibrosarcoma incidence
|
J:81054
|
increased lung carcinoma incidence
|
J:81054
|
increased malignant tumor incidence
|
J:81054
|
increased mammary adenocarcinoma incidence
|
J:81054
|
increased renal carcinoma incidence
|
J:81054
|
Dlg2tm1a(EUCOMM)Wtsi/Dlg2tm1a(EUCOMM)Wtsi Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * C57BL/6N * FVB/N)
|
increased osteosarcoma incidence
|
J:269943
|
Dmtf1tm1Cjs/Dmtf1+ Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
|
increased cholangiocarcinoma incidence
|
J:126002
|
increased lung adenocarcinoma incidence
|
J:126002
|
increased osteosarcoma incidence
|
J:126002
|
Dmtf1tm1Cjs/Dmtf1+ Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:126002
|
Dmtf1tm1Cjs/Dmtf1tm1Cjs Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:126002
|
Dmtf1tm1Cjs/Dmtf1tm1Cjs Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:126002
|
Dna2tm1.1Lzhg/Dna2+
(involves: 129S1/Sv)
|
increased lung adenocarcinoma incidence
|
J:198831
|
Dnai7Gt(VICTR21)709Lex/Dnai7+
(involves: 129S5/SvEvBrd)
|
increased lung adenocarcinoma incidence
|
J:111629
|
Dnai7Gt(VICTR21)709Lex/Dnai7Gt(VICTR21)709Lex
(involves: 129S5/SvEvBrd)
|
increased lung adenocarcinoma incidence
|
J:111629
|
Dnmt1tm1Jae/Dnmt1+ Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:75745
|
Dnmt1tm1Pwl/Dnmt1+ Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:75745
|
Dock1tm2.1Jfco/Dock1+ Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: C57BL/6 * FVB/NJ)
|
increased mammary adenocarcinoma incidence
|
J:196659
|
Dock1tm2.1Jfco/Dock1tm2.1Jfco Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: C57BL/6 * FVB/NJ)
|
increased mammary adenocarcinoma incidence
|
J:196659
|
Dok1tm1Ppp/Dok1tm1Ppp
(129S1/Sv-Dok1tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dok1tm1Ppp/Dok1tm1Ppp Dok2tm1Ppp/Dok2tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok2tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dok1tm1Ppp/Dok1tm1Ppp Dok2tm1Ppp/Dok2tm1Ppp Dok3tm1Ppp/Dok3tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok2tm1Ppp Dok3tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dok1tm1Ppp/Dok1tm1Ppp Dok3tm1Ppp/Dok3tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok3tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dok1tm1Yyam/Dok1tm1Yyam Dok2tm1Yyam/Dok2tm1Yyam
(B6.129-Dok1tm1Yyam Dok2tm1Yyam)
|
increased sarcoma incidence
|
J:95335
|
Dok1tm1Yyam/Dok1tm1Yyam Dok2tm1Yyam/Dok2tm1Yyam Dok3tm1Brs/Dok3tm1Brs
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:163407
|
Dok2tm1Ppp/Dok2tm1Ppp
(129S1/Sv-Dok2tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dok3tm1Ppp/Dok3tm1Ppp
(129S1/Sv-Dok3tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
E2f1tm1Njd/E2f1tm1Njd
(involves: 129S2/SvPas * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:33099
|
increased lung adenocarcinoma incidence
|
J:33099
|
increased lung non-small cell carcinoma incidence
|
J:33099
|
Eaf2tm1Zhow/Eaf2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:145228
|
Eaf2tm1Zhow/Eaf2tm1Zhow
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:145228
|
increased lung adenocarcinoma incidence
|
J:145228
|
Ednrbtm1Ywa/Ednrb+ Tg(Mt1-RET)304Ina/0
(involves: 129S7/SvEvBrd * BALB/c * C57BL/6)
|
increased melanoma incidence
|
J:155735
|
Eef1a1tm1(Kras*)Arge/Eef1a1+ Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary adenocarcinoma incidence
|
J:146290
|
Eef1e1Gt(OST377244)Lex/Eef1e1+
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased malignant tumor incidence
|
J:96923
|
Elavl1tm1.1Dkon/Elavl1tm1.1Dkon Lyz2tm1(cre)Ifo/Lyz2+
(B6.129P2-Elavl1tm1.1Dkon Lyz2tm1(cre)Ifo)
|
increased colon adenocarcinoma incidence
|
J:184388
|
Entpd5tm1Rre/Entpd5tm1Rre
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:163795
|
Ergtm1.1Sho/Ergtm1.1Sho Ptentm1Hwu/Ptentm1Hwu Tmprss2tm3Sho/Tmprss2tm3Sho Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:212219
|
Errfi1tm1Jwj/Errfi1tm1Jwj Pgrtm2(cre)Lyd/Pgr+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased endometrial carcinoma incidence
|
J:150007
|
Errfi1tm1Jwj/Errfi1tm1Jwj Pgrtm2(cre)Lyd/Pgr+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased endometrial carcinoma incidence
|
J:162027
|
Errfi1tm1Kln/Errfi1tm1Kln
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased carcinoma incidence
|
J:109556
|
Espl1Gt(XL058)Byg/Espl1+ Trp53tm1Tyj/Trp53+
(B6.129-Trp53tm1Tyj Espl1Gt(XL058)Byg)
|
increased carcinoma incidence
|
J:174926
|
Espl1Gt(XL058)Byg/Espl1+ Trp53tm1Tyj/Trp53tm1Tyj
(B6.129-Trp53tm1Tyj Espl1Gt(XL058)Byg)
|
increased carcinoma incidence
|
J:174926
|
Esr1tm1Ksk/Esr1tm1Ksk Tg(Wnt1)1Hev/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:54215
|
Exo1tm2Wed/Exo1tm2Wed
(involves: 129 * C57BL/6)
|
increased sarcoma incidence
|
J:198719
|
Exo1tm3.1Wed/Exo1tm3.1Wed
(involves: 129 * C57BL/6)
|
increased sarcoma incidence
|
J:198719
|
Exo1tm3.1Wed/Exo1tm3.1Wed Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased sarcoma incidence
|
J:198719
|
F2rtm1Pago/F2rtm1Pago Tg(MMTV-PyVT)634Mul/0
(B6.Cg-F2rtm1Pago Tg(MMTV-PyVT)634Mul)
|
increased mammary adenocarcinoma incidence
|
J:138924
|
F2rl1tm1Bpd/F2rl1tm1Bpd Tg(MMTV-PyVT)634Mul/0
(B6.Cg-F2rl1tm1Bpd Tg(MMTV-PyVT)634Mul)
|
increased mammary adenocarcinoma incidence
|
J:138924
|
F3tm1(F3)Lasn/F3tm1(F3)Lasn
(involves: 129S/SvEvBrd * C57BL/6)
|
increased lung carcinoma incidence
|
J:133293
|
Fahtm1Mgo/Fahtm1Mgo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:138701
|
Fahtm1Mgo/Fahtm1Mgo
(involves: 129S7/SvEvBrd * C57BL)
|
increased hepatocellular carcinoma incidence
|
J:27735
|
Fancd2Gt(OST57859)Lex/Fancd2Gt(OST57859)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased carcinoma incidence
|
J:146616
|
Fancd2tm1Hou/Fancd2tm1Hou
(129S4/SvJae-Fancd2tm1Hou)
|
increased carcinoma incidence
|
J:84892
|
Fancd2tm1Hou/Fancd2tm1Hou
(involves: 129S4/SvJae * C57BL/6J)
|
increased carcinoma incidence
|
J:84892
|
Faslgld/Faslgld
(involves: C3H/HeJ * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:153501
|
Fasltm1.1Ast/Fasltm1.1Ast
(involves: BALB/cJ * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:153501
|
Fbxo4tm1.1Jadi/Fbxo4+
(Not Specified)
|
increased hepatocellular carcinoma incidence
|
J:178645
|
increased histiocytic sarcoma incidence
|
J:178645
|
increased myeloid sarcoma incidence
|
J:178645
|
Fbxo4tm1.1Jadi/Fbxo4tm1.1Jadi
(Not Specified)
|
increased hepatocellular carcinoma incidence
|
J:178645
|
increased histiocytic sarcoma incidence
|
J:178645
|
increased myeloid sarcoma incidence
|
J:178645
|
Fbxw7tm1Iken/Fbxw7tm1Iken Krastm4Tyj/Kras+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA)
|
increased cholangiocarcinoma incidence
|
J:258194
|
Fdxrtm1Xch/Fdxr+
(B6.Cg-Fdxrtm1Xch)
|
increased hemangiosarcoma incidence
|
J:244082
|
increased hepatocellular carcinoma incidence
|
J:244082
|
increased lung carcinoma incidence
|
J:244082
|
increased myeloid sarcoma incidence
|
J:244082
|
increased sarcoma incidence
|
J:244082
|
Fen1tm1Rak/Fen1+ Apctm1Rak/Apc+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * SJL/J)
|
increased malignant tumor incidence
|
J:77962
|
Fen1tm2Klng/Fen1tm2Klng
(involves: 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:138901
|
Fen1tm3.1Bhsh/Fen1tm3.1Bhsh
(Not Specified)
|
increased lung adenocarcinoma incidence
|
J:231218
|
Fgfr4tm1Axul/Fgfr4+ Tg(WapTgfa)215Bri/0
(B6.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
|
increased mammary adenocarcinoma incidence
|
J:156750
|
Fgfr4tm1Axul/Fgfr4tm1Axul Tg(WapTgfa)215Bri/0
(B6.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
|
increased mammary adenocarcinoma incidence
|
J:156750
|
Fgfr4tm1Axul/Fgfr4tm1Axul Tg(WapTgfa)215Bri/0
(FVB.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
|
increased mammary adenocarcinoma incidence
|
J:156750
|
Fhittm1Tko/Fhittm1Tko
(involves: 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:93269
|
Flcntm1Btt/Flcntm1Btt Tg(Cdh16-cre)91Igr/0
(involves: 129S4/SvJaeSor * C57BL/6 * ICR)
|
increased renal carcinoma incidence
|
J:143922
|
Flt3tm2.1Dosm/Flt3+
(B6.129(C)-Flt3tm2.1Dosm)
|
increased hemangiosarcoma incidence
|
J:205200
|
increased histiocytic sarcoma incidence
|
J:205200
|
Fn1tm1Bwg/Fn1tm1Bwg Tg(RIP1-Tag)2Dh/0
(involves: 129S4/SvJae * BALB/c * C57BL/6J)
|
increased carcinoma incidence
|
J:93027
|
Fn1tm1Ksek/Fn1tm1Ksek Tg(RIP1-Tag)2Dh/0
(involves: 129S4/SvJae * C57BL/6J)
|
increased carcinoma incidence
|
J:93027
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg Krastm4Tyj/Kras+ Pggt1btm1Mbrg/Pggt1btm1.1Mbrg
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N)
|
increased lung carcinoma incidence
|
J:158937
|
Fntbtm1Bbd/Fntbtm1Bbd Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased lung adenocarcinoma incidence
|
J:98944
|
Fostm1Wag/Fostm1Wag Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased rhabdomyosarcoma incidence
|
J:89283
|
Fostm1Wag/Fostm1Wag Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased rhabdomyosarcoma incidence
|
J:89283
|
Foxa1tm1Khk/Foxa1tm1Khk Foxa2tm1Khk/Foxa2tm1Khk Tg(Alb1-cre)1Khk/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased hepatocellular carcinoma incidence
|
J:181296
|
Foxm1tm1Rhc/Foxm1tm1Rhc
(involves: 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:89472
|
Foxn1nu-str/Foxn1nu-str
(AKR/J-Foxn1nu-str/J)
|
increased sarcoma incidence
|
J:30715
|
Foxo1tm1Rdp/Foxo1tm1Rdp Foxo3tm1Rdp/Foxo3tm1Rdp Foxo4tm1Rdp/Foxo4tm1Rdp Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased hemangiosarcoma incidence
|
J:118179
|
Foxo1tm1Rdp/Foxo1tm1Rdp Foxo3tm1Rdp/Foxo3tm1Rdp Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased hemangiosarcoma incidence
|
J:118179
|
Foxo1tm1Rdp/Foxo1tm1Rdp Foxo4tm1Rdp/Foxo4tm1Rdp Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased hemangiosarcoma incidence
|
J:118179
|
Foxo3tm1.1Rdp/Foxo3tm1.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
|
increased hemangiosarcoma incidence
|
J:118179
|
Fshrtm1Saco/Fshrtm1Saco
(involves: 129)
|
increased ovarian carcinoma incidence
|
J:70933
|
Fzr1tm1.1Mama/Fzr1+
(involves: BALB/cJ * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:137456
|
Gadd45atm1Ajf/Gadd45atm1Ajf Xpctm1Ecf/Xpctm1Ecf
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129X1/SvJ * C57BL/6))
|
increased lung adenocarcinoma incidence
|
J:101421
|
Gfertm1.1Crg/Gfertm1.1Crg Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:227242
|
Gli1tm3(cre/ERT2)Alj/Gli1+ Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:139574
|
Gnai2tm1Lbi/Gnai2tm1Lbi
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:24434
|
Gnai2tm1Lbi/Gnai2tm1Lbi
(involves: 129S7/SvEvBrd)
|
increased intestinal adenocarcinoma incidence
|
J:24434
|
Gnmttm1Ymac/Gnmttm1Ymac
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:146081
|
Gon4ljusty/Gon4ljusty
(C3HeB/FeJ-Gon4ljusty)
|
increased salivary adenocarcinoma incidence
|
J:197352
|
Gpr37l1tm1.2Gtva/Gpr37l1tm1.2Gtva Ptch1tm1Zim/Ptch1+
(STOCK Gpr37l1tm1.2Gtva Ptch1tm1Zim/Cnrm)
|
increased medulloblastoma incidence
|
J:272049
|
Gprc5atm1Rlo/Gprc5atm1Rlo
(involves: 129 * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:127821
|
Gpx7tm1Whle/Gpx7tm1Whle
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:193993
|
increased mammary adenocarcinoma incidence
|
J:193993
|
increased sarcoma incidence
|
J:193993
|
Grb2tm1Paw/Grb2+ Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased endometrial carcinoma incidence
|
J:93530
|
Grb2tm1Paw/Grb2+ Tg(MMTV-PyVT)634Mul/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:51424
|
Grhl3tm1Jane/Grhl3+ Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * 129S1/Sv)
|
increased skin squamous cell carcinoma incidence
|
J:178952
|
Grhl3tm1Jane/Grhl3tm3.1Jane Tg(KRT14-cre)8Brn/0
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
increased skin squamous cell carcinoma incidence
|
J:178952
|
Grm1Tg(p18A4.B)1352Szc/0
(Not Specified)
|
increased cutaneous melanoma incidence
|
J:83183,
J:32786
|
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sor+ Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased malignant tumor incidence
|
J:234601
|
increased prostate gland adenocarcinoma incidence
|
J:234601
|
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sortm1(CAG-AR)Zsu Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:234601
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+ Ptentm1Mro/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:184533
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+ Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Gfap-cre)2Brn/0
(either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N))
|
increased carcinoma incidence
|
J:187257
|
increased medulloblastoma incidence
|
J:187257
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+ Tg(Dbh-icre)1Gsc/0
(involves: 129S6/SvEvTac * C57BL/6)
|
increased neuroblastoma incidence
|
J:222527
|
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+ Tg(MMTV-cre)7Mul/0
(involves: BALB/c * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:173655
|
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+ Tg(Wap-cre)1Gsc/0
(involves: BALB/c * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:173655
|
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh/Gt(ROSA)26Sor+ Tg(Sftpc-cre)1Blh/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:161806
|
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh/Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
(involves: 129S6/SvEv * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:161806
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+ Pdgfratm12Sor/Pdgfra+
(involves: 129 * C57BL/6)
|
increased sarcoma incidence
|
J:146617
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129 * 129S4/SvJae * BALB/c * C57BL/6)
|
increased skin squamous cell carcinoma incidence
|
J:130367
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc
(involves: 129 * 129S1/Sv * 129X1/SvJ)
|
increased sarcoma incidence
|
J:147728
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm4(EWSR1/ATF1)Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:217462
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:280854
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0 Trp53tm1Brn/Trp53+
(involves: 129 * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:289183
|
Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sor+ Tg(Mitf-cre)7114Gsb/0
(C3FeJ.Cg-Gt(ROSA)26Sortm1(GNAQ*)Cvkr Tg(Mitf-cre)7114Gsb/Cvrk)
|
increased intraocular melanoma incidence
|
J:225597
|
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))
|
increased histiocytic sarcoma incidence
|
J:172031
|
increased sarcoma incidence
|
J:172031
|
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+ Ighg1tm1(cre)Cgn/Ighg1+
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))
|
increased histiocytic sarcoma incidence
|
J:172031
|
increased sarcoma incidence
|
J:172031
|
Gt(ROSA)26Sortm1(JAG1)Xin/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)20Fwan/?
(involves: 129S4/SvJae * C57BL/6 * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:238768
|
Gt(ROSA)26Sortm1(MAML1)Wsp/Gt(ROSA)26Sor+ Tg(Tagln-cre)1Jjl/0
(involves: CD-1 * FVB/N)
|
increased squamous cell carcinoma incidence
|
J:112093
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu Tg(Adipoq-cre)1Evdr/0
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/NJ)
|
increased liposarcoma incidence
|
J:237232
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+ Tg(Adipoq-cre)1Evdr/0
(involves: 129S4/SvJaeSor * C57BL/6J * FVB/NJ)
|
increased liposarcoma incidence
|
J:237232
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+ TgTn(pb-sb-ATP1)S1Brd/0
(involves: 129S7/SvEvBrd * FVB)
|
increased carcinoma incidence
|
J:166063
|
increased sarcoma incidence
|
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+ TgTn(pb-sb-ATP1)S2Brd/0
(involves: 129S7/SvEvBrd * FVB)
|
increased carcinoma incidence
|
J:166063
|
increased sarcoma incidence
|
J:166063
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+ Tg(MMTV-cre)#Tfln/0
(involves: 129S6/SvEvTac)
|
increased mammary adenocarcinoma incidence
|
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+ Tg(MMTV-cre)#Tfln/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
increased mammary adenocarcinoma incidence
|
J:170898
|
Gt(ROSA)26Sortm1(RAC1*)Jkis/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:187582
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras2)12Hev/0 Trp53tm1Tyj/Trp53+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:184378
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras*G12D)#Rdp/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras*G12D)#Rdp/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras*G12D)#Rdp/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186194
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ Hprt1tm1(sb-Onco-Array)Peli/Y
(involves: 129S7/SvEvBrd)
|
increased hemangiosarcoma incidence
|
J:166283
|
increased lung adenocarcinoma incidence
|
J:166283
|
increased medulloblastoma incidence
|
J:166283
|
increased rhabdomyosarcoma incidence
|
J:166283
|
increased skin squamous cell carcinoma incidence
|
J:166283
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ Hprt1tm1(sb-Onco-Array)Peli/Hprt1+
(involves: 129S7/SvEvBrd)
|
increased hemangiosarcoma incidence
|
J:166283
|
increased lung adenocarcinoma incidence
|
J:166283
|
increased medulloblastoma incidence
|
J:166283
|
increased rhabdomyosarcoma incidence
|
J:166283
|
increased skin squamous cell carcinoma incidence
|
J:166283
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6057Njen/0
(involves: C3H * C57BL/6)
|
increased medulloblastoma incidence
|
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6070Njen/0
(involves: C3H * C57BL/6)
|
increased medulloblastoma incidence
|
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc3)12740Njen/0
(involves: C3H * C57BL/6J)
|
increased basal cell carcinoma incidence
|
J:153656
|
increased blastoma incidence
|
J:153656
|
increased carcinoma incidence
|
J:153656
|
increased hemangiosarcoma incidence
|
J:153656
|
increased hepatocellular carcinoma incidence
|
J:153656
|
increased lung carcinoma incidence
|
J:153656
|
increased melanoma incidence
|
J:153656
|
increased sarcoma incidence
|
J:153656
|
increased skin squamous cell carcinoma incidence
|
J:153656
|
increased squamous cell carcinoma incidence
|
J:153656
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/? Tg(CAG-cre/Esr1*)5Amc/?
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased basal cell carcinoma incidence
|
J:114992
|
increased medulloblastoma incidence
|
J:114992
|
increased rhabdomyosarcoma incidence
|
J:114992
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+ Hk2tm1.1Uku/Hk2+ Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased medulloblastoma incidence
|
J:210113
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+ Hk2tm1.1Uku/Hk2tm1.1Uku Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased medulloblastoma incidence
|
J:210113
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc Olig2tm2(TVA,cre)Rth/Olig2+
(involves: 129 * 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc Tg(Atoh1-cre/Esr1*)14Fsh/0
(involves: 129X1/SvJ * FVB/N)
|
increased medulloblastoma incidence
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc Tg(GFAP-cre)25Mes/0
(involves: 129X1/SvJ * FVB/N)
|
increased medulloblastoma incidence
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc Tg(Krt1-5-cre/ERT)1Ipc/0
(involves: 129X1/SvJ * C57BL/6 * SJL)
|
increased basal cell carcinoma incidence
|
J:158915
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc Tlx3tm1(cre)Qima/Tlx3+
(involves: 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm2(EGFP/cre)Alj Pgbd5tm1.1Aken/Pgbd5tm1.1Aken
(involves: 129 * C57BL/6J * C57BL/6NTac * SW)
|
increased medulloblastoma incidence
|
J:346387
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+ Ptentm2.1Ppp/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:239660
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:239660
|
Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:200002
|
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6J)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:140423
|
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+ Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:140423
|
Gt(ROSA)26Sortm1.1(rtTA2S*M2)Whsu/Gt(ROSA)26Sor+ Ncstntm1.1Akli/Ncstntm1.1Akli Tg(tetO-cre)1Jaw/0
(involves: 129 * 129S6/SvEvTac * C57BL/6)
|
increased urinary bladder carcinoma incidence
|
J:227748
|
Gt(ROSA)26Sortm2(CAG-Lin28b,-luc)Jhsc/Gt(ROSA)26Sor+ Tg(Dbh-icre)1Gsc/0
(involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
|
increased neuroblastoma incidence
|
J:241988
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+ Tg(RasE)290Biat/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:226601
|
increased pancreatic ductal adenocarcinoma incidence
|
J:226601
|
Gt(ROSA)26Sortm2(myc*T58A)Rcse/Gt(ROSA)26Sortm2(myc*T58A)Rcse Tg(Wap-cre)11738Mam/0
(involves: 129 * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:169403
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+ Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S6/SvEvTac)
|
increased carcinoma incidence
|
J:197054
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197054
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ TgTn(sb-T2/Onc)68Dla/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:147264
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+ Tg(Vil1-cre)20Syr/0 TgTn(sb-T2/Onc)68Dla/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased small intestine adenocarcinoma incidence
|
J:146887
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+ Tg(Vil1-cre)20Syr/0 TgTn(sb-T2/Onc)76Dla/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased small intestine adenocarcinoma incidence
|
J:146887
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+ Trp53tm3Tyj/Trp53+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ TgTn(sb-T2/Onc)68Dla/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:147264
|
Gt(ROSA)26Sortm2(SS18)Mrc/Gt(ROSA)26Sortm2(SS18)Mrc Myf5tm1(cre)Mrc/Myf5tm1(cre)Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:120967
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu Trp53tm1Thl/Trp53tm1Thl Tyrc-Brd/Tyrc-Brd
(involves: 129/Sv * 129S4/SvJae * C57BL/6)
|
increased glioblastoma incidence
|
J:172585
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu Tyrc-Brd/Tyrc-Brd
(involves: 129/Sv * 129S4/SvJae * C57BL/6)
|
increased glioblastoma incidence
|
J:172585
|
Gt(ROSA)26Sortm3(SS18/EGFP)Mrc/Gt(ROSA)26Sortm3(SS18/EGFP)Mrc Myf5tm1(cre)Mrc/Myf5tm1(cre)Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:120967
|
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+ Npm1tm1Gsva/Npm1+ TgTn(pb-sb-GrOnc)#aGsva/0 Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased hemangiosarcoma incidence
|
J:172071
|
Gt(ROSA)26Sortm5(ASPSCR1/TFE3)Mrc/Gt(ROSA)26Sortm1(cre/ERT)Nat
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:217462
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+ Hmga2tm1.1Mmw/Hmga2+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm2Tyj/Trp53+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Prdm1tm1Clme/Prdm1tm1Clme Tg(Pdx1-cre)6Tuv/0 Trp53tm2Tyj/Trp53+
(involves: 129 * C57BL/6NCrl * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm2Tyj/Trp53+
(involves: 129 * C57BL/6NCrl * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:245611
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/0 Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CBA * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:4527
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:34434,
J:101128
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+ Tg(Alb-E2F1)8Sst/0
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:101128
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+ Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CBA * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:34434
|
H2axtm1Fwa/H2ax+ Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased sarcoma incidence
|
J:84879
|
H2axtm1Fwa/H2axtm1Fwa Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased colon adenocarcinoma incidence
|
J:84879
|
increased sarcoma incidence
|
J:84879
|
Hat1tm1.1Mrpa/Hat1+
(B6.Cg-Hat1tm1.1Mrpa)
|
increased histiocytic sarcoma incidence
|
J:296531
|
Hcktm1Ern/Hcktm1Ern
(involves: 129S1/Sv * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:111432
|
Hic1tm1Sbb/Hic1+
(involves: 129S4/SvJae * C57BL/6)
|
increased carcinoma incidence
|
J:81448
|
increased hepatocellular carcinoma incidence
|
J:81448
|
increased lung adenocarcinoma incidence
|
J:81448
|
increased malignant tumor incidence
|
J:81448
|
increased pancreatic islet cell carcinoma incidence
|
J:81448
|
increased sarcoma incidence
|
J:81448
|
increased squamous cell carcinoma incidence
|
J:81448
|
Hip1tm4Tsr/Hip1+ Tg(Mx1-cre)1Cgn/0
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:151974
|
Hmgn1tm1Mbus/Hmgn1tm1Mbus
(involves: 129X1/SvJ)
|
increased malignant tumor incidence
|
J:100773
|
Hprt1tm1(CAG-BRF1)Gu/Hprt1+ Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:285667
|
Hprt1tm1(CUX1)Anep/Hprt1+
(FVB.129P2-Hprt1tm1(CUX1)Anep)
|
increased mammary adenocarcinoma incidence
|
J:152682
|
Hprt1tm1(Pbsn*-cre/ERT2)Jir/Y Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:144357
|
Hprt1tm2(CUX1)Anep/Hprt1+
(FVB.129P2-Hprt1tm2(CUX1)Anep)
|
increased mammary adenocarcinoma incidence
|
J:152682
|
Hrhr/Hrhr Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd)
|
increased skin squamous cell carcinoma incidence
|
J:79734
|
Hrhr/Hrhr Msh2tm1Htr/Msh2tm1Htr Xpatm1Tnka/Xpatm1Tnka
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased skin squamous cell carcinoma incidence
|
J:79734
|
Hrhr/Hrhr Tg(KRT14-Birc5)19Gros/0
(involves: C3H * C57BL/6 * SKH1)
|
increased squamous cell carcinoma incidence
|
J:95011
|
Hrastm1Jaf/Hras+ Tg(CAG-cre)13Miya/0
(involves: 129S6/SvEvTac * Black Swiss * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:148393
|
Hrastm2Xbr/Hrastm2Xbr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:137729
|
Hspa5tm1Alee/Hspa5+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/?
(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:142106
|
Htatip2tm1Hx/Htatip2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased carcinoma incidence
|
J:87066
|
increased hemangiosarcoma incidence
|
J:87066
|
increased hepatocellular carcinoma incidence
|
J:87066
|
increased malignant tumor incidence
|
J:87066
|
increased neuroblastoma incidence
|
J:87066
|
increased urinary bladder transitional cell carcinoma incidence
|
J:87066
|
Htatip2tm1Hx/Htatip2tm1Hx
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased carcinoma incidence
|
J:87066
|
increased duodenum adenocarcinoma incidence
|
J:87066
|
increased hepatocellular carcinoma incidence
|
J:87066
|
increased malignant tumor incidence
|
J:87066
|
increased sarcoma incidence
|
J:87066
|
Ifngtm1Ts/Ifngtm1Ts
(B6.129S7-Ifngtm1Ts)
|
increased sarcoma incidence
|
J:77491
|
Ifngtm1Ts/Ifngtm1Ts
(C.129S7-Ifngtm1Ts)
|
increased lung adenocarcinoma incidence
|
J:77491
|
Igs2tm1(CAG-Met)Zsu/Igs2+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2 * FVB/N)
|
increased carcinoma incidence
|
J:268934
|
increased prostate gland adenocarcinoma incidence
|
J:268934
|
Ikbkgtm1.1Chtr/Y Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased hepatocellular carcinoma incidence
|
J:151485
|
Ikbkgtm1.1Chtr/Ikbkgtm1.1Chtr Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased hepatocellular carcinoma incidence
|
J:151485
|
Ikbkgtm1.1Chtr/Ikbkgtm1.1Chtr Tg(Alb1-cre)7Gsc/0
(involves: FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:160521
|
Ikbkgtm1.1Mpa/Ikbkgtm1.1Mpa Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:118336
|
Il6tm1Kopf/Il6+ Ncoa5tm1Hxia/Ncoa5+
(involves: 129S2/SvPas * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:207622
|
Il10tm1Cgn/Il10tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:68476
|
increased large intestine adenocarcinoma incidence
|
J:35020
|
Il10tm1Cgn/Il10tm1Cgn
(B6.129P2-Il10tm1Cgn/J)
|
increased colon adenocarcinoma incidence
|
J:149347
|
Il10tm1Cgn/Il10tm1Cgn Tg(MUC1)79.24Gend/0
(B6.Cg-Il10tm1Cgn Tg(MUC1)79.24Gend)
|
increased colon adenocarcinoma incidence
|
J:149347
|
Il12rb2tm1Jm/Il12rb2tm1Jm
(B6;129S1-Il12rb2tm1Jm/J)
|
increased lung carcinoma incidence
|
J:106805
|
Immp2lTg(HLA-A/H2-D)2Enge/0 Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6 * CBA/Ca)
|
increased melanoma incidence
|
J:130879
|
Ing2tm1.1Ccha/Ing2tm1.1Ccha
(involves: 129 * C57BL/6J * FVB/N)
|
increased histiocytic sarcoma incidence
|
J:167311
|
increased sarcoma incidence
|
J:167311
|
Ino80tm1.1Schg/Ino80+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6J)
|
increased sarcoma incidence
|
J:221224
|
Iqgap1tm1Aber/Iqgap1tm1Aber Iqgap2tm1Vs/Iqgap2tm1Vs
(involves: 129S4/SvJae)
|
increased hepatocellular carcinoma incidence
|
J:132670
|
Iqgap2tm1Vs/Iqgap2tm1Vs
(either: 129S4/SvJae-Iqgap2tm1Vs or B6.129S4-Iqgap2tm1Vs)
|
increased hepatocellular carcinoma incidence
|
J:132670
|
Iqgap2tm1Vs/Iqgap2tm1Vs
(involves: 129S4/SvJae)
|
increased hepatocellular carcinoma incidence
|
J:205882
|
Irf1tm1Mak/Irf1tm1Mak Tg(HRAS)2Jic/?
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:55418
|
Irf1tm1Mak/Irf1tm1Mak Trp53tm1Sia/Trp53tm1Sia
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
increased hemangiosarcoma incidence
|
J:55418
|
Itgavtm2Hyn/Itgavtm2.1Hyn Tg(Tek-cre)1Ywa/?
(involves: 129S2/SvPas * C57BL/6 * FVB * SJL)
|
increased intestinal adenocarcinoma incidence
|
J:125508
|
KitW-v/Kit+ Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6)
|
increased melanoma incidence
|
J:88074
|
KitW-v/KitW-v Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6)
|
increased melanoma incidence
|
J:88074
|
KitlSl-d/KitlSl-d Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6 * DBA/2)
|
increased melanoma incidence
|
J:88074
|
Kmt2atm1(AFF1)Ksy/Kmt2a+
(involves: 129S1/Sv * C57BL/6 * FVB)
|
increased malignant tumor incidence
|
J:110241
|
Krastm1.1Khai/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:276349
|
Krastm1Bbd/Kras+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+ Map2k1tm1Chrn/Map2k1tm1Chrn
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+ Map2k2tm1Chrn/Map2k2tm1Chrn
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+ Mapk1tm1.1Hed/Mapk1tm1.1Hed
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+ Mapk3tm1Gpg/Mapk3tm1Gpg
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+ Mapk14tm1Nbr/Mapk14tm2Nbr Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased lung adenocarcinoma incidence
|
J:122397
|
Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:161780
|
Krastm1Bbd/Kras+ Tg(CMV-cre)1Cgn/?
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:86101
|
increased sarcoma incidence
|
J:86101
|
Krastm1Bbd/Kras+ Tg(CMV-cre/ERT)1Ipc/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased lung adenocarcinoma incidence
|
J:86101
|
Krastm1Bbd/Kras+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:143034
|
Krastm1Bbd/Kras+ Trp53tm1Brd/Trp53+ Tg(Cela1-tTA)#Eps/? Tg(tetO-cre)3Jig/?
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:119988
|
Krastm1Bbd/Krastm1Bbd Tg(Cela1-tTA)#Eps/? Tg(tetO-cre)3Jig/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:119988
|
Krastm1Bbd/Krastm2Bbd Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:161780
|
Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:68981
|
Krastm2Tyj/Kras+
(involves: 129S2/SvPas)
|
increased carcinoma incidence
|
J:129627
|
increased fibrosarcoma incidence
|
J:129627
|
increased hemangiosarcoma incidence
|
J:129627
|
increased lung adenocarcinoma incidence
|
J:136369
|
increased sarcoma incidence
|
J:129627
|
increased squamous cell carcinoma incidence
|
J:129627
|
Krastm2Tyj/Kras+ Trp53tm1Glo/Trp53+
(involves: 129S2/SvPas * 129S7/SvEvBrd)
|
increased fibrosarcoma incidence
|
J:129627
|
increased hemangiosarcoma incidence
|
J:129627
|
increased squamous cell carcinoma incidence
|
J:129627
|
Krastm2Tyj/Kras+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased fibrosarcoma incidence
|
J:68981
|
increased hemangiosarcoma incidence
|
J:68981
|
Krastm2Tyj/Kras+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased fibrosarcoma incidence
|
J:68981
|
increased hemangiosarcoma incidence
|
J:68981
|
Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:68981
|
Krastm3Tyj/Kras+ Tg(CAG-Mir21,-EGFP)#Eno/0
(involves: 129S4/SvJae * C3H * C57BL/6)
|
increased lung non-small cell carcinoma incidence
|
J:164198
|
Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:207982,
J:333347
|
Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:147590
|
increased lung carcinoma incidence
|
J:158937
|
Krastm4Tyj/Kras+
(B6.129S4-Krastm4Tyj)
|
increased lung adenocarcinoma incidence
|
J:177379
|
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
Krastm4Tyj/Kras+ Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+ Tg(Pdx1-cre)6Tuv/0 TgTn(sb-T2/Onc)#Dla/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186717
|
Krastm4Tyj/Kras+ Map2k7tm1.1Twad/Map2k7tm1.2Twad
(B6.Cg-Krastm4Tyj Map2k7tm1.1Twad/Map2k7tm1.2Twad)
|
increased lung adenocarcinoma incidence
|
J:170904
|
Krastm4Tyj/Kras+ Map2k7tm1.1Twad/Map2k7tm1.2Twad Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:170904
|
Krastm4Tyj/Kras+ Myod1tm1.1(cre/ERT,TVA)Gcg/Myod1+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased sarcoma incidence
|
J:205518
|
Krastm4Tyj/Kras+ Pax7tm2.1(cre/ERT2)Fan/Pax7+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129/Sv * 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
|
increased sarcoma incidence
|
J:205518
|
Krastm4Tyj/Kras+ Pdpk1tm1Mlw/Pdpk1tm1Mlw Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae)
|
increased lung non-small cell carcinoma incidence
|
J:197054
|
Krastm4Tyj/Kras+ Pggt1btm1Mbrg/Pggt1b+ Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:122107
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Pten+ Tg(Gfap-cre)77.6Mvs/0
(involves: 129S4/SvJae * BALB/c * C57BL/6NHsd)
|
increased neurofibrosarcoma incidence
|
J:154673
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:184935
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Pten+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:164210
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * C57BL/6J)
|
increased endometrial carcinoma incidence
|
J:96296
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu Scgb1a1tm1.1(cre)Fjd/Scgb1a1+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased lung adenocarcinoma incidence
|
J:131721
|
increased lung carcinoma incidence
|
J:131721
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:184935
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:164210
|
Krastm4Tyj/Kras+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0
(129.Cg-Krastm4Tyj Tg(Tpo-cre)1Shk Ptentm2.1Ppp)
|
increased thyroid carcinoma incidence
|
J:147732
|
Krastm4Tyj/Kras+ Ptentm2Mak/Pten+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:254370
|
increased hepatocellular carcinoma incidence
|
J:254370
|
Krastm4Tyj/Kras+ Ptentm2Mak/Ptentm2Mak Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:254370
|
Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130,
J:87973
|
Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(B6.129(Cg)-Krastm4Tyj Ptf1atm1.1(cre)Cvw)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:138959
|
Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(MUC1)79.24Gend/0
(B6.Cg-Krastm4Tyj Ptf1atm1.1(cre)Cvw Tg(MUC1)79.24Gend)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:138959
|
Krastm4Tyj/Kras+ Raf1tm2Bacc/Raf1tm2Bacc Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197054
|
Krastm4Tyj/Kras+ Rb1tm3Tyj/Rb1tm3Tyj
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:147590
|
Krastm4Tyj/Kras+ Rbl2tm2Tyj/Rbl2tm2Tyj
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:147590
|
Krastm4Tyj/Kras+ Rnf7Gt(XE423)Byg/Rnf7+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:207982
|
Krastm4Tyj/Kras+ Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+ Trp53tm5Tyj/Trp53+
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6)
|
increased adenocarcinoma incidence
|
J:182218
|
Krastm4Tyj/Kras+ Scribtm1.1Phum/Scrib+ Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:178461
|
Krastm4Tyj/Kras+ Scribtm1.1Phum/Scribtm1.1Phum Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl)
|
increased carcinoma incidence
|
J:178461
|
increased prostate gland adenocarcinoma incidence
|
J:178461
|
Krastm4Tyj/Kras+ Sftpctm1(cre/ERT2)Blh/Sftpc+ Trp53tm5Tyj/Trp53+
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6)
|
increased adenocarcinoma incidence
|
J:182218
|
Krastm4Tyj/Kras+ Sftpctm1.1(cre/ERT2)Ptch/Sftpc+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
|
increased lung adenocarcinoma incidence
|
J:195738
|
Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Krastm4Tyj/Kras+ Smad4tm2.1Cxd/Smad4tm2.1Cxd Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL/J)
|
increased skin squamous cell carcinoma incidence
|
J:203922
|
Krastm4Tyj/Kras+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:184949
|
Krastm4Tyj/Kras+ Stk11tm1.1Rdp/Stk11tm1.1Rdp
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
increased lung large cell carcinoma incidence
|
J:124682
|
increased lung squamous cell carcinoma incidence
|
J:124682
|
Krastm4Tyj/Kras+ Stk11tm1.1Rdp/Stk11tm1.2Rdp
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
increased lung large cell carcinoma incidence
|
J:124682
|
increased lung squamous cell carcinoma incidence
|
J:124682
|
Krastm4Tyj/Kras+ Tg(CAG-Bgeo,-tsA58T)T26Ichi/0 Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:214846
|
Krastm4Tyj/Kras+ Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae)
|
increased lung non-small cell carcinoma incidence
|
J:197054
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/?
(involves: 129S4/SvJae * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:87973
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm1Gev/Trp53tm1Gev
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:220300
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:276349
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm3Tyj/Trp53+
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130,
J:164210
|
Krastm4Tyj/Kras+ Tg(Scgb1a1-cre)1Kkw/?
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:107260
|
Krastm4Tyj/Kras+ Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129S4/SvJae * FVB)
|
increased melanoma incidence
|
J:164588
|
Krastm4Tyj/Kras+ Tgfbr2tm1.2Hlm/Tgfbr2+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116129
|
Krastm4Tyj/Kras+ Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
(B6.129-Krastm4Tyj Tgfbr2tm1.2Hlm)
|
increased lung adenocarcinoma incidence
|
J:177379
|
Krastm4Tyj/Kras+ Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116129
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:184949
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR)
|
increased carcinoma incidence
|
J:124222
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased adenocarcinoma incidence
|
J:103407
|
increased lung adenocarcinoma incidence
|
J:195492,
J:154041,
J:103407
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased sarcoma incidence
|
J:155389,
J:125101
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Krt19tm1(cre/ERT)Ggu/Krt19+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac)
|
increased carcinoma incidence
|
J:172048
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:184949
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR)
|
increased squamous cell carcinoma incidence
|
J:124222
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre/ERT)20Efu/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1)
|
increased skin squamous cell carcinoma incidence
|
J:172048
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S4/SvJae * FVB)
|
increased melanoma incidence
|
J:164588
|
increased spindle cell carcinoma incidence
|
J:164588
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased adenocarcinoma incidence
|
J:103407
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm2Tyj Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197054
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm3Glo Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR)
|
increased carcinoma incidence
|
J:124222
|
increased spindle cell carcinoma incidence
|
J:124222
|
Krastm4Tyj/Kras+ Trp53tm1Lejo/Trp53tm1Lejo
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:187012
|
increased lung non-small cell carcinoma incidence
|
J:187012
|
Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:191425
|
increased lung non-small cell carcinoma incidence
|
J:191425
|
Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:98936
|
increased teratocarcinoma incidence
|
J:98936
|
Krastm4Tyj/Kras+ Trp53tm3Glo/Trp53+ Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * C57BL/6 * FVB * ICR)
|
increased carcinoma incidence
|
J:124222
|
Krastm4Tyj/Krastm4Tyj Yap1tm1.1Dupa/Yap1tm1.1Dupa Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:162628
|
Krastm5Tyj/Kras+ Pdx1tm1.1(flpo)Most/Pdx1+ Trp53tm1.1Dgk/Trp53+
(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:248550
|
Krastm5Tyj/Kras+ Pdx1tm1.1(flpo)Most/Pdx1+ Trp53tm1.1Dgk/Trp53tm1.1Dgk
(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:248550
|
Krastm5Tyj/Kras+ Trp53tm1.1Dgk/Trp53tm1.1Dgk
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:180576
|
increased sarcoma incidence
|
J:180576
|
Krastm5Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sortm1(cre/ERT2)Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased sarcoma incidence
|
J:172206
|
Krt14tm1.1(cre)Wbm/Krt14+ Tg(KRT14-Snai1)1Efu/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * CD-1)
|
increased basal cell carcinoma incidence
|
J:229072
|
increased skin squamous cell carcinoma incidence
|
J:229072
|
Krt18tm1Tmm/Krt18tm1Tmm
(involves: 129P2/OlaHsd)
|
increased hepatocellular carcinoma incidence
|
J:309021
|
Lats1tm1Tx/Lats1tm1Tx
(involves: 129S2/SvPas * C57BL/6J)
|
increased sarcoma incidence
|
J:52536
|
Lect2tm1Ymg/Lect2tm1Ymg Tg(Pklr-Myc)73Ak/0
(B6.Cg-Lect2tm1Ymg Tg(Pklr-Myc)73Ak)
|
increased hepatocellular carcinoma incidence
|
J:184496
|
increased malignant tumor incidence
|
J:184496
|
Lgals3tm1Ftl/Lgals3tm1Ftl
(involves: 129S2/SvPas * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:221030
|
Lig1tm3Dwm/Lig1tm3Dwm
(involves: 129P2/OlaHsd * C57BL/6)
|
increased adenocarcinoma incidence
|
J:77902
|
Lig4tm1Icrf/Lig4tm1Icrf Trp53tm1Tyj/Trp53tm1Tyj
(either: (involves: 129P2/OlaHsd * 129S2/SvPas) or (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ))
|
increased medulloblastoma incidence
|
J:111068
|
Lig4tm1Pmc/Lig4tm1Pmc Trp53tm1Tyj/Trp53+ Xrcc2tm2Pmc/Xrcc2tm2Pmc Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Lig4tm1Pmc/Lig4tm1Pmc Trp53tm1Tyj/Trp53tm1Tyj Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Lig4tm1Pmc/Lig4tm1Pmc Trp53tm1Tyj/Trp53tm1Tyj Xrcc2tm2Pmc/Xrcc2tm2Pmc Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Lig4tm2.1Fwa/Lig4tm2.1Fwa
(involves: 129S6/SvEvTac)
|
increased colon adenocarcinoma incidence
|
J:157574
|
increased medulloblastoma incidence
|
J:157574
|
Lmo7tm1Miyo/Lmo7+
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:150612
|
Lmo7tm1Miyo/Lmo7+
(involves: 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:150612
|
Lmo7tm1Miyo/Lmo7tm1Miyo
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:150612
|
Lmo7tm1Miyo/Lmo7tm1Miyo
(involves: 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:150612
|
Lpoem1Zlu/Lpoem1Zlu
(involves: C57BL/6 * SJL)
|
increased histiocytic sarcoma incidence
|
J:307289
|
increased lung carcinoma incidence
|
J:307289
|
increased sarcoma incidence
|
J:307289
|
Ltbp4Gt(U3Cre)1Vmel/Ltbp4Gt(U3Cre)1Vmel
(B6.129S2-Ltbp4Gt(U3Cre)1Vmel)
|
increased large intestine adenocarcinoma incidence
|
J:78819
|
Ly6atm2(RUNX1)Grau/Ly6a+
(involves: 129X1/SvJ * C57BL/6J)
|
increased squamous cell carcinoma incidence
|
J:93408
|
Lzts1tm1Cro/Lzts1+
(involves: 129 * C57BL/6J)
|
increased carcinoma incidence
|
J:119989
|
increased gastric adenocarcinoma incidence
|
J:119989
|
increased hepatocellular carcinoma incidence
|
J:119989
|
Lzts1tm1Cro/Lzts1tm1Cro
(involves: 129 * C57BL/6J)
|
increased carcinoma incidence
|
J:119989
|
increased gastric adenocarcinoma incidence
|
J:119989
|
increased hepatocellular carcinoma incidence
|
J:119989
|
increased lung adenocarcinoma incidence
|
J:119989
|
increased sarcoma incidence
|
J:119989
|
Mad1l1tm1.1Ktj/Mad1l1+
(involves: BALB/c * C57BL/6J)
|
increased carcinoma incidence
|
J:117337
|
increased hemangiosarcoma incidence
|
J:117337
|
increased hepatocellular carcinoma incidence
|
J:117337
|
increased lung adenocarcinoma incidence
|
J:117337
|
increased osteosarcoma incidence
|
J:117337
|
increased rhabdomyosarcoma incidence
|
J:117337
|
increased sarcoma incidence
|
J:117337
|
Mad2l1tm1Sorg/Mad2l1+
(involves: 129S2/SvPas * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:67456
|
Map2k7tm1.1Twad/Map2k7tm1.2Twad Tg(MMTV-cre)4Mam/0 Tg(MMTV-Erbb2)1Pv/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:170904
|
Map3k7tm1Aki/Map3k7tm1Aki Tg(Alb1-cre)7Gsc/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:160521
|
Mapk14tm1Nbr/Mapk14tm2Nbr Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased lung adenocarcinoma incidence
|
J:122397
|
Mc1re/Mc1re Xpctm1Brd/Xpctm1Brd Tg(KRT14-Kitl)1Takk/0
(involves: 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased squamous cell carcinoma incidence
|
J:112959
|
Mc4rtm1Lowl/Mc4rtm1Lowl
(involves: 129S4/SvJae * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:177386
|
Mcctm1.1Maija/Mcctm1.1Maija Tg(Vil1-cre)997Gum/0
(involves: C57BL/6 * C57BL/6J * SJL)
|
increased large intestine adenocarcinoma incidence
|
J:294342
|
Mcm4chaos3/Mcm4chaos3
(C3.B6-Mcm4chaos3)
|
increased hepatocellular carcinoma incidence
|
J:117494
|
increased lung adenocarcinoma incidence
|
J:117494
|
increased mammary adenocarcinoma incidence
|
J:117494
|
Mcm9Gt(AW0655)Wtsi/Mcm9Gt(AW0655)Wtsi
(involves: 129P2/OlaHsd * C3HeB/FeJ)
|
increased hepatocellular carcinoma incidence
|
J:177420
|
Mcm9Gt(AW0655)Wtsi/Mcm9Gt(XG743)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ)
|
increased hepatocellular carcinoma incidence
|
J:177420
|
Mcm9Gt(XG743)Byg/Mcm9Gt(XG743)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ)
|
increased hepatocellular carcinoma incidence
|
J:177420
|
Mdm2tm3.1Glo/Mdm2tm3.1Glo
(B6.129S6-Mdm2tm3.1Glo)
|
increased mammary adenocarcinoma incidence
|
J:164201
|
Mdm2tm3.1Glo/Mdm2tm3.1Glo Trp53tm3.1Glo/Trp53+
(B6.129S-Mdm2tm3.1Glo Trp53tm3.1Glo)
|
increased adenocarcinoma incidence
|
J:164201
|
increased carcinoma incidence
|
J:164201
|
increased fibrosarcoma incidence
|
J:164201
|
increased hemangiosarcoma incidence
|
J:164201
|
increased histiocytic sarcoma incidence
|
J:164201
|
increased leiomyosarcoma incidence
|
J:164201
|
increased liver adenocarcinoma incidence
|
J:164201
|
increased mammary adenocarcinoma incidence
|
J:164201
|
increased osteosarcoma incidence
|
J:164201
|
increased sarcoma incidence
|
J:164201
|
increased squamous cell carcinoma incidence
|
J:164201
|
Mdm2tm4.1Glo/Mdm2tm4.1Glo
(B6.129S6-Mdm2tm4.1Glo)
|
increased sarcoma incidence
|
J:164201
|
Mdm2tm4.1Glo/Mdm2tm4.1Glo Trp53tm3.1Glo/Trp53+
(B6.129S-Mdm2tm4.1Glo Trp53tm3.1Glo)
|
increased adenocarcinoma incidence
|
J:164201
|
increased carcinoma incidence
|
J:164201
|
increased fibrosarcoma incidence
|
J:164201
|
increased histiocytic sarcoma incidence
|
J:164201
|
increased liver adenocarcinoma incidence
|
J:164201
|
increased osteosarcoma incidence
|
J:164201
|
increased sarcoma incidence
|
J:164201
|
increased squamous cell carcinoma incidence
|
J:164201
|
Men1tm1.1Ctre/Men1+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:120835
|
Men1tm1.1Ctre/Men1+ Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J * FVB/N)
|
increased thyroid C-cell carcinoma incidence
|
J:133299
|
Men1tm1Ctre/Men1+
(either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))
|
increased carcinoma incidence
|
J:67128
|
increased lung adenocarcinoma incidence
|
J:67128
|
Men1tm1Zqw/Men1+
(involves: 129/Sv * 129P2/OlaHsd)
|
increased pancreatic islet cell carcinoma incidence
|
J:85302
|
increased thyroid carcinoma incidence
|
J:85302
|
Mettm1Gvw/Met+
(involves: 129 * C57BL/6J)
|
increased carcinoma incidence
|
J:94722
|
increased histiocytic sarcoma incidence
|
J:94722
|
increased squamous cell carcinoma incidence
|
J:94722
|
Mettm2Gvw/Met+
(involves: 129 * C57BL/6J)
|
increased hemangiosarcoma incidence
|
J:94722
|
increased histiocytic sarcoma incidence
|
J:94722
|
Mettm3Gvw/Mettm3Gvw
(involves: 129 * C57BL/6J)
|
increased hemangiosarcoma incidence
|
J:94722
|
Mettm4Gvw/Met+
(involves: 129 * C57BL/6J)
|
increased sarcoma incidence
|
J:94722
|
Mettm4Gvw/Met+
(involves: 129 * C57BL/6J * FVB/N)
|
increased hemangiosarcoma incidence
|
J:151890
|
increased mammary adenocarcinoma incidence
|
J:151890
|
increased sarcoma incidence
|
J:151890
|
increased squamous cell carcinoma incidence
|
J:151890
|
Mfge8tm1Mcu/Mfge8tm1Mcu Tg(RIP1-Tag)2Dh/?
(involves: 129X1/SvJ * C57BL/6J * C57BL/6NCr * DBA/2J)
|
increased carcinoma incidence
|
J:123138
|
Miftm1Gfr/Miftm1Gfr
(C57BL/6-Miftm1Gfr)
|
increased fibrosarcoma incidence
|
J:84791
|
Mir34atm1.2Arte/Mir34a+ Tg(Neurod2-Smo*A1)199Jols/0
(involves: C57BL/6 * C57BL/6N)
|
increased medulloblastoma incidence
|
J:221990
|
Mir34atm1.2Arte/Mir34atm1.2Arte Tg(Neurod2-Smo*A1)199Jols/0
(involves: C57BL/6 * C57BL/6N)
|
increased medulloblastoma incidence
|
J:221990
|
Mir122tm1.1Apts/Mir122tm1.1Apts
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:190066
|
Mir122tm1.1Kgh/Mir122+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:190067
|
Mir122tm1.1Kgh/Mir122tm1.1Kgh
(involves: 129S1/Sv * 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:190067
|
Mir122tm1.2Kgh/Mir122+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:190067
|
Mir122tm1.2Kgh/Mir122tm1.2Kgh Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:190067
|
Mir146tm1.1Bal/Mir146tm1.1Bal
(involves: C57BL/6)
|
increased myeloid sarcoma incidence
|
J:173230
|
Mirc1tm2.1Aven/Mirc1tm2.1Aven Tg(ARR2/Pbsn-MYC)7Key/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL/J)
|
increased prostate gland adenocarcinoma incidence
|
J:223213
|
Mldhrtm1Zhgn/Mldhrtm1Zhgn Tg(GFAP-cre)25Mes/0
(involves: FVB/N)
|
increased glioblastoma incidence
|
J:303725
|
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:75745
|
Mlh1tm1Rak/Mlh1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased adenocarcinoma incidence
|
J:53451
|
increased carcinoma incidence
|
J:53451
|
increased lung carcinoma incidence
|
J:53451
|
increased squamous cell carcinoma incidence
|
J:53451
|
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased carcinoma incidence
|
J:53451
|
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd)
|
increased small intestine adenocarcinoma incidence
|
J:133352
|
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:153684
|
Mlh1tm1Wed/Mlh1tm1Wed
(involves: 129/Sv * C57BL/6J * SJL)
|
increased basal cell carcinoma incidence
|
J:133352
|
Mmp8tm1Otin/Mmp8tm1Otin
(involves: 129X1/SvJ * C57BL/6J)
|
increased fibrosarcoma incidence
|
J:86393
|
Mmp9tm1Tvu/Mmp9tm1Tvu Tg(KRT14-HPV16)wt1Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * FVB/N)
|
increased skin squamous cell carcinoma incidence
|
J:65699
|
Mmp11tm1Mrio/Mmp11tm1Mrio Tg(MMTV-vHaras)SH1Led/Tg(MMTV-vHaras)SH1Led
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6J * CD-1 * FVB)
|
increased carcinoma incidence
|
J:86074
|
Mnttm1Awb/Mnttm1.1Awb Tg(MMTV-cre)4Mam/?
(involves: 129S6/SvEvTac * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:110115
|
Mnttm1Phu/Mnttm1Phu Tg(MMTV-cre)4Mam/?
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:85481
|
Mob1atm1.1Asuz/Mob1atm1.1Asuz Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(B6.Cg-Mob1bGt(CC0690)Wtsi Mob1atm1.1Asuz Speer6-ps1Tg(Alb-cre)21Mgn)
|
increased cholangiocarcinoma incidence
|
J:228499
|
increased hepatocellular carcinoma incidence
|
J:228499
|
Mob1atm1.2Asuz/Mob1a+ Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
|
increased fibrosarcoma incidence
|
J:193981
|
increased osteosarcoma incidence
|
J:193981
|
Mob1atm1.2Asuz/Mob1atm1.2Asuz Mob1bGt(CC0690)Wtsi/Mob1b+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased fibrosarcoma incidence
|
J:193981
|
increased osteosarcoma incidence
|
J:193981
|
Msh2tm1Htr/Msh2+
(involves: 129P2/OlaHsd)
|
increased hemangiosarcoma incidence
|
J:45433
|
increased osteosarcoma incidence
|
J:45433
|
Msh2tm1Mak/Msh2+ Mutyhtm1Jhmi/Mutyhtm1Jhmi Ogg1tm1Tld/Ogg1tm1Tld
(involves: 129 * C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:89742
|
Msh2tm1Rak/Msh2tm2.1Rak Tg(Vil1-cre)20Syr/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL)
|
increased intestinal adenocarcinoma incidence
|
J:161577
|
Msh2tm1Wed/Msh2tm1Wed
(involves: C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:86278
|
Msh2tm1Wed/Msh2tm1Wed
(involves: 129 * C57BL/6 * SJL)
|
increased intestinal adenocarcinoma incidence
|
J:88092
|
Msh2tm1Whl/Msh2tm1Whl
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased squamous cell carcinoma incidence
|
J:79016
|
Msh2tm1Whl/Msh2tm1Whl Rb1tm1Brd/Rb1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
increased thyroid C-cell carcinoma incidence
|
J:79016
|
Msh2tm2.1Rak/Msh2tm2.1Rak Tg(Vil1-cre)20Syr/0
(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
|
increased small intestine adenocarcinoma incidence
|
J:161577
|
Msh2tm2.1Rak/Msh2tm3.1Rak Tg(Vil1-cre)20Syr/0
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
|
increased intestinal adenocarcinoma incidence
|
J:161577
|
Msh3tm1Rak/Msh3tm1Rak
(involves: 129/Sv * C57BL/6J * SJL)
|
increased intestinal adenocarcinoma incidence
|
J:60604
|
Msh3tm1Rak/Msh3tm1Rak Msh6tm1Rak/Msh6tm1Rak
(involves: 129/Sv * C57BL/6J * SJL)
|
increased intestinal adenocarcinoma incidence
|
J:60604
|
Msh6tm1Wed/Msh6tm1Wed
(involves: 129/Sv * C57BL/6J * SJL)
|
increased basal cell carcinoma incidence
|
J:92555
|
Msmbtm1Xuan/Msmbtm1Xuan
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * CD-1))
|
increased prostate gland adenocarcinoma incidence
|
J:96884
|
Mtv2a/Mtv2a
(DDD.GR-Mtv2a)
|
increased mammary adenocarcinoma incidence
|
J:109201
|
Muc2tm1Avel/Muc2tm1Avel
(involves: 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:75047
|
Mus81tm1Raz/Mus81+
(involves: 129P2/OlaHsd)
|
increased carcinoma incidence
|
J:91570
|
Mus81tm1Raz/Mus81tm1Raz
(involves: 129P2/OlaHsd)
|
increased carcinoma incidence
|
J:91570
|
Myf6tm1(cre)Mrc/Myf6+ Pax3tm1Mrc/Pax3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased rhabdomyosarcoma incidence
|
J:93444
|
Myf6tm1(cre)Mrc/Myf6+ Pax3tm1Mrc/Pax3tm1Mrc Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased rhabdomyosarcoma incidence
|
J:93444
|
Myf6tm1(cre)Mrc/Myf6+ Pax3tm1Mrc/Pax3tm1Mrc Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased rhabdomyosarcoma incidence
|
J:93444
|
Mzf1tm1Ppp/Mzf1tm1Ppp
(involves: 129)
|
increased hepatocellular carcinoma incidence
|
J:70407
|
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac)
|
increased hepatocellular carcinoma incidence
|
J:195140
|
Nbnem3Jpt/Nbnem3Jpt Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
increased hemangiosarcoma incidence
|
J:251434
|
increased histiocytic sarcoma incidence
|
J:251434
|
increased leiomyosarcoma incidence
|
J:251434
|
increased rhabdomyosarcoma incidence
|
J:251434
|
increased squamous cell carcinoma incidence
|
J:251434
|
Nbnem4Jpt/Nbnem4Jpt Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
increased hemangiosarcoma incidence
|
J:251434
|
increased histiocytic sarcoma incidence
|
J:251434
|
increased leiomyosarcoma incidence
|
J:251434
|
increased rhabdomyosarcoma incidence
|
J:251434
|
increased squamous cell carcinoma incidence
|
J:251434
|
Nbntm1Zqw/Nbn+
(involves: 129S2/SvPas * C57BL/6)
|
increased liver adenocarcinoma incidence
|
J:86563
|
increased lung adenocarcinoma incidence
|
J:86563
|
increased mammary adenocarcinoma incidence
|
J:86563
|
Nbntm2Zqw/Nbntm2Zqw Trp53tm1Brd/Trp53tm1Brd Tg(Nes-cre)1Wme/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA)
|
increased sarcoma incidence
|
J:98316
|
Ncoa3tm1Jxu/Ncoa3+ Tg(MMTV-vHaras)SH1Led/0
(involves: 129S6/SvEvTac * C57BL/6J * CD-1)
|
increased mammary adenocarcinoma incidence
|
J:88789
|
Ncoa5tm1Hxia/Ncoa5+
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:207622
|
Ncoa5tm1Hxia/Ncoa5+
(C.129(B6)-Ncoa5tm1Hxia)
|
increased hepatocellular carcinoma incidence
|
J:207622
|
Ncstntm1.1Akli/Ncstntm1.1Akli Tg(Upk2-cre,-EGFP)#Akli/0
(involves: 129)
|
increased urinary bladder carcinoma incidence
|
J:227748
|
Ndrg2tm1Kmori/Ndrg2+
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
|
increased hepatocellular carcinoma incidence
|
J:210264
|
increased lung carcinoma incidence
|
J:210264
|
Ndrg2tm1Kmori/Ndrg2tm1Kmori
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
|
increased hepatocellular carcinoma incidence
|
J:210264
|
increased lung carcinoma incidence
|
J:210264
|
Nf1tm1Fcr/Nf1+ Trp53tm1Brd/Trp53+
(B6.129-Trp53tm1Brd Nf1tm1Fcr)
|
increased malignant tumor incidence
|
J:95933
|
increased sarcoma incidence
|
J:95933
|
Nf1tm1Fcr/Nf1+ Trp53tm1Tyj/Trp53+
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
increased carcinoma incidence
|
J:58877
|
increased leiomyosarcoma incidence
|
J:58877
|
increased malignant triton tumor incidence
|
J:58877
|
increased neuroblastoma incidence
|
J:58877
|
increased neurofibrosarcoma incidence
|
J:58877
|
increased rhabdomyosarcoma incidence
|
J:58877
|
increased sarcoma incidence
|
J:58877
|
Nf1tm1Tyj/? Nstr1C57BL/6J/Nstr1C57BL/6J Trp53tm1Tyj/?
(involves: 129S2/SvPas * A/J * C57BL/6J)
|
increased neurofibrosarcoma incidence
|
J:105038
|
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * C57BL/6)
|
increased fibrosarcoma incidence
|
J:18542
|
increased lung adenocarcinoma incidence
|
J:18542
|
increased neurofibrosarcoma incidence
|
J:18542
|
Nf1tm1Tyj/Nf1+ Suz12Gt(Betageo)1Khe/Suz12+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:217077
|
increased histiocytic sarcoma incidence
|
J:217077
|
increased neurofibrosarcoma incidence
|
J:217077
|
Nf1tm1Tyj/Nf1+ Suz12Gt(Betageo)1Khe/Suz12+ Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:217077
|
increased histiocytic sarcoma incidence
|
J:217077
|
increased neurofibrosarcoma incidence
|
J:217077
|
Nf1tm1Tyj/Nf1+ Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:41126
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
(involves: 129/Sv * C57BL/6)
|
increased neurofibrosarcoma incidence
|
J:58876
|
increased sarcoma incidence
|
J:58876
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas)
|
increased neurofibrosarcoma incidence
|
J:131914
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
(B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)
|
increased glioblastoma incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
((C3H/HeJ x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1)
|
increased glioblastoma incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
((CAST/EiJ x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1)
|
increased glioblastoma incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
((SJL/J x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1)
|
increased glioblastoma incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:217077
|
increased neuroblastoma incidence
|
J:217077
|
increased neurofibrosarcoma incidence
|
J:217077
|
increased sarcoma incidence
|
J:228258
|
Nf2tm1Gth/Nf2+
(involves: 129P2/OlaHsd * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:63264
|
increased neurofibrosarcoma incidence
|
J:63264
|
increased osteosarcoma incidence
|
J:63264
|
increased renal carcinoma incidence
|
J:63264
|
increased sarcoma incidence
|
J:63264
|
Nf2tm1Gth/Nf2tm2Gth Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased neurofibrosarcoma incidence
|
J:63264
|
increased odontosarcoma incidence
|
J:63264
|
Nf2tm1Tyj/Nf2+
(either: (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6) or (involves: 129S2/SvPas * C57BL/6J))
|
increased carcinoma incidence
|
J:47282
|
increased fibrosarcoma incidence
|
J:47282
|
increased lung adenocarcinoma incidence
|
J:47282
|
increased malignant tumor incidence
|
J:47282
|
increased osteosarcoma incidence
|
J:47282
|
increased sarcoma incidence
|
J:47282
|
Nf2tm2.1Gth/Nf2+
(involves: 129P2/OlaHsd * FVB/N)
|
increased fibrosarcoma incidence
|
J:63264
|
increased lung adenocarcinoma incidence
|
J:63264
|
increased osteosarcoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2+ Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2+ Trp53tm1Brd/Trp53+ Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
increased neurofibrosarcoma incidence
|
J:92413
|
increased osteosarcoma incidence
|
J:92413
|
Nf2tm2Gth/Nf2tm2Gth Ptgdstm1.1(cre)Gvn/Ptgds+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * FVB/N)
|
increased osteosarcoma incidence
|
J:173718
|
Nf2tm2Gth/Nf2tm2Gth Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:162628
|
Nf2tm2Gth/Nf2tm2Gth Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased extremity angiosarcoma incidence
|
J:92413
|
increased lung adenocarcinoma incidence
|
J:92413
|
increased neurofibrosarcoma incidence
|
J:92413
|
increased renal carcinoma incidence
|
J:92413
|
Nf2tm2Gth/Nf2tm2Gth Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:63264
|
increased neurofibrosarcoma incidence
|
J:63264
|
increased osteosarcoma incidence
|
J:63264
|
increased renal carcinoma incidence
|
J:63264
|
increased sarcoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2tm2Gth Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased neurofibrosarcoma incidence
|
J:63264
|
increased odontosarcoma incidence
|
J:63264
|
increased osteosarcoma incidence
|
J:63264
|
increased renal carcinoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2tm2Gth Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased renal carcinoma incidence
|
J:150071
|
Nf2tm2Gth/Nf2tm2Gth Tg(Postn-cre)1Sjc/0
(involves: 129P2/OlaHsd * FVB/NTac)
|
increased neurofibrosarcoma incidence
|
J:216420
|
Nf2tm2Gth/Nf2tm2Gth Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased renal carcinoma incidence
|
J:150071
|
Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brd/Trp53+ Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
increased leiomyosarcoma incidence
|
J:92413
|
increased neurofibrosarcoma incidence
|
J:92413
|
increased sarcoma incidence
|
J:92413
|
Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brd/Trp53+ Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
increased neurofibrosarcoma incidence
|
J:92413
|
Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brd/Trp53tm1Brd Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
increased extremity angiosarcoma incidence
|
J:92413
|
increased neurofibrosarcoma incidence
|
J:92413
|
increased osteosarcoma incidence
|
J:92413
|
increased rhabdomyosarcoma incidence
|
J:92413
|
increased sarcoma incidence
|
J:92413
|
Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased rhabdomyosarcoma incidence
|
J:132943
|
Nfe2tm1.1Hlpa/?
(involves: 129 * C57BL/6)
|
increased myeloid sarcoma incidence
|
J:275444
|
Nfe2l1tm1Jefc/Nfe2l1tm1Ywk Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129X1/SvJ * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:97188
|
Nhej1tm1Fwa/Nhej1tm1Fwa Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129)
|
increased medulloblastoma incidence
|
J:138774
|
Nkx2-9tm1Jlck/Nkx2-9tm1Jlck
(involves: 129/Sv * C57BL/6 * SJL)
|
increased squamous cell carcinoma incidence
|
J:115581
|
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:153425
|
Nmitm1.1Geno/Nmitm1.1Geno Tg(KRT14-cre)1Amc/0 Tg(MMTVneu)202Mul/0
(involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:261035
|
Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lung squamous cell carcinoma incidence
|
J:234268
|
Nr1h4tm1Gonz/Nr1h4tm1Gonz
(involves: 129X1/SvJ * C57BL/6N)
|
increased hepatocellular carcinoma incidence
|
J:121075
|
Nr1h4tm1Gonz/Nr1h4tm1Gonz
(involves: 129X1/SvJ * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:118204
|
Nrastm1Tyj/Nrastm1Tyj Tg(Tyr-cre)1Lru/0
(involves: C57BL/6 * DBA/2)
|
increased melanoma incidence
|
J:198244
|
Nrbp1tm1.1Dja/Nrbp1tm1.1Dja Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J)
|
increased lung carcinoma incidence
|
J:184685
|
Nrbp1tm1.1Dja/Nrbp1tm1.2Dja Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J)
|
increased lung carcinoma incidence
|
J:184685
|
Nsmce2Gt(AA0032)Wtsi/Nsmce2+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:227197
|
Nudt1tm1Tts/Nudt1tm1Tts
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:71836
|
Ogg1tm1Yun/Ogg1tm1Yun
(involves: 129S/SvEv * C57BL/6J)
|
increased lung carcinoma incidence
|
J:82287
|
Ossc1C3H/HeJ/? Ossc2102/El/?
(involves: 102/El * C3H/HeJ)
|
increased sarcoma incidence
|
J:75213
|
Ossc3BALB/c/Ossc3CBA/Ca
(involves: BALB/c * CBA/Ca)
|
increased osteosarcoma incidence
|
J:107725
|
Otulinem1Gvl/Otulintm1c(EUCOMM)Hmgu Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6J * C57BL/6N * DBA/2)
|
increased squamous cell carcinoma incidence
|
J:312394
|
Otulintm1c(EUCOMM)Hmgu/Otulintm1c(EUCOMM)Hmgu Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6N * DBA/2)
|
increased skin squamous cell carcinoma incidence
|
J:312394
|
Paqr3tm1Ychn/Paqr3tm1Ychn
(involves: 129 * C57BL/6J)
|
increased carcinoma incidence
|
J:139058
|
Parms1BALB/cByJ/Parms1C57BL/6NCrl Ptch1tm1Zim/Ptch1+
(involves: 129/Sv * BALB/cByJ * C57BL/6NCrl)
|
increased rhabdomyosarcoma incidence
|
J:93364
|
Parms1C57BL/6NCrl/Parms1C57BL/6NCrl Ptch1tm1Zim/Ptch1+
(involves: 129/Sv * BALB/cByJ * C57BL/6NCrl)
|
increased rhabdomyosarcoma incidence
|
J:93364
|
Pcbp4Gt(D136D11)Wrst/Pcbp4+
(involves: 129S2/SvPas * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:231514
|
Pcbp4Gt(D136D11)Wrst/Pcbp4Gt(D136D11)Wrst
(involves: 129S2/SvPas * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:231514
|
Pcsk2tm1Dfs/Pcsk2tm1Dfs
(B6;129-Pcsk2tm1Dfs/J)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:236905
|
Perptm2Att/Perptm2Att Tg(KRT14-cre/ERT2)1Ipc/0
(involves: 129S4/SvJae)
|
increased skin squamous cell carcinoma incidence
|
J:167545
|
Pgbd5tm1.1Aken/Pgbd5tm1.2Aken Ptch1tm1Bjw/Ptch1tm1Bjw Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * C57BL/6J * C57BL/6NTac * FVB/N * SW)
|
increased medulloblastoma incidence
|
J:346387
|
Pgrtm2(cre)Lyd/Pgr+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased endometrial carcinoma incidence
|
J:139053
|
Pgrtm2(cre)Lyd/Pgr+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased endometrial carcinoma incidence
|
J:162027,
J:218222
|
Pgrtm2(cre)Lyd/Pgr+ Ptentm1Hwu/Ptentm1Hwu Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * C57BL/6)
|
increased endometrial carcinoma incidence
|
J:139053
|
Pik3catm1.1Waph/Pik3ca+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * BALB/c * C57BL/6)
|
increased adenocarcinoma incidence
|
J:184382
|
Pik3catm1.1Waph/Pik3ca+ Tg(MMTV-cre)#Mam/0
(involves: 129S1/Sv * C57BL/6 * FVB)
|
increased mammary adenoacanthoma incidence
|
J:187299
|
increased osteosarcoma incidence
|
J:187299
|
increased sarcoma incidence
|
J:187299
|
Pinx1tm1.1Kplu/Pinx1+
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased carcinoma incidence
|
J:171997
|
increased hemangiosarcoma incidence
|
J:171997
|
increased histiocytic sarcoma incidence
|
J:171997
|
increased sarcoma incidence
|
J:171997
|
Pinx1tm1.1Kplu/Pinx1+ Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased carcinoma incidence
|
J:171997
|
increased hepatocellular carcinoma incidence
|
J:171997
|
increased lung carcinoma incidence
|
J:171997
|
Pinx1tm1.1Kplu/Pinx1+ Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased carcinoma incidence
|
J:171997
|
increased hepatocellular carcinoma incidence
|
J:171997
|
increased lung carcinoma incidence
|
J:171997
|
Plautm1Mlg/Plautm1Mlg Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6)
|
increased carcinoma incidence
|
J:65019
|
Plgtm1Jld/Plgtm1Jld Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * Black Swiss * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48285
|
Plk1Gt(RRR358)Byg/Plk1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lung carcinoma incidence
|
J:142593
|
increased sarcoma incidence
|
J:142593
|
increased squamous cell carcinoma incidence
|
J:142593
|
Plk3tm1Dai/Plk3tm1Dai
(involves: 129S4/SvJae * C57BL/6)
|
increased leiomyosarcoma incidence
|
J:136425
|
increased lung adenocarcinoma incidence
|
J:136425
|
Pmltm1Ppp/Pml+ Trp53tm3.1Glo/Trp53+
(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo)
|
increased carcinoma incidence
|
J:317504
|
increased osteosarcoma incidence
|
J:317504
|
increased sarcoma incidence
|
J:317504
|
Pmltm1Ppp/Pmltm1Ppp Trp53tm3.1Glo/Trp53+
(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo)
|
increased carcinoma incidence
|
J:317504
|
increased osteosarcoma incidence
|
J:317504
|
increased sarcoma incidence
|
J:317504
|
Pms2tm1.1Wed/Pms2tm1.1Wed
(involves: 129S6/SvEvTac * C57BL/6NCr)
|
increased adenocarcinoma incidence
|
J:162378
|
increased sarcoma incidence
|
J:162378
|
Pms2tm1Lisk/Pms2tm1Lisk
(involves: 129S2/SvPas * C57BL/6)
|
increased sarcoma incidence
|
J:27389
|
Pms2tm1Lisk/Pms2tm1Lisk
(involves: 129S2/SvPas)
|
increased carcinoma incidence
|
J:125218
|
increased sarcoma incidence
|
J:125218
|
Pms2tm1Lisk/Pms2tm1Lisk Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * 129S2/SvPas * C57BL/6 * C57BL/6J * SJL)
|
increased carcinoma incidence
|
J:125218
|
increased sarcoma incidence
|
J:125218
|
Pold1tm1.1Bdp/Pold1tm1.1Bdp
(B6.129-Pold1tm1.1Bdp)
|
increased intestinal adenocarcinoma incidence
|
J:153684
|
Pold1tm1Bdp/Pold1tm1Bdp
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:100685
|
increased sarcoma incidence
|
J:100685
|
increased squamous cell carcinoma incidence
|
J:100685
|
Poletm1.1Bdp/Poletm1.1Bdp
(B6.129-Poletm1.1Bdp)
|
increased colon adenocarcinoma incidence
|
J:153684
|
increased histiocytic sarcoma incidence
|
J:153684
|
increased intestinal adenocarcinoma incidence
|
J:153684
|
increased small intestine adenocarcinoma incidence
|
J:153684
|
Polhtm1.1Rak/Polhtm1.1Rak
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased squamous cell carcinoma incidence
|
J:105034
|
Ppardtm1Jps/Ppardtm1Jps
(involves: 129/Sv * C57BL/6N)
|
increased intestinal adenocarcinoma incidence
|
J:90217
|
Ppp2r1atm1.2Wltr/Ppp2r1atm2.1Wltr
(FVB.129-Ppp2r1atm1.2Wltr/Ppp2r1atm2.1Wltr)
|
increased lung adenocarcinoma incidence
|
J:175748
|
Prdm2tm1Shg/Prdm2+
(involves: 129S2/SvPas * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:71406
|
increased lung adenocarcinoma incidence
|
J:71406
|
Prdm2tm1Shg/Prdm2tm1Shg
(involves: 129S2/SvPas * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:71406
|
increased lung adenocarcinoma incidence
|
J:71406
|
Prdx1tm1Rave/Prdx1+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased fibrosarcoma incidence
|
J:84677
|
increased hemangiosarcoma incidence
|
J:84677
|
increased hepatocellular carcinoma incidence
|
J:84677
|
increased histiocytic sarcoma incidence
|
J:84677
|
increased lung adenocarcinoma incidence
|
J:84677
|
increased malignant tumor incidence
|
J:84677
|
increased mammary adenocarcinoma incidence
|
J:84677
|
increased osteosarcoma incidence
|
J:84677
|
Prdx1tm1Rave/Prdx1tm1Rave
(involves: 129S6/SvEvTac * C57BL/6)
|
increased carcinoma incidence
|
J:84677
|
increased fibrosarcoma incidence
|
J:84677
|
increased hemangiosarcoma incidence
|
J:84677
|
increased hepatocellular carcinoma incidence
|
J:84677
|
increased histiocytic sarcoma incidence
|
J:84677
|
increased lung adenocarcinoma incidence
|
J:84677
|
increased mammary adenocarcinoma incidence
|
J:84677
|
increased sarcoma incidence
|
J:84677
|
Prf1tm1Sdz/Prf1tm1Sdz
(C.B6-Prf1tm1Sdz)
|
increased lung adenocarcinoma incidence
|
J:77491
|
increased sarcoma incidence
|
J:77491
|
Prkacatm1Gsm/Prkaca+ Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased osteosarcoma incidence
|
J:160299
|
Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased osteosarcoma incidence
|
J:160299
|
Prkar1atm1.2Lsk/Prkar1a+ Rb1tm2Brn/Rb1+ Tg(Col1a1-cre)1Kry/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Prkar1atm1.2Lsk/Prkar1a+ Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Prkar1atm1.2Lsk/Prkar1a+ Tg(Bglap2-TAg)1Rkho/0 Tg(Col1a1-cre)1Kry/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteosarcoma incidence
|
J:165282
|
Prkar1atm1.2Lsk/Prkar1a+ Tg(Col1a1-cre)1Kry/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk Ptentm1.1Mwst/Ptentm1.1Mwst Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr)
|
increased thyroid carcinoma incidence
|
J:225245
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr)
|
increased thyroid carcinoma incidence
|
J:225245,
J:241066
|
Prkar1atm1Gsm/Prkar1a+
(involves: 129X1/SvJ)
|
increased fibrosarcoma incidence
|
J:93393
|
increased hemangiosarcoma incidence
|
J:93393
|
increased hepatocellular carcinoma incidence
|
J:93393
|
increased sarcoma incidence
|
J:93393
|
Prlrtm1Cnp/Prlrtm1Cnp
(involves: 129/Sv * 129P2/OlaHsd)
|
increased thyroid carcinoma incidence
|
J:101609
|
Prmt1tm1c(EUCOMM)Wtsi/Prmt1+ Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:245660
|
Pscatm1Witt/Psca+ Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:133908
|
Pscatm1Witt/Pscatm1Witt Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:133908
|
Psmb9tm1Stl/Psmb9tm1Stl
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:73945
|
increased leiomyosarcoma incidence
|
J:73945
|
Psmb9tm1Stl/Psmb9tm1Stl Trp53tm1Brd/Trp53tm1Brd
(involves: 129P2/OlaHsd * C57BL/6)
|
increased sarcoma incidence
|
J:67509
|
Ptch1tm1.1Hahn/Ptch1+
(involves: 129 * BALB/c * C57BL/6 * FVB/N)
|
increased medulloblastoma incidence
|
J:149148
|
increased rhabdomyosarcoma incidence
|
J:149148
|
Ptch1tm1Bjw/Ptch1tm1Bjw Tg(Atoh1-cre)1Bfri/0
(involves: 129T2/SvEms * C57BL/6 * CBA)
|
increased medulloblastoma incidence
|
J:139573
|
Ptch1tm1Bjw/Ptch1tm1Bjw Tg(Atoh1-cre/Esr1*)14Fsh/0
(involves: 129T2/SvEms * FVB/N)
|
increased medulloblastoma incidence
|
J:139573
|
Ptch1tm1Bjw/Ptch1tm1Bjw Tg(GFAP-cre)25Mes/0
(involves: 129T2/SvEms * FVB/N)
|
increased medulloblastoma incidence
|
J:139573
|
Ptch1tm1Bjw/Ptch1tm1Bjw Tg(KRT14-cre)8Brn/0
(involves: 129T2/SvEms * FVB/N)
|
increased basal cell carcinoma incidence
|
J:231264
|
Ptch1tm1Cklr/Ptch1+ Pax7tm1(cre)Mrc/Pax7+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:159972
|
Ptch1tm1Cklr/Ptch1+ Trp53tm1Brn/? Pax7tm1(cre)Mrc/Pax7+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:159972
|
Ptch1tm1Hahn/Ptch1tm1Hahn Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased basal cell carcinoma incidence
|
J:149148
|
Ptch1tm1Hahn/Ptch1tm1Hahn Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
|
increased basal cell carcinoma incidence
|
J:158915
|
Ptch1tm1Hahn/Ptch1tm1Hahn Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)
|
increased basal cell carcinoma incidence
|
J:149148
|
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:205254
|
increased medulloblastoma incidence
|
J:205254
|
increased rhabdomyosarcoma incidence
|
J:205254
|
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased medulloblastoma incidence
|
J:42441
|
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:144811,
J:114992,
J:102702
|
increased rhabdomyosarcoma incidence
|
J:114992
|
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2J)
|
increased basal cell carcinoma incidence
|
J:58328
|
Ptch1tm1Mps/Ptch1+ Ptch2tm1Pmc/Ptch2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased basal cell carcinoma incidence
|
J:112118
|
increased rhabdomyosarcoma incidence
|
J:112118
|
Ptch1tm1Mps/Ptch1+ Ptch2tm1Pmc/Ptch2tm1Pmc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased basal cell carcinoma incidence
|
J:112118
|
increased medulloblastoma incidence
|
J:112118
|
increased rhabdomyosarcoma incidence
|
J:112118
|
Ptch1tm1Mps/Ptch1+ Tg(Atoh1-GFP)1Jejo/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased medulloblastoma incidence
|
J:144811
|
Ptch1tm1Mps/Ptch1+ Tg(Atoh1-sb11)1Mtay/0 TgTn(sb-T2/Onc3)12740Njen/0
(involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6J * ICR)
|
increased medulloblastoma incidence
|
J:181542
|
Ptch1tm1Mps/Ptch1+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129 * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:125534
|
increased rhabdomyosarcoma incidence
|
J:125534
|
Ptch1tm1Yy/Ptch1+ Trp53tm1Brd/Trp53+ Tg(BGLAP-cre)1Clem/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/NJ)
|
increased osteosarcoma incidence
|
J:214349
|
Ptch1tm1Zim/Ptch1+
(either: (involves: 129 * C57BL/6) or (involves: 129 * CD-1))
|
increased medulloblastoma incidence
|
J:47421
|
increased rhabdomyosarcoma incidence
|
J:47421
|
Ptch1tm1Zim/Ptch1+
(involves: 129 * CD-1)
|
increased medulloblastoma incidence
|
J:79666,
J:165388
|
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * BALB/c)
|
increased mammary adenocarcinoma incidence
|
J:110567
|
Ptentm1.1Mwst/Ptentm1.1Mwst Tg(MMTVneu)202Mul/0 Tg(S100a4-cre)1Gle/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153747
|
Ptentm1.2Mwst/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
|
increased mammary adenoacanthoma incidence
|
J:158751
|
increased uterus carcinoma incidence
|
J:158751
|
Ptentm1Hwu/Pten+ Tg(ARR2/Pbsn-FGF8)3Prb/0 Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:106650
|
Ptentm1Hwu/Pten+ Tg(KRT14-cre)#Smr/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J)
|
increased mammary adenocarcinoma incidence
|
J:138927
|
Ptentm1Hwu/Pten+ Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:212219
|
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae)
|
increased prostate gland adenocarcinoma incidence
|
J:144810
|
Ptentm1Hwu/Ptentm1Hwu Cop1tm2.1Vmd/Cop1tm2.1Vmd Tg(Pbsn-cre)4Prb/0
(B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb)
|
increased prostate gland adenocarcinoma incidence
|
J:172653
|
Ptentm1Hwu/Ptentm1Hwu Ptpn1tm1Bpk/Ptpn1tm1Bpk Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:231906
|
Ptentm1Hwu/Ptentm1Hwu Smad4tm2.1Cxd/Smad4tm2.1Cxd Tg(Alb1-cre)1Dlr/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased cholangiocarcinoma incidence
|
J:111718
|
Ptentm1Hwu/Ptentm1Hwu Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:218587
|
increased hepatocellular carcinoma incidence
|
J:218587
|
Ptentm1Hwu/Ptentm1Hwu Tg(Alb1-cre)1Dlr/0
(involves: 129S4/SvJae * FVB/N)
|
increased cholangiocarcinoma incidence
|
J:111718
|
increased hepatocellular carcinoma incidence
|
J:111718
|
Ptentm1Hwu/Ptentm1Hwu Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0 Tg(TPO-cre)1Shk/0
(involves: 129S4/SvJae * FVB/NCr * FVB/NJ)
|
increased thyroid carcinoma incidence
|
J:177181
|
Ptentm1Hwu/Ptentm1Hwu Tg(CAG-MYC,-GFP*)#Rugg/0 Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:261540
|
Ptentm1Hwu/Ptentm1Hwu Tg(Fabp1-cre)1Jig/0
(involves: 129S4/SvJae * FVB/N)
|
increased carcinoma incidence
|
J:106662
|
increased colon adenocarcinoma incidence
|
J:106662
|
increased renal carcinoma incidence
|
J:106662
|
increased squamous cell carcinoma incidence
|
J:106662
|
increased urinary bladder carcinoma incidence
|
J:106662
|
Ptentm1Hwu/Ptentm1Hwu Tg(KRT14-cre)#Smr/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J)
|
increased mammary adenocarcinoma incidence
|
J:138927
|
Ptentm1Hwu/Ptentm1Hwu Tg(MMTV-cre)#Tfln/0
(involves: 129S4/SvJae)
|
increased mammary adenocarcinoma incidence
|
J:78415
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:142106
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased carcinoma incidence
|
J:268934
|
increased prostate gland adenocarcinoma incidence
|
J:268934,
J:184935,
J:212219
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:93902,
J:124208
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)20Fwan/?
(involves: 129S4/SvJae * C57BL/6 * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:238768
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased malignant tumor incidence
|
J:102226
|
increased pancreatic ductal adenocarcinoma incidence
|
J:102226
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pdx1-cre)89.1Dam/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic acinar cell carcinoma incidence
|
J:102226
|
increased pancreatic ductal adenocarcinoma incidence
|
J:102226
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pgc-cre,-secNluc)#Hcz/0
(involves: 129S4/SvJae)
|
increased mammary adenocarcinoma incidence
|
J:338079
|
Ptentm1Hwu/Ptentm1Hwu Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl Tg(KRT14-cre/ERT)20Efu/0
(involves: 129 * 129S4/SvJae * C57BL/6 * CD-1 * FVB/N)
|
increased squamous cell carcinoma incidence
|
J:209026,
J:194652
|
Ptentm1Hwu/Ptentm1Hwu Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
|
increased carcinoma incidence
|
J:146760
|
increased urinary bladder carcinoma incidence
|
J:146760
|
Ptentm1Hwu/Ptentm1Hwu Trp53tm2Tyj/Trp53+ Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
increased ovarian carcinoma incidence
|
J:222579
|
Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased carcinoma incidence
|
J:50437
|
increased endometrial carcinoma incidence
|
J:63478
|
increased mammary adenocarcinoma incidence
|
J:63478
|
Ptentm1Mak/Pten+
(B6.129P2-Ptentm1Mak)
|
increased endometrial carcinoma incidence
|
J:93530
|
Ptentm1Mro/Pten+ Tg(KLK3-cre)D4Trp/0
(involves: 129P2/OlaHsd * FVB)
|
increased prostate gland adenocarcinoma incidence
|
J:99524
|
Ptentm1Mro/Ptentm1Mro Tg(KRT14-cre)8Brn/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * DBA/2J * FVB/N)
|
increased carcinoma incidence
|
J:144831
|
Ptentm1Ppp/Pten+
(involves: 129S1/Sv * C57BL/6J)
|
increased malignant tumor incidence
|
J:49532
|
Ptentm1Ppp/Pten+ Tg(Pbsn-TAg)15Tvd/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:103408
|
Ptentm1Rdp/Pten+ Trp53tm1Brn/Trp53tm1Brn Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased glioblastoma incidence
|
J:140704
|
Ptentm1Rdp/Ptentm1Rdp Smad4tm1Rdp/Smad4tm1Rdp Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp Terttm1Rdp/Tert+ Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp Terttm3Rdp/Terttm3Rdp Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
Ptentm1Rps/Pten+
(involves: 129S1/Sv * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:53065
|
Ptentm1Rps/Pten+ Tg(Wnt1)1Hev/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased adenocarcinoma incidence
|
J:67497
|
increased mammary adenocarcinoma incidence
|
J:67497
|
increased mammary gland ductal carcinoma incidence
|
J:67497
|
increased salivary adenocarcinoma incidence
|
J:67497
|
Ptentm2.1Gle/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
|
increased mammary adenoacanthoma incidence
|
J:158751
|
Ptentm2.1Ppp/Pten+ Tg(Cnp-EGFR)10Nrat/0 Tg(Dhh-cre)1Mejr/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased neurofibrosarcoma incidence
|
J:195067
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Cnp-EGFR)10Nrat/0 Tg(Dhh-cre)1Mejr/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased neurofibrosarcoma incidence
|
J:195067
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Dhh-cre)1Mejr/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased neurofibrosarcoma incidence
|
J:195067
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:163589,
J:100683
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0
(129S1.Cg-Ptentm2.1Ppp Tg(TPO-cre)1Shk)
|
increased thyroid carcinoma incidence
|
J:165293
|
Ptentm2.1Ppp/Ptentm2.1Ppp Trp53tm1Brn/Trp53tm1Brn Tg(TPO-cre)1Shk/0
(129.Cg-Tg(TPO-cre)1Shk Trp53tm1Brn Ptentm2.1Ppp)
|
increased thyroid carcinoma incidence
|
J:211100
|
Ptentm2.1Ppp/Ptentm2.1Ppp Trp53tm1Thl/Trp53tm1Thl Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased carcinoma incidence
|
J:100683
|
Ptentm2Mak/Ptentm2Mak Smad4tm2.1Cxd/Smad4tm2.1Cxd Tg(KRT5-cre)1Xya/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
increased carcinoma incidence
|
J:101602
|
Ptentm2Mak/Ptentm2Mak Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:138099
|
Ptentm2Mak/Ptentm2Mak Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * DBA)
|
increased hepatocellular carcinoma incidence
|
J:90905
|
Ptentm2Mak/Ptentm2Mak Stk11tm1Keis/Stk11tm1Keis Tg(Cyp1a1-cre/ERT)1Dwi/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA)
|
increased urinary bladder carcinoma incidence
|
J:169565
|
Ptentm2Mak/Ptentm2Mak Tg(Cyp1a1-cre)1Dwi/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:143082
|
Ptentm2Mak/Ptentm2Mak Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased urinary bladder transitional cell carcinoma incidence
|
J:113388
|
Ptentm2Mak/Ptentm2Mak Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * FVB/NJ)
|
increased glioblastoma incidence
|
J:290447
|
Ptentm2Mak/Ptentm2Mak Tg(KLK3-cre)13Saa/0
(involves: 129P2/OlaHsd * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:214242
|
Ptentm2Mak/Ptentm2Mak Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased spindle cell carcinoma incidence
|
J:224955
|
Ptentm2Mak/Ptentm2Mak Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:127405
|
increased lung squamous cell carcinoma incidence
|
J:127405
|
Ptentm2Mak/Ptentm2Mak Tg(Wap-cre)11738Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased spindle cell carcinoma incidence
|
J:224955
|
Ptentm2Mak/Ptentm2Mak Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased spindle cell carcinoma incidence
|
J:224955
|
Ptentm2Mak/Ptentm2Mak Trp53tm1Brn/Trp53tm1Brn Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
(involves: 129P2/OlaHsd)
|
increased medulloblastoma incidence
|
J:237990
|
Ptentm2Mak/Ptentm2Mak Trp53tm1Brn/Trp53tm1Brn Tg(Wap-cre)11738Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased spindle cell carcinoma incidence
|
J:224955
|
Ptprz1tm1Schl/Ptprz1+ Trp53tm1Tyj/Trp53+
(involves: 129 * 129S2/SvPas * C57BL/6J)
|
increased osteosarcoma incidence
|
J:243104
|
Ptprz1tm1Schl/Ptprz1tm1Schl
(involves: 129)
|
increased osteosarcoma incidence
|
J:243104
|
Ptprz1tm1Schl/Ptprz1tm1Schl Trp53tm1Tyj/Trp53+
(involves: 129 * 129S2/SvPas * C57BL/6J)
|
increased osteosarcoma incidence
|
J:243104
|
Rab25tm1Jrgo/Rab25tm1Jrgo Smad3tm1Par/Smad3+
(129-Rab25tm1Jrgo Smad3tm1Par)
|
increased colon adenocarcinoma incidence
|
J:158733
|
Rad50tm4.1Jpt/Rad50+
(involves: 129/Sv * C57BL/6)
|
increased hepatoblastoma incidence
|
J:209141
|
Rag1tm1Mom/Rag1tm1Mom Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL)
|
increased hemangiosarcoma incidence
|
J:141515
|
increased hepatocellular carcinoma incidence
|
J:141515
|
increased medulloblastoma incidence
|
J:141515
|
increased sarcoma incidence
|
J:141515
|
Rag1tm1Mom/Rag1tm1Mom Trp53tm1Brd/Trp53tm1Brd Xrcc5tm1Dbr/Xrcc5tm1Dbr
(involves: 129S7/SvEvBrd * C57BL)
|
increased medulloblastoma incidence
|
J:141515
|
increased sarcoma incidence
|
J:141515
|
Rag2tm1Fwa/Rag2tm1Fwa Stat1tm1Rds/Stat1tm1Rds
(involves: 129S/SvEv * 129S6/SvEvTac)
|
increased mammary adenocarcinoma incidence
|
J:216040
|
Rag2tm1Fwa/Rag2tm1Fwa Tg(Cd4-NPM/ALK)N1Ingh/0 Tg(TcraTcrb)1100Mjb/0
(involves: 129S/SvEv * C57BL/6 * Swiss Webster)
|
increased hepatocellular carcinoma incidence
|
J:235890
|
increased sarcoma incidence
|
J:235890
|
Ranbp2tm1Jvd/Ranbp2tm1.1Jvd
(involves: 129/Sv * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:137482
|
increased lung carcinoma incidence
|
J:137482
|
increased sarcoma incidence
|
J:137482
|
Ranbp2tm1Jvd/Ranbp2tm1Jvd
(involves: 129/Sv * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:137482
|
increased lung carcinoma incidence
|
J:137482
|
increased sarcoma incidence
|
J:137482
|
Raph1tm1.2Fbg/Raph1tm1.2Fbg
(involves: 129S4/SvJae * C57BL/6)
|
increased carcinoma incidence
|
J:238262
|
Rasal2Gt(463C12)Cmhd/Rasal2Gt(463C12)Cmhd Tg(MMTVneu)202Mul/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrl * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:202603
|
Rasal2Gt(463C12)Cmhd/Rasal2Gt(463C12)Cmhd Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S * 129X1/SvJ * C57BL/6 * C57BL/6NCrl)
|
increased hepatocellular carcinoma incidence
|
J:202603
|
Rassf1tm1.2Brd/Rassf1tm1.2Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:101369
|
Rassf1tm1Gpp/Rassf1tm1Gpp
(involves: 129S1/SvImJ)
|
increased hepatocellular carcinoma incidence
|
J:231761
|
Rassf1tm1Gpp/Rassf1tm1Gpp Sav1tm1.1Gpp/Sav1+
(involves: 129S1/Sv * 129S1/SvImJ)
|
increased hepatoblastoma incidence
|
J:231761
|
increased hepatocellular carcinoma incidence
|
J:231761
|
Rassf5tm1Kina/Rassf5tm1Kina
(B6.Cg-Rassf5tm1Kina)
|
increased hepatocellular carcinoma incidence
|
J:168749
|
increased lung adenocarcinoma incidence
|
J:168749
|
Rb1tm1.1Jyjw/Rb1tm1.1Jyjw Trp53tm1Tyj/Trp53tm1Tyj
(129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw)
|
increased intestinal adenocarcinoma incidence
|
J:102483
|
Rb1tm1Brd/Rb1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
increased thyroid C-cell carcinoma incidence
|
J:79016
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6J)
|
increased thyroid C-cell carcinoma incidence
|
J:133299
|
Rb1tm1Tyj/Rb1+ Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:41126
|
Rb1tm1Tyj/Rb1+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased leiomyosarcoma incidence
|
J:19542
|
increased pancreatic islet cell carcinoma incidence
|
J:19542
|
increased sarcoma incidence
|
J:19542
|
Rb1tm1Tyj/Rb1tm2Brn Rbl1tm1Tyj/Rbl1+ Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased retinoblastoma incidence
|
J:120315
|
Rb1tm1Tyj/Rb1tm2Brn Rbl1tm1Tyj/Rbl1+ Trp53tm1Brn/Trp53tm1Brn Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased retinoblastoma incidence
|
J:120315
|
Rb1tm1Tyj/Rb1tm2Brn Rbl1tm1Tyj/Rbl1tm1Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased retinoblastoma incidence
|
J:120315
|
Rb1tm1Tyj/Rb1tm2Brn Rbl1tm1Tyj/Rbl1tm1Tyj Trp53tm1Brn/Trp53tm1Tyj Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased retinoblastoma incidence
|
J:120315
|
Rb1tm2Brn/Rb1+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:86077
|
increased lung small cell carcinoma incidence
|
J:86077
|
Rb1tm2Brn/Rb1+ Trp53tm1Brn/Trp53tm1Brn Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Rb1tm2Brn/Rb1tm2Brn Rbl1tm1Tyj/Rbl1tm1Tyj Rbl2tm2Tyj/Rbl2tm2Tyj
(involves: 129 * 129S2/SvPas * 129S4/SvJae)
|
increased urinary bladder carcinoma incidence
|
J:217195
|
Rb1tm2Brn/Rb1tm2Brn Tg(Gfap-cre)2Brn/0
(involves: 129 * FVB/N)
|
increased carcinoma incidence
|
J:187257
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brd/Trp53tm1Brd Tg(Gfap-cre)2Brn/0
(involves: 129 * 129S7/SvEvBrd * FVB/N)
|
increased medulloblastoma incidence
|
J:61961
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:86077,
J:157319
|
increased lung small cell carcinoma incidence
|
J:86077,
J:157319
|
increased thyroid carcinoma incidence
|
J:86077,
J:157319
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
increased lung carcinoma incidence
|
J:86077
|
increased lung small cell carcinoma incidence
|
J:86077,
J:157319
|
increased ovarian carcinoma incidence
|
J:84345
|
increased thyroid carcinoma incidence
|
J:86077,
J:157319
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(BGLAP-cre)1Clem/0
(involves: 129 * 129P2/OlaHsd * FVB/NJ)
|
increased osteosarcoma incidence
|
J:326989
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Gfap-cre)2Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased medulloblastoma incidence
|
J:61961
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Gfap-cre)2Brn/0
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased carcinoma incidence
|
J:187257
|
increased medulloblastoma incidence
|
J:187257
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)105Ayn/0
(FVB.Cg-Trp53tm1Brn Rb1tm2Brn Tg(MMTV-cre)105Ayn)
|
increased carcinoma incidence
|
J:165292
|
increased squamous cell carcinoma incidence
|
J:165292
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Ren-cre)#Kwg/0
(involves: 129 * 129P2/OlaHsd)
|
increased pancreatic islet cell carcinoma incidence
|
J:216559
|
increased sarcoma incidence
|
J:216559
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Lejo/Trp53tm1Lejo
(involves: 129)
|
increased lung small cell carcinoma incidence
|
J:187012
|
Rb1tm3Tyj/Rb1+ Trp53tm1Brn/Trp53+ Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693
|
Rb1tm3Tyj/Rb1+ Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693
|
Rb1tm3Tyj/Rb1+ Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:318885
|
Rb1tm3Tyj/Rb1tm3Tyj Rbl1tm1Tyj/Rbl1tm1Tyj Rbl2tm2.1Tyj/Rbl2tm2.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:177573
|
Rb1tm3Tyj/Rb1tm3Tyj Rbl1tm1Tyj/Rbl1tm1Tyj Tg(Pax6-cre,GFP)2Pgr/0
(involves: 129S2/SvPas * 129S4/SvJae * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased retinoblastoma incidence
|
J:119919
|
Rb1tm3Tyj/Rb1tm3Tyj Rbl2tm1Tyj/Rbl2tm1Tyj Tg(Nes-cre)1Atp/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
|
increased retinoblastoma incidence
|
J:91406
|
Rb1tm3Tyj/Rb1tm3Tyj Rbl2tm2.1Tyj/Rbl2tm2.1Tyj Tg(Pax6-cre,GFP)2Pgr/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased retinoblastoma incidence
|
J:119919
|
Rb1tm3Tyj/Rb1tm3Tyj Rbl2tm2Tyj/Rbl2tm2Tyj Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung small cell carcinoma incidence
|
J:160148
|
Rb1tm3Tyj/Rb1tm3Tyj Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 Tg(tetO-RNAi:Trp53)ASlowe/0
(involves: 129S4/SvJae * C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:199542
|
Rb1tm3Tyj/Rb1tm3Tyj Tg(tetO-MYC)36aBop/0 Tg(Cebpb-tTA)5Bjd/0
(involves: FVB/N * NMRI)
|
increased hepatocellular carcinoma incidence
|
J:172430
|
Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53+ Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693
|
Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung small cell carcinoma incidence
|
J:160148
|
Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693,
J:318035
|
Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:199542
|
Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1)
|
increased osteosarcoma incidence
|
J:329449
|
Rbm38tm1.1Xch/Rbm38tm1.1Xch
(involves: C57BL/6 * FVB/N)
|
increased hemangiosarcoma incidence
|
J:216929
|
Rcbtb2tm1.1Xyw/Rcbtb2+
(involves: C57BL/6 * CBA)
|
increased histiocytic sarcoma incidence
|
J:282928
|
Rcbtb2tm1.1Xyw/Rcbtb2tm1.1Xyw
(involves: C57BL/6 * CBA)
|
increased histiocytic sarcoma incidence
|
J:282928
|
Recql4tm1Glu/Recql4tm1Glu
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased sarcoma incidence
|
J:97101
|
Rettm2.1Cos/? Tg(Th-MYCN)41Waw/0
(involves: 129S1/Sv * BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:261033
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased carcinoma incidence
|
J:158922
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd Trp53tm1Brd/Trp53+ Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased carcinoma incidence
|
J:158922
|
increased osteosarcoma incidence
|
J:158922
|
Rgsc682/Rgsc682+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased squamous cell carcinoma incidence
|
J:133634
|
Rgsc814/Rgsc814+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased squamous cell carcinoma incidence
|
J:133634
|
Rgsc1033/Rgsc1033+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased thyroid carcinoma incidence
|
J:133634
|
Rgsc1049/Rgsc1049+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased squamous cell carcinoma incidence
|
J:133634
|
Rgsc1050/Rgsc1050+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased renal carcinoma incidence
|
J:133634
|
Rhoctm1Mak/Rhoctm1Mak Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:100482
|
Rint1tm1Whl/Rint1+
(Not Specified)
|
increased hepatocellular carcinoma incidence
|
J:122805
|
increased lung adenocarcinoma incidence
|
J:122805
|
increased mammary adenocarcinoma incidence
|
J:122805
|
increased skin squamous cell carcinoma incidence
|
J:122805
|
Rnf8Gt(AS0574)Wtsi/Rnf8Gt(AS0574)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:161240
|
increased sarcoma incidence
|
J:161240
|
Rnf8Gt(RRR260)Byg/Rnf8Gt(RRR260)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:161240
|
increased sarcoma incidence
|
J:161240
|
Rnf20Gt(RRJ249)Byg/Rnf20+
(involves: 129P2/OlaHsd)
|
increased colon adenocarcinoma incidence
|
J:268221
|
increased large intestine adenocarcinoma incidence
|
J:268221
|
Rnf168Gt(156B6)Cmhd/Rnf168Gt(156B6)Cmhd Trp53tm1Brd/Trp53tm1Brd
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:198260
|
increased sarcoma incidence
|
J:198260
|
Rnf168Gt(405F11)Cmhd/Rnf168Gt(405F11)Cmhd Trp53tm1Brd/Trp53tm1Brd
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:198260
|
increased sarcoma incidence
|
J:198260
|
Robo1tm1Phr/Robo1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased carcinoma incidence
|
J:93666
|
increased lung adenocarcinoma incidence
|
J:93666
|
RrsvA/WySnJ/RrsvA/WySnJ
(involves: A/WySnJ * SW)
|
increased sarcoma incidence
|
J:6009
|
RrsvCBA/J/RrsvCBA/J
(involves: CBA/J * SW)
|
increased sarcoma incidence
|
J:6009
|
Rtel1tm2.1Hdin/Rtel1tm2.1Hdin Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased medulloblastoma incidence
|
J:202812
|
increased sarcoma incidence
|
J:202812
|
Runx1tm3Dow/Runx1+ Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased sarcoma incidence
|
J:77129
|
Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs/Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs Trp53tm1Sia/Trp53+
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased rhabdomyosarcoma incidence
|
J:117828
|
Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs/Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs Trp53tm1Sia/Trp53tm1Sia
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased rhabdomyosarcoma incidence
|
J:117828
|
S100a4tm1Amba/S100a4tm1Amba
(involves: 129S1/Sv * 129X1/SvJ * NMRI)
|
increased fibrosarcoma incidence
|
J:89563
|
increased hepatocellular carcinoma incidence
|
J:89563
|
increased lung carcinoma incidence
|
J:89563
|
increased mammary adenocarcinoma incidence
|
J:89563
|
Sav1tm1.1Gpp/Sav1+
(involves: 129S1/Sv)
|
increased hepatocellular carcinoma incidence
|
J:231761
|
Sav1tm1.1Rjo/Sav1tm1.1Rjo Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * DBA * SJL)
|
increased carcinoma incidence
|
J:156531
|
increased hepatocellular carcinoma incidence
|
J:156531
|
Sav1tm1Dlim/Sav1+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased osteosarcoma incidence
|
J:160325
|
Sav1tm2.1Dlim/Sav1tm2.1Dlim Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:238319
|
Scribtm1.2Phum/Scrib+
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:178461
|
increased lung non-small cell carcinoma incidence
|
J:216266
|
SfnEr/Sfn+
(involves: 129/Sv * C57BL/6)
|
increased squamous cell carcinoma incidence
|
J:12025
|
Sirt1tm1.1Cxd/Sirt1+ Trp53tm1Brd/Trp53+
(either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB/N) or (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N))
|
increased carcinoma incidence
|
J:140089
|
increased sarcoma incidence
|
J:140089
|
Sirt2tm1.1Cxd/Sirt2tm1.1Cxd
(either: (involves: C57BL/6 * FVB/N) or (involves: FVB/N * NIH Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:177486
|
Slc29a3tm1Lex/Slc29a3tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:179286
|
Slc33a1tm1.1Lpu/Slc33a1+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased sarcoma incidence
|
J:211266
|
Sluc10B10.O20/Dem/Sluc10B10.O20/Dem Sluc25O20/A/Sluc25O20/A
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc10O20/A/Sluc10O20/A Sluc25O20/A/Sluc25O20/A
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc18B10.O20/Dem/Sluc18B10.O20/Dem Sluc26B10.O20/Dem/Sluc26B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc25O20/A/Sluc25O20/A Sluc5B10.O20/Dem/Sluc5B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc25O20/A/Sluc25O20/A Sluc9B10.O20/Dem/Sluc9O20/A
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc25O20/A/Sluc25O20/A Sluc9O20/A/Sluc9O20/A
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Smad3tm1Cxd/Smad3tm1Cxd
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * NIH Black Swiss))
|
increased intestinal adenocarcinoma incidence
|
J:53510
|
Smad3tm1Par/Smad3tm1Par
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
increased intestinal adenocarcinoma incidence
|
J:49839
|
Smad3tm1Par/Smad3tm1Par
(129-Smad3tm1Par/J)
|
increased intestinal adenocarcinoma incidence
|
J:106572
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd Tg(KRT5-cre)1Xya/0
(involves: 129S6/SvEvTac)
|
increased carcinoma incidence
|
J:101602
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)7Mul/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:212549
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased intestinal adenocarcinoma incidence
|
J:212549
|
Smarca2tm1Mya/Smarca2tm1Mya Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * 129S2/SvPas * C57BL/6J * CD-1)
|
increased hemangiosarcoma incidence
|
J:132091
|
Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * C57BL/6J * CD-1)
|
increased mammary adenocarcinoma incidence
|
J:132091
|
increased osteosarcoma incidence
|
J:132091
|
Smarcb1tm1Gvk/Smarcb1+
(involves: 129/Sv * C57BL/6J * SJL/J)
|
increased blastoma incidence
|
J:101185
|
Smarcb1tm1Mya/Smarcb1+
(involves: 129S2/SvPas * C57BL/6)
|
increased sarcoma incidence
|
J:68501
|
Smarcb1tm1Sho/Smarcb1+
(involves: 129S6/SvEvTac * C57BL/6J * DBA/2J)
|
increased malignant tumor incidence
|
J:120820
|
Smarcb1tm1Sho/Smarcb1+ Tg(LPV-TAg121)2Tvd/0
(involves: 129S6/SvEvTac * C57BL/6J * DBA/2J)
|
increased carcinoma incidence
|
J:120820
|
increased malignant tumor incidence
|
J:120820
|
Smg1Gt(AG0297)Wtsi/Smg1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:193626
|
Smurf2Gt(RRA098)Byg/Smurf2Gt(RRA098)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:189320
|
increased sarcoma incidence
|
J:189320
|
increased small intestine adenocarcinoma incidence
|
J:189320
|
Sod1m1H/Sod1m1H
(involves: C3H/HeH * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:219360
|
Sptbn1tm1Mish/Sptbn1+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:132133
|
Sptbn1tm1Mish/Sptbn1+
(involves: 129S6/SvEvTac)
|
increased carcinoma incidence
|
J:166879
|
increased hepatocellular carcinoma incidence
|
J:166879
|
increased lung adenocarcinoma incidence
|
J:166879
|
increased renal carcinoma incidence
|
J:166879
|
increased sarcoma incidence
|
J:166879
|
increased thyroid carcinoma incidence
|
J:166879
|
Srpxtm1Hzi/Srpxtm1Hzi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:119999
|
increased sarcoma incidence
|
J:119999
|
Ssbp2tm1Lana/Ssbp2tm1Lana
(involves: 129S/SvEv * C57BL/6)
|
increased carcinoma incidence
|
J:162035
|
increased jejunum adenocarcinoma incidence
|
J:162035
|
increased malignant tumor incidence
|
J:162035
|
increased sarcoma incidence
|
J:162035
|
increased squamous cell carcinoma incidence
|
J:162035
|
Ssic1C57BL/10J/Ssic1C57BL/10J
(involves: C57BL/10 * O20/A)
|
increased small intestine adenocarcinoma incidence
|
J:26873
|
Stag1Gt(P099A04)Wrst/Stag1+
(involves: 129S2/SvPas)
|
increased carcinoma incidence
|
J:184720
|
increased hepatocellular carcinoma incidence
|
J:184720
|
increased histiocytic sarcoma incidence
|
J:184720
|
Stat1tm1Dlv/Stat1tm1Dlv
(B6.129S-Stat1tm1Dlv)
|
increased mammary adenocarcinoma incidence
|
J:216040
|
Stat1tm1Rds/Stat1tm1Rds
(129S6/SvEv-Stat1tm1Rds/Tac)
|
increased mammary adenocarcinoma incidence
|
J:216040
|
Stat3tm1Dlv/Stat3tm1Dlv Tg(Csf1r-icre)1Jwp/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased carcinoma incidence
|
J:156593
|
Stat3tm4Vpo/Stat3tm4Vpo Tg(MMTV-Erbb2)1Pv/0
(involves: 129P2/OlaHsd * BALB/cAn * C57BL/6 * CD-1 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:157976
|
Stk3tm1.1Jav/Stk3+ Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1.1Jav/Stk3tm1.1Jav Stk4Gt(AJ0315)Wtsi/Stk4+
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1.1Jav/Stk3tm1Jav Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1.1Rjo/Stk3tm1.1Rjo Stk4tm1.1Rjo/Stk4tm1.1Rjo Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * DBA * SJL)
|
increased hepatocellular carcinoma incidence
|
J:156531
|
Stk3tm1.1Yy/Stk3tm1Yy Stk4tm1.1Yy/Stk4tm1.1Yy Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6 * CBA)
|
increased carcinoma incidence
|
J:156541
|
increased hepatocellular carcinoma incidence
|
J:156541
|
Stk3tm1Jav/Stk3tm1Jav Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1Jav/Stk3tm1Jav Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1Jav/Stk3tm1Jav Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * 129P2/OlaHsd * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:238319
|
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:153945
|
Stk11tm1.1Mlfr/Stk11+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J)
|
increased osteosarcoma incidence
|
J:104347
|
increased sarcoma incidence
|
J:104347
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
|
increased endometrial carcinoma incidence
|
J:131865
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp Tg(KRT14-cre)1Ipc/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
increased squamous cell carcinoma incidence
|
J:131037
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp Tg(Sprr2f-cre)1Dcas/0
(involves: 129S6/SvEvTac * FVB/N)
|
increased endometrial carcinoma incidence
|
J:158190
|
Stk11tm1.2Rdp/Stk11+
(involves: 129S6/SvEvTac * FVB/N)
|
increased endometrial carcinoma incidence
|
J:131865
|
Stk11tm1Mmt/Stk11+
(involves: 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:76202
|
Stk11tm1Mmt/Stk11+ Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:107275
|
Stk11tm1Tpm/Stk11+
(Not Specified)
|
increased endometrial carcinoma incidence
|
J:79074
|
increased hepatocellular carcinoma incidence
|
J:79074
|
SufuGt(XB699)Byg/Sufu+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:125534
|
increased rhabdomyosarcoma incidence
|
J:125534
|
Suz12Gt(Betageo)1Khe/Suz12+
(involves: 129P2/OlaHsd)
|
increased histiocytic sarcoma incidence
|
J:217077
|
T(9;17)138Ca/T(9;17)138Ca
(Not Specified)
|
increased adenocarcinoma incidence
|
J:189952
|
Taf4tm1Idvd/Taf4tm1Idvd Tg(KRT14-cre/ERT2)1Ipc/0
(involves: C57BL/6 * SJL)
|
increased malignant tumor incidence
|
J:124111
|
increased squamous cell carcinoma incidence
|
J:124111
|
Tbx21tm1Glm/Tbx21tm1Glm Tg(TRAMP)8247Ng/0
(involves: 129S6/SvEvTac * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:88093
|
Tcf7tm1Cle/Tcf7tm1Cle
(involves: 129P2/OlaHsd)
|
increased mammary adenoacanthoma incidence
|
J:57721
|
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi Tg(Pklr-Myc)73Ak/0
(B6.Cg-Tcra-Jtm1Tgi Tg(Pklr-Myc)73Ak)
|
increased hepatocellular carcinoma incidence
|
J:184496
|
increased malignant tumor incidence
|
J:184496
|
Terctm1Rdp/Terctm1Rdp Wrntm1Lgu/Wrntm1Lgu
(involves: 129/Sv * BALB/c * C57BL/6 * SLJ)
|
increased osteosarcoma incidence
|
J:91715
|
increased sarcoma incidence
|
J:91715
|
Terf1tm1.1Blas/Terf1tm1.1Blas Tg(KRT5-cre)1Tak/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129 * C3H * C57BL/6 * SJL)
|
increased skin squamous cell carcinoma incidence
|
J:152077
|
Testm1Cro/Tes+
(involves: 129X1/SvJ * C57BL/6J)
|
increased carcinoma incidence
|
J:100181
|
Testm1Cro/Testm1Cro
(involves: 129X1/SvJ * C57BL/6J)
|
increased carcinoma incidence
|
J:100181
|
Tff1tm1Mrio/Tff1tm1Mrio
(involves: 129S2/SvPas * 129X1/SvJ)
|
increased carcinoma incidence
|
J:35923
|
Tg(Acta2-RAC1*G12V)33Pjgc/0
(involves: C57BL/6 * FVB/N)
|
increased sarcoma incidence
|
J:150015
|
Tg(Acta2-RAC1*G12V)33Pjgc/Tg(Acta2-RAC1*G12V)33Pjgc
(involves: C57BL/6 * FVB/N)
|
increased sarcoma incidence
|
J:150015
|
Tg(ACTB-Eif4e)#Ppp/?
(Not Specified)
|
increased lung adenocarcinoma incidence
|
J:89878
|
increased sarcoma incidence
|
J:89878
|
Tg(ACTB-KRAS*G12V,-luc)#Lche/0
(involves: C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:199528
|
Tg(Alb1-Myc)#Sst/0
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:34434
|
Tg(Alb1-Myc)#Sst/0 Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CBA * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:34434
|
Tg(Alb1-Myc)#Sst/0 Tg(MtTGFA)Lmb/0
(involves: C57BL/6 * CBA * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:176432
|
Tg(Alb1HBV)44Bri/0
(involves: C57BL/6J * SJL/J)
|
increased hepatocellular carcinoma incidence
|
J:86165
|
Tg(Alb1HBV)44Bri/0
(C57BL/6J-Tg(Alb1HBV)44Bri/J)
|
increased hepatocellular carcinoma incidence
|
J:223921
|
Tg(Alb-E2F1)8Sst/0
(involves: C57BL/6J * CBA/J)
|
increased hepatocellular carcinoma incidence
|
J:65354,
J:101128
|
Tg(Alb-HBx)A112Tfts/0
(involves: C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:104728
|
Tg(Alb-HRAS*G12V)28Yu/0
(involves: C57BL/6J * CBA/J)
|
increased hepatocellular carcinoma incidence
|
J:107083,
J:238319
|
Tg(Alb-PDGFC)#Jcam/0
(involves: C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:96979,
J:211984
|
Tg(Alb-SND1)3aDsar/0
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:242582
|
Tg(Alb-TAg)1Gjh/0
(C3.Cg-Tg(Alb-TAg)1Gjh)
|
increased hepatocellular carcinoma incidence
|
J:105110
|
Tg(Alb-TAg)#Arnd/0
(C3Fe.Cg-Tg(Alb-TAg)#Arnd)
|
increased hepatocellular carcinoma incidence
|
J:171880
|
Tg(AMH-Fshr*D580H)#Hht/0
(involves: FVB/N)
|
increased ovarian carcinoma incidence
|
J:160015
|
Tg(Amhr2-SV40TAg)1Dcco/0
((C57BL/6 x C3H)F1)
|
increased ovarian carcinoma incidence
|
J:82550
|
Tg(Amy1TAg)501Knw/?
(C57BL/6-Tg(Amy1TAg)501Knw)
|
increased osteosarcoma incidence
|
J:90730
|
Tg(ARR2/Pbsn-MYC)7Key/?
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:223213,
J:85480
|
Tg(Atoh1-sb11)1Mtay/0 TgTn(sb-T2/Onc3)12740Njen/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C3H * C57BL/6J * ICR)
|
increased medulloblastoma incidence
|
J:181542
|
Tg(Atp4b-TAg)#Jig/0
(involves: FVB/N)
|
increased carcinoma incidence
|
J:89240
|
Tg(Bglap2-TAg)1Rkho/0
(FVB/N-Tg(Bglap2-TAg)1Rkho)
|
increased osteosarcoma incidence
|
J:165282
|
Tg(Bglap2-TAg)1Rkho/0
(involves: FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Tg(Bglap2-TAg)1Rkho/0 Tg(Col1a1-cre)1Kry/0 Tnfrsf11atm1.1Pngr/Tnfrsf11atm1.1Pngr
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Tg(Bglap2-TAg)1Rkho/0 Tnfsf11tm1Pngr/Tnfsf11+
(involves: 129P2/OlaHsd * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Tg(C3-1-TAg)cJeg/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:52786,
J:46513
|
increased prostate gland adenocarcinoma incidence
|
J:52786,
J:46513,
J:72324
|
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0 Tg(Dbh-icre)1Gsc/0
(involves: C57BL/6 * FVB/N)
|
increased neuroblastoma incidence
|
J:186696
|
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0 Tg(Dbh-icre)1Gsc/0 Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J * FVB/N)
|
increased neuroblastoma incidence
|
J:186696
|
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0 Thtm1(cre)Te/Th+
(involves: 129X1/SvJ * C57BL/6 * FVB/N)
|
increased neuroblastoma incidence
|
J:186696
|
Tg(CAG-Bgeo,-Tle1,-ALPP)1Lbe/0 Tg(CAG-cre)1Nagy/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
increased lung adenocarcinoma incidence
|
J:106684
|
Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0 Tg(Pdx1-cre)6Tuv/0 Tg(tetO-MYC)36Bop/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197052
|
Tg(CAG-Has2)99Nita/0 Tg(MMTV-cre)4Mam/0 Tg(MMTVneu)202Mul/0
(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTV-cre)4Mam Tg(MMTVneu)202Mul)
|
increased mammary adenocarcinoma incidence
|
J:130531,
J:164205
|
Tg(CAG-Has2)99Nita/0 Tg(MMTVneu)202Mul/0
(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTVneu)202Mul)
|
increased mammary adenocarcinoma incidence
|
J:130531
|
Tg(CAG-lacZ,-SV40)#Bcv/0
(involves: FVB/N)
|
increased ovarian carcinoma incidence
|
J:158388
|
Tg(CAG-Ptafr)1Tksh/0
(B6;D2-Tg(CAG-Ptafr)1Tksh/TkshRbrc)
|
increased cutaneous melanoma incidence
|
J:38639
|
Tg(CAG-Tle1,-ALPP)1Lbe/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
increased lung adenocarcinoma incidence
|
J:106684
|
Tg(CAG-TRIM29)ADims/0
(FVB/NJ-Tg(CAG-TRIM29)ADims)
|
increased urinary bladder carcinoma incidence
|
J:226764
|
Tg(Cd4-NPM/ALK)N1Ingh/0 Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6 * Swiss Webster)
|
increased hepatocellular carcinoma incidence
|
J:235890
|
increased sarcoma incidence
|
J:235890
|
Tg(CEACAM5-Tag)L5496Wzm/0
(involves: C57BL/6 * CBA)
|
increased gastric adenocarcinoma incidence
|
J:62581
|
Tg(Cebpb-tTA)5Bjd/0 Tg(tetO-MYC,-OVAL)#Gtgm/0
(B6J.Cg-Tg(Cebpb-tTA)5Bjd Tg(tetO-MYC,-OVAL)#Gtgm)
|
increased hepatocellular carcinoma incidence
|
J:186226
|
Tg(Cela1-luc,Cela1-TAg)#Nzh/0
(involves: FVB/N)
|
increased pancreatic acinar cell carcinoma incidence
|
J:207960
|
Tg(CMV-tTA)3Bjd/0 Tg(tetO-Prkar1a*x2as)1Stra/0
(involves: C57BL/6 * NMRI * SJL)
|
increased histiocytic sarcoma incidence
|
J:94953
|
increased spindle cell carcinoma incidence
|
J:94953
|
Tg(Cnp-EGFR)10Nrat/0
(involves: C57BL/6 * SJL)
|
increased malignant triton tumor incidence
|
J:95933
|
increased rhabdomyosarcoma incidence
|
J:95933
|
Tg(Dct-Birc5)21Gros/0 Tg(Mt1-Hgf)19Lmb/0
(involves: C57BL/6 * CBA * FVB/N)
|
increased melanoma incidence
|
J:122181
|
Tg(Dct-Grm1)ESzc/0
(involves: C57BL/6J)
|
increased cutaneous melanoma incidence
|
J:83183
|
Tg(Dct-Grm1)ESzc/0
(C57BL/6J-Tg(Dct-Grm1)ESzc)
|
increased intraocular melanoma incidence
|
J:230115
|
Tg(ED-L2-IL1RN/IL1B)#Tcw/?
(B6.Cg-Tg(ED-L2-IL1RN/IL1B)#Tcw)
|
increased adenocarcinoma incidence
|
J:180282
|
Tg(Ela1-Myc)158Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreatic acinar cell carcinoma incidence
|
J:76992
|
Tg(Ela1-Myc)159Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreatic acinar cell carcinoma incidence
|
J:76992
|
Tg(Ela1-Myc)160Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreatic acinar cell carcinoma incidence
|
J:76992
|
Tg(Ela1-TAg)18Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreatic acinar cell carcinoma incidence
|
J:76995
|
Tg(Ela1-TAg)19Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreatic acinar cell carcinoma incidence
|
J:76995
|
Tg(Ela1-TAg*)79Mjt/0
(involves: C57BL/6 * DBA/2)
|
increased pancreatic acinar cell carcinoma incidence
|
J:78026
|
Tg(Ela1-TAg*)79Mjt/0 Tg(MUC1)79.24Gend/0
(involves: C57BL/6 * DBA/2)
|
increased pancreatic acinar cell carcinoma incidence
|
J:64570
|
Tg(Ela1-TAg*)289Mjt/0
(involves: C57BL/6 * DBA/2)
|
increased pancreatic acinar cell carcinoma incidence
|
J:78026
|
Tg(Ela1-Tgfa)150Bri/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
|
increased malignant tumor incidence
|
J:67389
|
increased pancreatic ductal adenocarcinoma incidence
|
J:67389
|
Tg(EmuSR-HDAC9)1468Kpet/0
(involves: C57BL/6 * CBA)
|
increased histiocytic sarcoma incidence
|
J:237420
|
Tg(Erbb2-Erbb2*V664E)#Led/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:62441
|
Tg(Fabp1-Ccnd1)4Rdb/0
(C57BL/6-Tg(Fabp1-Ccnd1)4Rdb/J)
|
increased hepatocellular carcinoma incidence
|
J:70394
|
Tg(Fabp4-Il22)#Ychn/0
(involves: ICR)
|
increased liposarcoma incidence
|
J:176141
|
Tg(Gcg-TAg)25Ddr/?
(involves: CD-1)
|
increased large intestine adenocarcinoma incidence
|
J:91490,
J:101537
|
Tg(GFAP-tTA)67Pop/0 Tg(tetO-Ifng)184Pop/0
(B6.Cg-Tg(GFAP-tTA)67Pop Tg(tetO-Ifng)184Pop)
|
increased medulloblastoma incidence
|
J:94092
|
Tg(GFAP-tTA)67Pop/0 Tg(tetO-Ifng)184Pop/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased medulloblastoma incidence
|
J:94092
|
Tg(Ggt1-Hif1a*)43Log/0
(involves: C57BL/6)
|
increased renal carcinoma incidence
|
J:177381
|
Tg(Ggt1-tTA)#Agoc/0 Tg(tetO-MYC)36aBop/0
(involves: FVB/N)
|
increased renal carcinoma incidence
|
J:222943
|
Tg(H2-K-Fosl2,-EGFP)13Wag/0
(either: 129.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag or B6.Cg-Tg(H2-K-Fosl2,-EGFP)13Wag)
|
increased fibrosarcoma incidence
|
J:139032
|
Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:206727,
J:184212
|
Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0 Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:206727
|
increased spindle cell carcinoma incidence
|
J:206727
|
Tg(HBV-HCV)21Kko/0
(C57BL/6N-Tg(HBV-HCV)21Kko)
|
increased hepatocellular carcinoma incidence
|
J:52686
|
Tg(HBV-HCV)49Kko/0
(C57BL/6N-Tg(HBV-HCV)49Kko)
|
increased hepatocellular carcinoma incidence
|
J:52686
|
Tg(HBV-HCV)Kko/0
(C57BL/6N-Tg(HBV-HCV)Kko)
|
increased hepatocellular carcinoma incidence
|
J:52686
|
Tg(HBVX*,-Myc)#Skp/0
(Not Specified)
|
increased hepatocellular carcinoma incidence
|
J:81098
|
Tg(HBVX*,-Myc)#Skp/Tg(HBVX*,-Myc)#Skp
(Not Specified)
|
increased hepatocellular carcinoma incidence
|
J:81098
|
Tg(HBx)3Yu/0
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:56196
|
Tg(HRAS)2Jic/?
(involves: BALB/c * C57BL/6)
|
increased adenocarcinoma incidence
|
J:64968
|
increased lung adenocarcinoma incidence
|
J:64968
|
increased sarcoma incidence
|
J:64968
|
Tg(HRAS)7Mok/?
(involves: C57BL/6)
|
increased adenocarcinoma incidence
|
J:64968
|
increased lung adenocarcinoma incidence
|
J:64968
|
increased sarcoma incidence
|
J:64968
|
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased sarcoma incidence
|
J:78177
|
Tg(Ins1-GAS)1Sbr/0
(involves: FVB/NTac)
|
increased carcinoma incidence
|
J:59575
|
Tg(Ins2-Akt1*)3Mbb/0
(B6.Cg-Tg(Ins2-Akt1*)3Mbb)
|
increased pancreatic islet cell carcinoma incidence
|
J:144599
|
Tg(Ins2-IGF1R)1Dh/0 Tg(RIP1-Tag)2Dh/0
(involves: C3H * C57BL/6 * C57BL/6J * DBA/2J)
|
increased pancreatic islet cell carcinoma incidence
|
J:205389
|
Tg(Ins2-Tag*,-flpe)#Gne/0
(involves: C57BL/6J)
|
increased pancreatic islet cell carcinoma incidence
|
J:187012
|
Tg(Ins2-Tag*,-flpe)#Gne/0
(Not Specified)
|
increased pancreatic islet cell carcinoma incidence
|
J:188693
|
Tg(IRS1)1Mhep/0 Tg(SERPINA1-HBVX)1655Jtsb/0
(involves: C3H * C57BL/6 * FVB * ICR)
|
increased hepatocellular carcinoma incidence
|
J:227278
|
Tg(K5-Ptgs2)19Kmd/0
(involves: NMRI)
|
increased squamous cell carcinoma incidence
|
J:79071
|
Tg(K5-Ptgs2)667Kmd/0
(involves: NMRI)
|
increased squamous cell carcinoma incidence
|
J:79071
|
Tg(KRT5-Akt1*)Jmpa/0
(involves: C57BL/6 * DBA/2 * DBA/2J * FVB/N)
|
increased adenocarcinoma incidence
|
J:144831
|
increased carcinoma incidence
|
J:144831
|
increased squamous cell carcinoma incidence
|
J:144831
|
Tg(KRT5-rtTA)#Glk/0 Tg(tetO/CMV-Dek,-luc)317Siwe/0
(involves: FVB/N)
|
increased squamous cell carcinoma incidence
|
J:261249
|
Tg(KRT5-Terf2)PMBlas/Y
(involves: C57BL/6 * CBA)
|
increased skin squamous cell carcinoma incidence
|
J:102653
|
Tg(KRT5-Terf2)POBlas/0
(involves: C57BL/6 * CBA)
|
increased skin squamous cell carcinoma incidence
|
J:102653
|
Tg(KRT14-cre)8Brn/0 Tg(KRT5-Akt1*)Jmpa/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * DBA/2J * FVB/N)
|
increased carcinoma incidence
|
J:144831
|
increased squamous cell carcinoma incidence
|
J:144831
|
Tg(KRT14-Fyn*)aJsey/0
(involves: C57BL/6 * CBA)
|
increased skin squamous cell carcinoma incidence
|
J:155536
|
Tg(KRT14-Fyn*)aJsey/0
(involves: C57BL/6 * CBA * FVB/N)
|
increased skin squamous cell carcinoma incidence
|
J:155536
|
Tg(KRT14-HPV8)9Vuc/0
(FVB.Cg-Tg(KRT14-HPV8)9Vuc)
|
increased skin squamous cell carcinoma incidence
|
J:96784
|
Tg(KRT14-HPV8)85Vuc/0
(FVB.Cg-Tg(KRT14-HPV8)85Vuc)
|
increased skin squamous cell carcinoma incidence
|
J:96784
|
Tg(KRT14-HPV8)#Vuc/0
(involves: C57BL/6 * DBA * FVB/N)
|
increased skin squamous cell carcinoma incidence
|
J:96784
|
Tg(KRT14-HPV16)wt1Dh/0
(FVB.Cg-Tg(KRT14-HPV16)wt1Dh/Nci)
|
increased skin squamous cell carcinoma incidence
|
J:65699
|
Tg(KRT14-HPV16)wt1Dh/0
(either: FVB.Cg-Tg(KRT14-HPV16)wt1Dh or (involves: C57BL/6 * DBA/2 * FVB/N))
|
increased skin squamous cell carcinoma incidence
|
J:20130
|
increased spindle cell carcinoma incidence
|
J:20130
|
Tg(KRT14-HPV16E7)2304Plam/0
(involves: FVB/N)
|
increased skin squamous cell carcinoma incidence
|
J:86018
|
Tg(KRT14-HPV16E7)2326Plam/0
(involves: FVB/N)
|
increased skin squamous cell carcinoma incidence
|
J:86018
|
Tg(KRT14-Shh)#Cobm/0
(involves: C57BL/6 * CBA)
|
increased basal cell carcinoma incidence
|
J:150375
|
Tg(KRT14-Snai1)1Efu/0
(involves: CD-1)
|
increased basal cell carcinoma incidence
|
J:229072
|
increased skin squamous cell carcinoma incidence
|
J:229072
|
Tg(Krt18-EGFP,-TAg121)36Ysng/0
(involves: C57BL/6 * DBA/2)
|
increased ovarian carcinoma incidence
|
J:189304
|
Tg(Krt19-Ptgs2,Krt19-Ptges)8Tko/0 Tg(Krt19-Wnt1)2Maos/0
(involves: C3H * C57BL/6)
|
increased gastric adenocarcinoma incidence
|
J:116782
|
Tg(KRT19-TAg)7Eps/0
(involves: FVB/N)
|
increased urinary bladder transitional cell carcinoma incidence
|
J:64395
|
Tg(LPV-TAg121)2Tvd/0
(involves: 129S6/SvEvTac * C57BL/6J * DBA/2J)
|
increased carcinoma incidence
|
J:120820
|
Tg(Ly6a-BCR/ABL1)IS1AIsg/0
(involves: C57BL/6J * CBA)
|
increased lung adenocarcinoma incidence
|
J:144382
|
increased osteosarcoma incidence
|
J:144382
|
Tg(Ly6a-BCR/ABL1)IS1BIsg/0
(involves: C57BL/6J * CBA)
|
increased lung adenocarcinoma incidence
|
J:144382
|
increased osteosarcoma incidence
|
J:144382
|
Tg(Mdm2)1Snj/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased adenocarcinoma incidence
|
J:51661
|
increased hemangiosarcoma incidence
|
J:51661
|
increased rhabdomyosarcoma incidence
|
J:51661
|
increased sarcoma incidence
|
J:51661
|
Tg(Mdm2)1Snj/0 Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:51661
|
increased medulloblastoma incidence
|
J:51661
|
increased osteosarcoma incidence
|
J:51661
|
increased squamous cell carcinoma incidence
|
J:51661
|
Tg(MMTV-AURKA)#Cxd/?
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:145680
|
Tg(MMTV-AURKA)#Cxd/? Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:145680
|
Tg(MMTV-CCND1)1Esmp/0
(Not Specified)
|
increased mammary adenoacanthoma incidence
|
J:70571
|
increased mammary adenocarcinoma incidence
|
J:70571
|
increased sarcoma incidence
|
J:70571
|
Tg(MMTV-CCND1)1Esmp/0 Tg(MMTV-Cdc37)1Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:62465
|
Tg(MMTV-Cdc37)1Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased mammary adenoacanthoma incidence
|
J:62465
|
increased mammary adenocarcinoma incidence
|
J:62465
|
Tg(MMTV-Cdc37)1Stp/0 Tg(MMTV-Myc)141-3Led/0
(involves: C57BL/6 * CD-1 * DBA/2 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:62465
|
increased salivary adenocarcinoma incidence
|
J:62465
|
Tg(MMTV-Cdc37)2Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased mammary adenoacanthoma incidence
|
J:62465
|
increased sarcoma incidence
|
J:62465
|
Tg(MMTV-ENPP2)20Gbm/0
(FVB/N-Tg(MMTV-ENPP2)20Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-ENPP2)21Gbm/0
(FVB/N-Tg(MMTV-ENPP2)21Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-ENPP2)#Gbm/0
(FVB/N-Tg(MMTV-ENPP2)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-Erbb2)1Pv/0
(involves: BALB/c * C57BL/6 * CD-1 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:234420
|
Tg(MMTV-ERBB2)5Erick/?
(FVB/N-Tg(MMTV-ERBB2)5Erick)
|
increased mammary adenocarcinoma incidence
|
J:90202
|
Tg(MMTV-Erbb2)9Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
Tg(MMTV-Erbb2)10Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
Tg(MMTV-Erbb2)12Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
Tg(MMTV-Erbb2)17Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
Tg(MMTV-Erbb2)NA1Mul/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NF1Mul/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NF1Mul/0
(involves: CD-1 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NF1Mul/0
(FVB/N-Tg(MMTV-Erbb2)NF1Mul)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NK1Mul/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Tg(MMTV-ERBB2*,-luc)6157Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6157Aami)
|
increased mammary adenocarcinoma incidence
|
J:172352
|
Tg(MMTV-ERBB3)1Slg/0
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:80974
|
Tg(MMTV-ERBB3)1Slg/0 Tg(MMTVneu)202Mul/0
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:80974
|
Tg(MMTV-Espl1)1Pati/0
(involves: C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:216267
|
Tg(MMTV-KLF4)1Rup/0 Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6NTac * FVB/NJ * SJL)
|
increased sarcoma incidence
|
J:96886
|
Tg(MMTV-KRAS*G12V)3025Mrl/0
(involves: C57BL/6 * FVB * SJL)
|
increased mammary adenocarcinoma incidence
|
J:77272
|
Tg(MMTV-LPAR1)2Gbm/Tg(MMTV-LPAR1)2Gbm
(FVB/N-Tg(MMTV-LPAR1)2Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-LPAR1)7Gbm/Tg(MMTV-LPAR1)7Gbm
(FVB/N-Tg(MMTV-LPAR1)7Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-LPAR1)27Gbm/Tg(MMTV-LPAR1)27Gbm
(FVB/N-Tg(MMTV-LPAR1)27Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-LPAR1)#Gbm/Tg(MMTV-LPAR1)#Gbm
(FVB/N-Tg(MMTV-LPAR1)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-LPAR2)3Gbm/Tg(MMTV-LPAR2)3Gbm
(FVB/N-Tg(MMTV-LPAR2)3Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-LPAR2)6Gbm/Tg(MMTV-LPAR2)6Gbm
(FVB/N-Tg(MMTV-LPAR2)6Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-LPAR2)#Gbm/Tg(MMTV-LPAR2)#Gbm
(FVB/N-Tg(MMTV-LPAR2)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-LPAR3)3Gbm/Tg(MMTV-LPAR3)3Gbm
(FVB/N-Tg(MMTV-LPAR3)3Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-LPAR3)22Gbm/Tg(MMTV-LPAR3)22Gbm
(FVB/N-Tg(MMTV-LPAR3)22Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-LPAR3)#Gbm/Tg(MMTV-LPAR3)#Gbm
(FVB/N-Tg(MMTV-LPAR3)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
Tg(MMTV-Myc)WT13Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
Tg(MMTV-Myc)WT21Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
Tg(MMTV-Myc*T58A)TA14Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
Tg(MMTV-Myc*T58A)TA41Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
Tg(MMTV-NCOA3)#Mybr/0
(FVB/N-Tg(MMTV-NCOA3)#Mybr)
|
increased leiomyosarcoma incidence
|
J:93548
|
increased lung adenocarcinoma incidence
|
J:93548
|
increased mammary adenocarcinoma incidence
|
J:93548
|
Tg(MMTV-neu/OT-I/OT-II)CBnel/? Tg(Trp53R172H)8512Jmr/?
(involves: C57BL/6 * FVB)
|
increased mammary adenocarcinoma incidence
|
J:122846
|
Tg(MMTV-Notch4)3Rnc/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:11644
|
increased salivary adenocarcinoma incidence
|
J:11644
|
Tg(MMTV-PTGS2)#Thla/0
(involves: CD-1)
|
increased adenocarcinoma incidence
|
J:68565
|
increased mammary adenocarcinoma incidence
|
J:68565
|
increased mammary gland ductal carcinoma incidence
|
J:68565
|
Tg(MMTV-PyVT)634Mul/0
(FVB/N-Tg(MMTV-PyVT)634Mul/Nci)
|
increased mammary adenocarcinoma incidence
|
J:46460,
J:51424,
J:87544,
J:48285
|
Tg(MMTV-PyVT)634Mul/0
(multiple strains)
|
increased mammary adenocarcinoma incidence
|
J:48854
|
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Tg(MMTV-PyVT)#Mul/0
(B6.FVB-Tg(MMTV-PyVT)#Mul)
|
increased mammary adenocarcinoma incidence
|
J:147923
|
Tg(MMTV-PyVT*Y250F)250-2Mul/?
(FVB/N-Tg(MMTV-PyVT*Y250F)250-2Mul)
|
increased mammary adenocarcinoma incidence
|
J:56327
|
Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?
(FVB/N-Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul)
|
increased mammary adenocarcinoma incidence
|
J:56327
|
Tg(MMTV-rtTA)1Lach/0 Tg(TetO-Erbb2)1Lach/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:81083
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-ERBB2)#Jjz/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:231766
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Esr1)#Paf/0
(involves: FVB/N)
|
increased mammary gland ductal carcinoma incidence
|
J:96383
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-IGF1R)1Ramo/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:121069
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-MYC)1Lach/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:67498
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-PIK3CA*H1047R,-luc)2239Jjz/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:175839
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-PyVT,-cre)1Mul/0
(FVB/N-Tg(MMTV-rtTA)1Lach Tg(tetO-PyVT,-cre)#Mul)
|
increased mammary adenocarcinoma incidence
|
J:231983
|
Tg(MMTV-TGFBR2)7Hlm/? Tg(MMTVTGFA)29Rjc/?
(involves: C57BL/6 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:85799
|
Tg(MMTV-TGFBR2)7Hlm/Tg(MMTV-TGFBR2)7Hlm
(involves: C57BL/6 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:85799
|
Tg(MMTV-vHaras)SH1Led/Tg(MMTV-vHaras)SH1Led
(involves: 129X1/SvJ * C57BL/6J * CD-1 * FVB)
|
increased carcinoma incidence
|
J:86074
|
increased mammary adenocarcinoma incidence
|
J:86074
|
Tg(MMTVneu)202Mul/0
(FVB/N-Tg(MMTVneu)202Mul)
|
increased mammary adenocarcinoma incidence
|
J:56332
|
Tg(MMTVneu)202Mul/0 Tg(Trp53R172H)8512Jmr/0
(C.FVB-Tg(MMTVneu)202Mul Tg(Trp53R172H)8512Jmr)
|
increased mammary adenocarcinoma incidence
|
J:115041
|
Tg(MMTVTGFA)29Rjc/0
(involves: C57BL/6 * DBA/2)
|
increased mammary adenocarcinoma incidence
|
J:72085,
J:72080,
J:28453,
J:71696
|
increased squamous cell carcinoma incidence
|
J:72080
|
Tg(MMTVTGFA)254Rjc/0
(involves: C57BL/6 * DBA/2)
|
increased mammary adenocarcinoma incidence
|
J:72085
|
Tg(Msmb-TAg)183-2Xuan/0
(either: (involves: C57BL/6 * CBA) or (involves: C57BL/6 * CBA * CD-1))
|
increased carcinoma incidence
|
J:96884
|
Tg(Msmb-TAg)183-2Xuan/0
(involves: C57BL/6 * CBA)
|
increased prostate gland adenocarcinoma incidence
|
J:80313
|
Tg(Msmb-TAg)186-3Xuan/0
(either: (involves: C57BL/6 * CBA) or (involves: C57BL/6 * CBA * CD-1))
|
increased carcinoma incidence
|
J:96884
|
Tg(Msmb-TAg)186-3Xuan/0
(involves: C57BL/6 * CBA)
|
increased carcinoma incidence
|
J:80313
|
Tg(Mt1-Hgf)19Lmb/0
(involves: FVB/N)
|
increased cutaneous melanoma incidence
|
J:50947
|
increased melanoma incidence
|
J:50947
|
Tg(Mt1-RET)304Ina/0
(B6.C-Tg(Mt1-RET)304Ina)
|
increased cutaneous melanoma incidence
|
J:50392
|
Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6)
|
increased cutaneous melanoma incidence
|
J:88074,
J:155735
|
increased melanoma incidence
|
J:155735
|
Tg(Mt1-Tgfa)147Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:56318
|
Tg(MtTGFA)42Lmb/Tg(MtTGFA)42Lmb
(involves: CD-1)
|
increased hepatocellular carcinoma incidence
|
J:28452
|
Tg(MtTGFA)100Lmb/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:72083
|
Tg(MtTPRMET)243Lng/0
(FVB/N-Tg(MtTPRMET)243Lng)
|
increased osteosarcoma incidence
|
J:71573
|
increased sarcoma incidence
|
J:71573
|
Tg(MtTPRMET)773Lng/0
(FVB/N-Tg(MtTPRMET)773Lng)
|
increased sarcoma incidence
|
J:71573
|
Tg(Mup3-Plau)350-2Eps/?
(C57BL/6-Tg(Mup3-Plau)350-2Eps)
|
increased hepatocellular carcinoma incidence
|
J:233146
|
Tg(Myl2-FGF19)1Dfre/?
(involves: FVB)
|
increased hepatocellular carcinoma incidence
|
J:187236,
J:77160
|
Tg(Neurod2-Smo*A1)199Jols/0
(C57BL/6-Tg(Neurod2-Smo*A1)199Jols)
|
increased medulloblastoma incidence
|
J:93861
|
Tg(Neurod2-Smo*A1)199Jols/0
(involves: C57BL/6)
|
increased medulloblastoma incidence
|
J:221990
|
Tg(Neurod2-Smo*A1)199Jols/Tg(Neurod2-Smo*A1)199Jols
(C57BL/6-Tg(Neurod2-Smo*A1)199Jols)
|
increased medulloblastoma incidence
|
J:133312,
J:189258
|
Tg(Neurod2-Smo*A2)#Jols/0
(C57BL/6-Tg(Neurod2-Smo*A2)#Jols)
|
increased medulloblastoma incidence
|
J:189258
|
Tg(OMP-SV40T)13Bse/0
(involves: C57BL/6 * SJL)
|
increased neuroblastoma incidence
|
J:54269
|
Tg(Pax6-TAg)1796Hur/0
(involves: FVB)
|
increased retinoblastoma incidence
|
J:196814
|
Tg(Pax8-rtTA2S*M2)1Koes/0 Tg(tetO-MYC)36aBop/0
(involves: C57BL/6 * DBA * FVB/N)
|
increased renal carcinoma incidence
|
J:140925
|
Tg(Pbsn-Ar*E231G)7353Ng/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:96117
|
Tg(Pbsn-ERG*)1Vv/0
(involves: 129S1/SvImJ * C57BL/6J * CBA)
|
increased prostate gland adenocarcinoma incidence
|
J:222916
|
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
(FVB-Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp)
|
increased prostate gland adenocarcinoma incidence
|
J:130340
|
increased sarcoma incidence
|
J:130340
|
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0 Tg(Pbsn-Lrp5/Fkbp1a,-luc*)#Dmps/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:206727
|
Tg(Pbsn-Hpn,-GFP)DVv/0 Tg(Pbsn-Tag)12T7fRjm/0
(involves: C57BL/6J * CBA * CD-1)
|
increased prostate gland adenocarcinoma incidence
|
J:92562
|
Tg(Pbsn-MYC)6Key/?
(involves: FVB)
|
increased prostate gland adenocarcinoma incidence
|
J:85480
|
Tg(Pbsn-MYC)#Tt/?
(involves: C57BL/6J)
|
increased prostate gland adenocarcinoma incidence
|
J:205395
|
Tg(Pbsn-Tag)12T7fRjm/0
(involves: CD-1)
|
increased prostate gland adenocarcinoma incidence
|
J:48623
|
Tg(Pbsn-Tag)12T10Rjm/0
(involves: CD-1)
|
increased prostate gland adenocarcinoma incidence
|
J:68483,
J:48623
|
Tg(Pbsn-TAg)15Tvd/0
(involves: C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:103408
|
Tg(Pklr-HRAS*G12V)23Ak/0
(involves: C57BL/6 * DBA/2)
|
increased hepatocellular carcinoma incidence
|
J:44803
|
Tg(Pklr-Myc)73Ak/0
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:185488
|
Tg(Pklr-Myc)73Ak/0
(B6.Cg-Tg(Pklr-Myc)73Ak)
|
increased hepatocellular carcinoma incidence
|
J:184496
|
Tg(Pklr-SV40)1Ak/0
(involves: C57BL/6 * DBA)
|
increased adenocarcinoma incidence
|
J:185488
|
increased hepatocellular carcinoma incidence
|
J:185488
|
increased osteosarcoma incidence
|
J:185488
|
Tg(RasE)290Biat/0
(involves: C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:226601
|
Tg(Rbp3-SV40)IT-2Jjw/?
(involves: BALB/c * C57BL/6)
|
increased retinoblastoma incidence
|
J:60231
|
Tg(Ren2-TAg)4Kwg/?
(involves: C3H/HeRos * C57BL/10Ros)
|
increased sarcoma incidence
|
J:36423
|
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6J * DBA/2J)
|
increased pancreatic islet cell carcinoma incidence
|
J:205389
|
Tg(rTH-Tag)20Dmc/0
(involves: C57BL/6NTac * DBA/2NTac)
|
increased neuroblastoma incidence
|
J:90323
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*delta19)11Hev/0
(involves: C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:109092
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*L858R)56Hev/0
(involves: C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:109092
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*L858R)57Hev/0
(involves: C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:109092
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*L858R)#Hev/0
(involves: 129 * C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:128700,
J:213447
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*T790M)8Paow/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:128700
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*T790M*L858R)19Kkw/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:122849
|
increased lung carcinoma incidence
|
J:122849
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*T790M*L858R)51Paow/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:128700
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-ERBB2*)5BKkw/0
(involves: FVB/N)
|
increased lung carcinoma incidence
|
J:143874
|
increased lung non-small cell carcinoma incidence
|
J:143874
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-ERBB2*)26Kkw/0
(involves: FVB/N)
|
increased lung carcinoma incidence
|
J:143874
|
increased lung non-small cell carcinoma incidence
|
J:143874
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-Kras2)12Hev/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:73468
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-Kras2)12Hev/0 Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:73468
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-MYC)36Bop/0
(involves: 129 * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:169920
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-PIK3CA*H1047R)13Lca/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:142254
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-PTPN11*E76K)#Jiwu/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung non-small cell carcinoma incidence
|
J:212505
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:102839
|
Tg(SERPINA1-TAg)1812Jtsb/0
(involves: C3H * C57BL/6 * ICR)
|
increased hepatocellular carcinoma incidence
|
J:101633
|
Tg(SERPINC1-SV40)A1Pbr/0
(involves: C57BL/6 * DBA/2)
|
increased hepatocellular carcinoma incidence
|
J:101541
|
Tg(SERPINC1-SV40)A1Pbr/Tg(SERPINC1-SV40)A1Pbr
(involves: C57BL/6 * DBA/2)
|
increased hepatocellular carcinoma incidence
|
J:101541
|
X/Tg(SERPINC1-SV40)BPbr
(involves: C57BL/6 * DBA/2)
|
increased hepatocellular carcinoma incidence
|
J:84204,
J:101541
|
Tg(SFTPC-CCNE1)1Edm/?
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:122698
|
Tg(SFTPC-CCNE1*T62A*T380A)3Edm/?
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:122698
|
Tg(SFTPC-CCNE1*T62A*T380A)4Edm/?
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:122698
|
Tg(SFTPC-CD74/ROS1)125Tno/0
(C57BL/6J-Tg(SFTPC-CD74/ROS1)125Tno)
|
increased lung adenocarcinoma incidence
|
J:231770
|
increased lung non-small cell carcinoma incidence
|
J:231770
|
Tg(SFTPC-EGFR*L858R)4-3Kkiu/0
(involves: C57BL/6Cr)
|
increased lung adenocarcinoma incidence
|
J:152157
|
increased lung carcinoma incidence
|
J:152157
|
Tg(SFTPC-EML4/ALK)502-4Hima/0
(involves: C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:142679
|
Tg(SFTPC-env)1Yhch/0
(FVB/N-Tg(SFTPC-env)1Yhch)
|
increased lung adenocarcinoma incidence
|
J:153538,
J:247986
|
Tg(SFTPC-EZR/ROS1)AShiba/0
(C57BL/6-Tg(SFTPC-EZR/ROS1)AShiba)
|
increased lung adenocarcinoma incidence
|
J:199415
|
Tg(SFTPC-KIF5B/RET)1Tkoh/0
(involves: C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:215989
|
Tg(SFTPC-MST1R)71Mhw/0
(involves: C3H * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:79080
|
Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-Fgf9,-EGFP)#Dor/0
(involves: FVB)
|
increased blastoma incidence
|
J:224791
|
increased lung adenocarcinoma incidence
|
J:204282
|
increased malignant tumor incidence
|
J:204282
|
Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-MYC)36Bop/0
(Not Specified)
|
increased lung adenocarcinoma incidence
|
J:169920
|
Tg(SFTPC-SDC4/ROS1)141Tno/0
(C57BL/6J-Tg(SFTPC-SDC4/ROS1)141Tno)
|
increased lung adenocarcinoma incidence
|
J:231770
|
increased lung non-small cell carcinoma incidence
|
J:231770
|
Tg(Slc1a2-tTA)#Waw/0 Tg(tetO-MYCN,-luc)#Waw/0
(involves: FVB/NJ)
|
increased malignant tumor incidence
|
J:160518
|
increased medulloblastoma incidence
|
J:160518
|
Tg(Slc1a2-tTA)#Waw/0 Tg(tetO-MYCN,-luc)#Waw/Tg(tetO-MYCN,-luc)#Waw
(involves: FVB/NJ)
|
increased malignant tumor incidence
|
J:160518
|
increased medulloblastoma incidence
|
J:160518
|
Tg(Smgb-TAg)8Mir/Tg(Smgb-TAg)8Mir
(involves: BALB/cJ * C57BL/6J)
|
increased salivary adenocarcinoma incidence
|
J:66189
|
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 Tg(tetO-RNAi:Trp53)ASlowe/0
(involves: C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:199542
|
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * 129P2/OlaHsd * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693
|
Tg(SV40-NRAS*G12D)1Sco/?
(Not Specified)
|
increased sarcoma incidence
|
J:125150
|
Tg(TagRb)1Plm/?
(involves: BALB/cJ * C57BL/6J)
|
increased retinoblastoma incidence
|
J:10320
|
Tg(Tal1-cre/ERT)1Jrg/0 Tsc1tm1Djk/Tsc1tm1Djk
(involves: 129S4/SvJae * C57BL/6)
|
increased extremity angiosarcoma incidence
|
J:231316
|
increased hemangiosarcoma incidence
|
J:231316
|
Tg(tetO-BCR/ABL1)2Dgt/0 Tg(Tal1-tTA)19Dgt/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased sarcoma incidence
|
J:96511
|
Tg(tetO-BRAF*V600E)26Jaf/0 Tg(TG-rtTA)30Jaf/0
(involves: FVB/N)
|
increased thyroid carcinoma incidence
|
J:184420
|
Tg(tetO-MET)23Rwng/0 Tg(Cebpb-tTA)5Bjd/0
(involves: FVB/N * NMRI)
|
increased hepatocellular carcinoma incidence
|
J:69731
|
Tg(tetO-MYC)36aBop/0 Tg(Cebpb-tTA)5Bjd/0
(involves: FVB/N * NMRI)
|
increased hepatoblastoma incidence
|
J:93899
|
increased hepatocellular carcinoma incidence
|
J:172430,
J:186226,
J:190067,
J:93899
|
Tg(tetO-TAg)2-5Hiwa/0
(involves: C57BL/6)
|
increased neuroblastoma incidence
|
J:156984,
J:175962
|
Tg(tetO-TAg,CMV-rtTA)123Yihu/0
(involves: FVB/N)
|
increased medulloblastoma incidence
|
J:141623
|
Tg(TetOp-Polb/tTA)2Sbl/0
(B6.Cg-Tg(TetOp-Polb/tTA)2Sbl)
|
increased osteosarcoma incidence
|
J:152481
|
Tg(Tff3-Tmem207)1Tamo/0
(C57BL/6-Tg(Tff3-Tmem207)1Tamo)
|
increased carcinoma incidence
|
J:217436
|
Tg(TG-BRAF*V600E)2Jaf/0
(FVB/N-Tg(TG-BRAF*V600E)2Jaf)
|
increased thyroid carcinoma incidence
|
J:98550
|
Tg(TG-BRAF*V600E)3Jaf/0
(FVB/N-Tg(TG-BRAF*V600E)3Jaf)
|
increased thyroid carcinoma incidence
|
J:98550
|
Tg(TG-NRAS*Q61K)#Msnt/0
(Not Specified)
|
increased thyroid carcinoma incidence
|
J:210016
|
Tg(TG-RET/CCDC6)1Cled/0
(involves: FVB/N)
|
increased thyroid carcinoma incidence
|
J:55883,
J:93679
|
Tg(TG-RET/CCDC6)42Cled/0
(involves: FVB/N)
|
increased thyroid carcinoma incidence
|
J:55883,
J:93679
|
Tg(TG-RET/NCOA4)3209Rstn/0
(involves: C57BL/6)
|
increased thyroid carcinoma incidence
|
J:51366
|
Tg(TG-SV40)#Cled/0
(involves: C57BL/6J * DBA/2J)
|
increased thyroid carcinoma incidence
|
J:209788
|
Tg(TG-TPR/NTRK1)5215Rstn/0
(involves: C3H * C57BL/6)
|
increased thyroid carcinoma incidence
|
J:67120
|
Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:210015
|
Tg(Th-ALK*F1174L)2Loch/0 Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6J * CBA)
|
increased neuroblastoma incidence
|
J:191012
|
Tg(Th-MYCN)41Waw/0
(involves: BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:41126
|
Tg(Th-MYCN)41Waw/0
(involves: BALB/c * C57BL/6J * FVB/N)
|
increased neuroblastoma incidence
|
J:41126
|
Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:172448
|
Tg(Th-MYCN)41Waw/0 Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * BALB/c * C57BL/6J * FVB/N)
|
increased neuroblastoma incidence
|
J:41126
|
Tg(Th-MYCN)41Waw/Tg(Th-MYCN)41Waw
(involves: BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:41126
|
Tg(TRAMP)8247Ng/0
(involves: C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:217920,
J:65303
|
Tg(TRAMP)8247Ng/0
(involves: C3H * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:125633
|
Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:133908
|
Tg(TRAMP)8247Ng/0 Usp11tm1Tac/Y
(involves: 129 * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:270214
|
Tg(TRP53)4Dgj/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * FVB)
|
increased osteosarcoma incidence
|
J:162466
|
Tg(TRP53*R72P)7Dgj/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * FVB)
|
increased hemangiosarcoma incidence
|
J:162466
|
Tg(Trp53A135V)L3Ber/0
(involves: C57BL/6 * CD-1)
|
increased lung adenocarcinoma incidence
|
J:73757
|
Tg(Trp53R172H)8512Jmr/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:46426
|
Tg(Tyr-BRAF*V600E)470Fgh/0
(involves: C57BL/6J * CBA)
|
increased malignant tumor incidence
|
J:151455
|
Tg(Tyr-BRAF*V600E)476Fgh/0
(involves: C57BL/6J * CBA)
|
increased malignant tumor incidence
|
J:151455
|
Tg(UPII-SV40T)2Xrw/0
(involves: FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:56305
|
increased urinary bladder transitional cell carcinoma incidence
|
J:56305
|
Tg(UPII-SV40T)9Xrw/0
(involves: FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:56305
|
Tg(UPII-SV40T)29Xrw/0
(involves: FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:56305
|
increased urinary bladder transitional cell carcinoma incidence
|
J:56305
|
Tg(Upk2-TAg)1Rkl/0
(involves: C57BL/6)
|
increased urinary bladder carcinoma incidence
|
J:173505
|
increased urinary bladder transitional cell carcinoma incidence
|
J:173505
|
Tg(Utg-TAg)7593Fjd/?
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:70785
|
Tg(Utg-TAg)7736Fjd/?
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:70785
|
Tg(Utg-TAg)#Fjd/?
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:70785
|
Tg(Vav1-Asxl1*Y588X)#Fcy/0
(C57BL/6-Tg(Vav1-Asxl1*Y588X)#Fcy)
|
increased myeloid sarcoma incidence
|
J:257690
|
Tg(Vav-BCL2)69Jad/0
(involves: C57BL/6J)
|
increased histiocytic sarcoma incidence
|
J:88565
|
Tg(Vil1-Lin28b,-tdTomato)HiAru/0
(involves: C57BL/6J * SJL)
|
increased small intestine adenocarcinoma incidence
|
J:202923
|
Tg(Vil1-Lin28b,-tdTomato)MedAru/0
(involves: C57BL/6J * SJL)
|
increased small intestine adenocarcinoma incidence
|
J:202923
|
Tg(Wap-Hgf)402Mig/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:86776
|
Tg(Wap-Hgf)402Mig/0
(FVB/N-Tg(Wap-Hgf)402Mig)
|
increased mammary adenocarcinoma incidence
|
J:206839
|
X/Tg(Wap-HRAS)69Lln
(involves: C57BL/6 * SJL)
|
increased adenocarcinoma incidence
|
J:72262
|
increased salivary adenocarcinoma incidence
|
J:46458
|
Tg(Wap-TAg)1Depp/0
(involves: BALB/c * C57BL/6)
|
increased mammary gland ductal carcinoma incidence
|
J:61012
|
Tg(Wap-tAg)1Gmn/?
(involves: NMRI)
|
increased mammary adenocarcinoma incidence
|
J:69711
|
Tg(Wap-TAg)NP8Depp/0
(involves: BALB/c * C57BL/6)
|
increased mammary gland ductal carcinoma incidence
|
J:61012
|
Tg(Wap-Tsg101)4389Kuw/0
(FVB/N-Tg(Wap-Tsg101)4389Kuw)
|
increased mammary adenocarcinoma incidence
|
J:121475
|
Tg(WapMyc)212Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:56318
|
Tg(WapNotch4)10Rnc/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:33193
|
Tg(WapTAg)1Knw/0
(C57BL/6J-Tg(WapTAg)1Knw/J)
|
increased mammary adenocarcinoma incidence
|
J:53175
|
increased sarcoma incidence
|
J:53175
|
Tg(WapTAg)3Knw/0
(C57BL/6J-Tg(WapTAg)3Knw)
|
increased adenocarcinoma incidence
|
J:53175
|
increased mammary adenocarcinoma incidence
|
J:53175
|
increased osteosarcoma incidence
|
J:53175
|
increased sarcoma incidence
|
J:53175
|
Tg(WapTgfa)215Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:56318
|
Tg(Wnt1)1Hev/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:54215
|
Tg(Wnt1)1Hev/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:61009
|
Tgfb1tm1Rif/Tgfb1tm1Rif
(either: (involves: 129) or (involves: 129S/SvEv * C57BL/6))
|
increased anal adenocarcinoma incidence
|
J:142353
|
increased colon adenocarcinoma incidence
|
J:142353
|
increased gastric adenocarcinoma incidence
|
J:142353
|
increased large intestine adenocarcinoma incidence
|
J:142353
|
increased rectum adenocarcinoma incidence
|
J:142353
|
Tgfbitm1Zhao/Tgfbitm1Zhao
(involves: 129 * C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:143036
|
increased malignant tumor incidence
|
J:143036
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Tg(Col1a2-cre/ERT,-ALPP)7Cpd/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:204736
|
Thbs1tm1Hyn/Thbs1tm1Hyn Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased adenocarcinoma incidence
|
J:72391
|
increased carcinoma incidence
|
J:72391
|
increased fibrosarcoma incidence
|
J:72391
|
increased histiocytic sarcoma incidence
|
J:72391
|
increased liver adenocarcinoma incidence
|
J:72391
|
increased lung adenocarcinoma incidence
|
J:72391
|
increased mammary adenocarcinoma incidence
|
J:72391
|
increased osteosarcoma incidence
|
J:72391
|
increased sarcoma incidence
|
J:72391
|
increased squamous cell carcinoma incidence
|
J:72391
|
Thbs1tm1Hyn/Thbs1tm1Hyn Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased adenocarcinoma incidence
|
J:72391
|
increased carcinoma incidence
|
J:72391
|
increased fibrosarcoma incidence
|
J:72391
|
increased hemangiosarcoma incidence
|
J:72391
|
increased histiocytic sarcoma incidence
|
J:72391
|
increased sarcoma incidence
|
J:72391
|
increased small intestine adenocarcinoma incidence
|
J:72391
|
Thrbtm1.1Syc/Thrbtm1.1Syc
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:92629
|
Thrbtm1Df/Thrbtm1.1Syc
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:92629
|
Tiam1tm1Jgc/Tiam1tm1Jgc
(involves: 129P2/OlaHsd * FVB)
|
increased malignant tumor incidence
|
J:77148
|
increased squamous cell carcinoma incidence
|
J:77148
|
Tle5tm1.1Mmt/Tle5tm1.1Mmt Apctm1Mmt/Apc+ Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S2/SvPas * C57BL/6 * DBA * SJL)
|
increased colon adenocarcinoma incidence
|
J:168065
|
increased small intestine adenocarcinoma incidence
|
J:168065
|
Tlr2tm1Kir/Tlr2tm1Kir
(B6.129-Tlr2tm1Kir)
|
increased carcinoma incidence
|
J:165105
|
Tnk1tm1Sksuf/Tnk1+
(involves: 129X1/SvJ * C57BL/6)
|
increased carcinoma incidence
|
J:140639
|
increased hepatocellular carcinoma incidence
|
J:140639
|
increased intestinal adenocarcinoma incidence
|
J:140639
|
increased malignant tumor incidence
|
J:140639
|
Tnk1tm1Sksuf/Tnk1tm1Sksuf
(involves: 129X1/SvJ * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:140639
|
increased hepatocellular carcinoma incidence
|
J:140639
|
increased lung adenocarcinoma incidence
|
J:140639
|
Tom1l2Gt(XG909)Byg/Tom1l2Gt(XG909)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased basal cell carcinoma incidence
|
J:133892
|
Tpx2Gt(D028B03)Wrst/Tpx2+
(involves: 129S2/SvPas * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:184948
|
increased lung adenocarcinoma incidence
|
J:184948
|
Trim24tm1.1Los/Trim24tm1.1Los
(involves: 129/Sv * C57BL/6 * SJL)
|
increased hepatocellular carcinoma incidence
|
J:130210
|
Trim37Gt(RRO307)Byg/Trim37Gt(RRO307)Byg
(B6J.129P2-Trim37Gt(RRO307)Byg)
|
increased carcinoma incidence
|
J:232482
|
increased medulloblastoma incidence
|
J:232482
|
Trim62tm1Akil/Trim62+
(involves: 129S/SvEv * C57BL/6)
|
increased adenocarcinoma incidence
|
J:204336
|
increased hepatocellular carcinoma incidence
|
J:204336
|
increased liver adenocarcinoma incidence
|
J:204336
|
increased lung adenocarcinoma incidence
|
J:204336
|
increased mammary adenocarcinoma incidence
|
J:204336
|
increased sarcoma incidence
|
J:204336
|
increased spindle cell carcinoma incidence
|
J:204336
|
Trim62tm1Akil/Trim62tm1Akil
(involves: 129S/SvEv * C57BL/6)
|
increased adenocarcinoma incidence
|
J:204336
|
increased liver adenocarcinoma incidence
|
J:204336
|
increased lung adenocarcinoma incidence
|
J:204336
|
increased mammary adenocarcinoma incidence
|
J:204336
|
increased sarcoma incidence
|
J:204336
|
increased squamous cell carcinoma incidence
|
J:204336
|
Trp53Bbl/Trp53+
(C57BL/6JSfdAnu-Trp53Bbl/Anu)
|
increased fibrosarcoma incidence
|
J:104190
|
increased hemangiosarcoma incidence
|
J:104190
|
increased osteosarcoma incidence
|
J:104190
|
Trp53bhy/Trp53+
(C57BL/6JSfdAnu-Trp53bhy/Anu)
|
increased fibrosarcoma incidence
|
J:104190
|
increased hemangiosarcoma incidence
|
J:104190
|
increased osteosarcoma incidence
|
J:104190
|
increased teratocarcinoma incidence
|
J:104190
|
Trp53tm1.1Awbr/Trp53tm1.1Awbr
(involves: C57BL/6)
|
increased fibrosarcoma incidence
|
J:169434
|
increased histiocytic sarcoma incidence
|
J:173271
|
increased osteosarcoma incidence
|
J:173271
|
Trp53tm1.1Thst/Trp53tm1.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased carcinoma incidence
|
J:198482
|
increased hemangiosarcoma incidence
|
J:198482
|
increased leiomyosarcoma incidence
|
J:198482
|
Trp53tm1.2Awbr/Trp53+
(involves: C57BL/6)
|
increased osteosarcoma incidence
|
J:173271
|
Trp53tm1.2Awbr/Trp53tm1.2Awbr
(involves: C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:173271
|
increased osteosarcoma incidence
|
J:173271
|
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased carcinoma incidence
|
J:73757
|
increased osteosarcoma incidence
|
J:73757
|
increased sarcoma incidence
|
J:73757
|
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd)
|
increased carcinoma incidence
|
J:51661
|
increased osteosarcoma incidence
|
J:51661
|
increased rhabdomyosarcoma incidence
|
J:51661
|
increased sarcoma incidence
|
J:51661
|
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:1999
|
increased osteosarcoma incidence
|
J:1999
|
increased sarcoma incidence
|
J:1999,
J:126497
|
Trp53tm1Brd/Trp53tm1Brd Xrcc4tm2.1Fwa/Xrcc4tm2Fwa Tg(Nes-cre)1Kln/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:109585
|
Trp53tm1Brd/Trp53tm1Brd Xrcc5tm1Dbr/Xrcc5tm1Dbr
(involves: 129S7/SvEvBrd * C57BL)
|
increased medulloblastoma incidence
|
J:141515
|
Trp53tm1Brd/Trp53tm1Ldo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased sarcoma incidence
|
J:73757
|
Trp53tm1Brn/Trp53+ Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd)
|
increased mammary adenocarcinoma incidence
|
J:170898
|
Trp53tm1Brn/Trp53+ Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * 129P2/OlaHsd * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693
|
Trp53tm1Brn/Trp53tm1.1Brn
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:86077,
J:157319
|
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:86077,
J:157319
|
Trp53tm1Brn/Trp53tm1Brn Tg(Cdh16-cre)91Igr/0
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N * ICR)
|
increased endometrial carcinoma incidence
|
J:214850,
J:215149
|
Trp53tm1Brn/Trp53tm1Brn Tg(KRT5-cre/PGR)1Der/0
(involves: 129P2/OlaHsd * C57BL/6N * FVB/N * ICR)
|
increased skin squamous cell carcinoma incidence
|
J:216813
|
Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
increased squamous cell carcinoma incidence
|
J:116152
|
Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)105Ayn/0
(FVB.Cg-Trp53tm1Brn Tg(MMTV-cre)105Ayn)
|
increased carcinoma incidence
|
J:165292
|
increased squamous cell carcinoma incidence
|
J:165292
|
Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased spindle cell carcinoma incidence
|
J:224955
|
Trp53tm1Brn/Trp53tm1Brn Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
(involves: 129P2/OlaHsd)
|
increased medulloblastoma incidence
|
J:237990
|
Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:199542
|
Trp53tm1Brn/Trp53tm1Brn Tg(Tyr-cre/ERT2)13Bos/0 Tg(Tyr-NRAS*Q61K)1Bee/0
(FVB.Cg-Tg(Tyr-cre/ERT2)13Bos Trp53tm1Brn Tg(Tyr-NRAS*Q61K)1Bee)
|
increased cutaneous melanoma incidence
|
J:222847
|
Trp53tm1Brn/Trp53tm1Brn Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:171765
|
Trp53tm1Brn/Trp53tm1Tyj Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:102702
|
Trp53tm1Elee/Trp53tm1Elee Tg(GFAP-cre)25Mes/0
(involves: 129S4/SvJae * FVB/N)
|
increased medulloblastoma incidence
|
J:149662
|
increased sarcoma incidence
|
J:149662
|
Trp53tm1Elee/Trp53tm1Elee Tg(MMTV-cre)AElee/0
(involves: 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:90247
|
Trp53tm1Elee/Trp53tm1Elee Tg(MMTV-cre)BElee/0
(involves: 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:90247
|
Trp53tm1Elee/Trp53tm1Elee Tg(Wap-rtTA-cre)10Whl/0
(involves: 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:90247
|
Trp53tm1Elee/Trp53tm1Tyj Tg(GFAP-cre)25Mes/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
|
increased medulloblastoma incidence
|
J:149662
|
increased sarcoma incidence
|
J:149662
|
Trp53tm1Glo/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased carcinoma incidence
|
J:61683
|
increased fibrosarcoma incidence
|
J:61683
|
increased hemangiosarcoma incidence
|
J:61683
|
increased osteosarcoma incidence
|
J:61683
|
increased sarcoma incidence
|
J:61683
|
increased squamous cell carcinoma incidence
|
J:61683
|
Trp53tm1Glo/Trp53+
(involves: 129S7/SvEvBrd)
|
increased carcinoma incidence
|
J:129627
|
increased osteosarcoma incidence
|
J:129627
|
increased sarcoma incidence
|
J:129627
|
increased squamous cell carcinoma incidence
|
J:129627
|
Trp53tm1Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased adenocarcinoma incidence
|
J:171821
|
increased sarcoma incidence
|
J:171821
|
increased spindle cell carcinoma incidence
|
J:171821
|
Trp53tm1Thst/Trp53tm1Thst
(involves: 129S1/Sv * 129X1/SvJ)
|
increased carcinoma incidence
|
J:198482
|
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased adenocarcinoma incidence
|
J:72391
|
increased carcinoma incidence
|
J:72391,
J:95318
|
increased fibrosarcoma incidence
|
J:17728
|
increased hemangiosarcoma incidence
|
J:72391,
J:17728
|
increased histiocytic sarcoma incidence
|
J:72391
|
increased leiomyosarcoma incidence
|
J:17728
|
increased lung adenocarcinoma incidence
|
J:72391
|
increased mammary adenocarcinoma incidence
|
J:72391
|
increased osteosarcoma incidence
|
J:72391,
J:17728
|
increased rhabdomyosarcoma incidence
|
J:17728
|
increased sarcoma incidence
|
J:72391,
J:17728,
J:95318
|
increased squamous cell carcinoma incidence
|
J:72391
|
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas)
|
increased carcinoma incidence
|
J:95316
|
Trp53tm1Tyj/Trp53+ Trp63tm1Fmc/Trp63+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:98958
|
increased osteosarcoma incidence
|
J:98958
|
increased rhabdomyosarcoma incidence
|
J:98958
|
increased squamous cell carcinoma incidence
|
J:98958
|
increased urinary bladder transitional cell carcinoma incidence
|
J:98958
|
Trp53tm1Tyj/Trp53+ Trp73tm1Fmc/Trp73+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:98958
|
increased lung adenocarcinoma incidence
|
J:98958
|
increased pancreatic acinar cell carcinoma incidence
|
J:98958
|
increased sarcoma incidence
|
J:98958
|
Trp53tm1Tyj/Trp53tm1.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased carcinoma incidence
|
J:228632
|
increased sarcoma incidence
|
J:228632
|
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased carcinoma incidence
|
J:72391
|
increased fibrosarcoma incidence
|
J:72391
|
increased hemangiosarcoma incidence
|
J:72391,
J:17728
|
increased osteosarcoma incidence
|
J:72391,
J:17728
|
increased rhabdomyosarcoma incidence
|
J:17728
|
increased sarcoma incidence
|
J:72391,
J:17728,
J:95318
|
increased squamous cell carcinoma incidence
|
J:72391
|
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
increased hemangiosarcoma incidence
|
J:95316
|
increased medulloblastoma incidence
|
J:102702
|
Trp53tm1Tyj/Trp53tm1Tyj Tg(Prrx1-FUS/DDIT3)1Mete/0
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
increased liposarcoma incidence
|
J:184491
|
increased sarcoma incidence
|
J:184491
|
Trp53tm1Tyj/Trp53tm1Tyj Xrcc2tm1Pmc/Xrcc2tm1Pmc
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:111068
|
increased sarcoma incidence
|
J:111068
|
Trp53tm1Tyj/Trp53tm1Tyj Xrcc2tm2Pmc/Xrcc2tm2Pmc Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Trp53tm1Tyj/Trp53tm2.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae)
|
increased carcinoma incidence
|
J:95316
|
increased hemangiosarcoma incidence
|
J:95316
|
Trp53tm1Tyj/Trp53tm2.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased carcinoma incidence
|
J:228632
|
increased sarcoma incidence
|
J:228632
|
Trp53tm1Tyj/Trp53tm3.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae)
|
increased carcinoma incidence
|
J:95316
|
Trp53tm1Yjc/Trp53tm1Yjc
(B6.129S1-Trp53tm1Yjc)
|
increased sarcoma incidence
|
J:195018
|
Trp53tm2.1Thst/Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased carcinoma incidence
|
J:282255
|
increased sarcoma incidence
|
J:282255
|
Trp53tm2Glo/Trp53tm2Glo
(involves: 129/Sv * C57BL/6)
|
increased sarcoma incidence
|
J:87501
|
Trp53tm2Thst/Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased carcinoma incidence
|
J:282255
|
increased sarcoma incidence
|
J:282255
|
Trp53tm3.1Glo/Trp53+
(B6.129S7-Trp53tm3.1Glo)
|
increased carcinoma incidence
|
J:317504,
J:95318
|
increased osteosarcoma incidence
|
J:317504
|
increased sarcoma incidence
|
J:317504,
J:95318
|
Trp53tm3.1Glo/Trp53tm3.1Glo
(B6.129S7-Trp53tm3.1Glo)
|
increased sarcoma incidence
|
J:95318
|
Trp53tm3.1Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased adenocarcinoma incidence
|
J:171821
|
increased sarcoma incidence
|
J:171821
|
increased spindle cell carcinoma incidence
|
J:171821
|
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae)
|
increased carcinoma incidence
|
J:95316
|
increased hepatocellular carcinoma incidence
|
J:95316
|
increased lung adenocarcinoma incidence
|
J:95316
|
increased squamous cell carcinoma incidence
|
J:95316
|
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * SKH1)
|
increased mammary adenocarcinoma incidence
|
J:121734
|
Trp53tm3Tyj/Trp53+ Tg(Wap-cre)11738Mam/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:101617
|
increased sarcoma incidence
|
J:101617
|
Trp53tm4Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased adenocarcinoma incidence
|
J:171821
|
increased sarcoma incidence
|
J:171821
|
increased spindle cell carcinoma incidence
|
J:171821
|
Trp53tm4Tyj/Trp53tm4Tyj
(involves: 129S4/SvJae * C57BL/6)
|
increased sarcoma incidence
|
J:92917
|
Trp53tm4Xu/Trp53tm4Xu
(Not Specified)
|
increased sarcoma incidence
|
J:126497
|
Trp53tm7.1Xu/Trp53tm7.1Xu
(Not Specified)
|
increased sarcoma incidence
|
J:160414
|
Trp53bp2tm1Xlu/Trp53bp2+
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased hemangiosarcoma incidence
|
J:108701
|
increased rhabdomyosarcoma incidence
|
J:108701
|
increased squamous cell carcinoma incidence
|
J:108701
|
Trp63tm1Fmc/Trp63+
(involves: 129S4/SvJae * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:98958
|
increased malignant tumor incidence
|
J:98958
|
increased squamous cell carcinoma incidence
|
J:98958
|
Trp63tm1Fmc/Trp63+ Trp73tm1Fmc/Trp73+
(involves: 129S4/SvJae * C57BL/6)
|
increased carcinoma incidence
|
J:98958
|
increased hemangiosarcoma incidence
|
J:98958
|
increased lung adenocarcinoma incidence
|
J:98958
|
increased mammary adenocarcinoma incidence
|
J:98958
|
increased squamous cell carcinoma incidence
|
J:98958
|
Trp73tm1Fmc/Trp73+
(involves: 129S4/SvJae * C57BL/6)
|
increased hemangiosarcoma incidence
|
J:98958
|
increased lung adenocarcinoma incidence
|
J:98958
|
increased malignant tumor incidence
|
J:98958
|
Trp73tm1Fmc/Trp73tm1Fmc
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:98958
|
Trp73tm1Mak/Trp73+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased carcinoma incidence
|
J:142848
|
increased hemangiosarcoma incidence
|
J:142848
|
increased lung adenocarcinoma incidence
|
J:142848
|
Trp73tm1Mak/Trp73tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased carcinoma incidence
|
J:142848
|
increased lung adenocarcinoma incidence
|
J:142848
|
Ts(1716)65Dn/0
(involves: C3H/HeJ * C57BL/6J * DBA/2J)
|
increased malignant tumor incidence
|
J:174270
|
Tsc1tm1.1Djk/Tsc1+
(either: 129S4/SvJae-Tsc1tm1Djk or (involves: 129S4/SvJae * BALB/cJ) or (involves: 129S4/SvJae * C57BL/6J))
|
increased hemangiosarcoma incidence
|
J:75243
|
increased renal carcinoma incidence
|
J:75243
|
Tsc1tm1Chdl/Tsc1+
(involves: 129P2/OlaHsd * C57BL/6JOlaHsd)
|
increased renal carcinoma incidence
|
J:99796
|
Tsc1tm1Chdl/Tsc1+
(involves: 129P2/OlaHsd * Balb/cOlaHsd * C57BL/6JOlaHsd)
|
increased renal carcinoma incidence
|
J:99796
|
Tsc1tm1Hin/Tsc1+
(involves: 129S4/SvJae * C57BL/6J)
|
increased leiomyosarcoma incidence
|
J:70463
|
increased renal carcinoma incidence
|
J:70463
|
Tsc2tm1Djk/Tsc2+
(either: (involves: 129S4/SvJae * BALB/cJ) or (involves: 129S4/SvJae * Black Swiss) or (involves: 129S4/SvJae * C57BL/6J))
|
increased extremity angiosarcoma incidence
|
J:57631
|
increased renal carcinoma incidence
|
J:57631
|
Tsc2tm1Tno/Tsc2+
(involves: 129S4/SvJae * C57BL/6J)
|
increased renal carcinoma incidence
|
J:52464
|
Tusc2tm1Avi/Tusc2+
(involves: 129S1/Sv * C57BL/6J)
|
increased hemangiosarcoma incidence
|
J:119985
|
Tusc2tm1Avi/Tusc2tm1Avi
(involves: 129S1/Sv * C57BL/6J)
|
increased hemangiosarcoma incidence
|
J:119985
|
increased squamous cell carcinoma incidence
|
J:119985
|
TxnipHyplip1/Txnip+
(involves: CAST/Ei * HcB19/Dem)
|
increased hepatocellular carcinoma incidence
|
J:112292
|
TxnipHyplip1/TxnipHyplip1
(HcB19/Dem-TxnipHyplip1)
|
increased hepatocellular carcinoma incidence
|
J:112292
|
TxnipHyplip1/TxnipHyplip1
(involves: CAST/Ei * HcB19/Dem)
|
increased hepatocellular carcinoma incidence
|
J:112292
|
Uacatm1Kiy/Uacatm1Kiy
(B6.129P2-Uacatm1Kiy)
|
increased hepatocellular carcinoma incidence
|
J:157049
|
Urahplt2/Urahplt2
(C57BL/6-Urahplt2)
|
increased hepatocellular carcinoma incidence
|
J:164423
|
Usp44tm1.2Pjgl/Usp44tm1.2Pjgl
(involves: 129S4/SvJae * 129S7/SvEvBrd)
|
increased sarcoma incidence
|
J:193965
|
Vhltm1.1Wkr/Vhl+
(involves: 129S4/SvJae * C57BL/6)
|
increased adenocarcinoma incidence
|
J:157369
|
Wif1tm1Dmth/Wif1tm1Dmth
(involves: 129 * C57BL/6)
|
increased osteosarcoma incidence
|
J:149607
|
increased sarcoma incidence
|
J:149607
|
WwoxGt(XG218)Byg/WwoxGt(XG218)Byg
(involves: 129P2/OlaHsd)
|
increased malignant tumor incidence
|
J:132078
|
Wwoxtm1Ria/Wwoxtm1Ria
(involves: 129X1/SvJ * C57BL/6)
|
increased osteosarcoma incidence
|
J:120064
|
Xpatm1Tnka/Xpatm1Tnka
(involves: C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:62877
|
increased skin squamous cell carcinoma incidence
|
J:28709
|
Xpctm1Ecf/Xpctm1Ecf
(involves: 129 * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:101421
|
Xrcc1tm1Pmc/Xrcc1tm1Pmc Trp53tm1Tyj/Trp53+ Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:152528
|
Xrcc1tm1Pmc/Xrcc1tm1Pmc Trp53tm1Tyj/Trp53tm1Tyj Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:152528
|
Yy1tm2.1Yshi/Yy1tm2.1Yshi Tg(Nkx2-1-cre)2Sand/0
(involves: 129S4/SvJae * C57BL/6J)
|
increased blastoma incidence
|
J:239777
|